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ABSTRACT 
 
Boron dipyrromethene (BODIPY) dyes, have garnered much attention in recent decades 
due to their enticing photophysical properties and their bioimaging applicability. Despite the 
progression of this field, the development of BODIPY based anti-cancer agents and radioimaging 
dyes has seen little progress. The utilization of fluorescent BODIPYs as photosensitizers for 
photodynamic therapy, and as boron delivery agents for boron neutron capture therapy offers 
promise as theranostic agents. Additionally, BODIPY derivatives that absorb and emit in the near-
IR regions of the electromagnetic spectrum and bear radioisotopes suitable for radioimaging 
techniques are of great interest.  
Chapter 1 is a concise overview of the fundamental concepts of the BODIPY 
fluorophores. The synthetic routes, post-synthetic modification strategies, and several biological 
applications of BODIPYs are introduced and will be elaborated upon in subsequent chapters.  
Chapter 2 describes the synthesis, characterization, computational modeling and in vitro 
biological investigations of a series of meso-aryl tetramethyl BODIPYs and their diiodo 
derivatives as photodynamic therapy photosensitizers. Variances in the meso-substituent of 
BODIPY were found to influence the phototoxicity of diiodo-BODIPYs, with some possessing 
phototoxicity while others were non-toxic. The photophysical properties of these compounds were 
also explored computationally in collaboration with Dr. Petia Bobadova-Parvanova of Rockhurst 
University. 
Chapter 3 reports on the synthesis of several near-IR styrylated diiodo-BODIPYs prepared 
via the Knoevenagel reaction strategy from one of the most phototoxic BODIPYs described in 
xii 
 
Chapter 2. The effects of the number and type of styryl substituents on their photophysical 
properties and in vitro photodynamic activities are discussed.  
Chapter 4 explores the synthesis, photophysical, and in vitro biological properties of near-
IR styryl BODIPYs with applications in near-IR fluorescence, PET, and SPECT imaging. The 
exploration of radiolabelling highly functionalized long wavelength BODIPYs is detailed herein.  
Chapter 5 conveys an effective method towards the preparation of carborane-appended 
BODIPYs for boron neutron capture therapy. The use of highly efficient palladium-catalyzed 
Suzuki coupling yielded two carboranyl-BODIPYs of varying optical properties in good yield. The 
photophysical properties and blood brain permeability of these novel-carboranyl BODIPYs was 
reported.  
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CHAPTER 1: INTRODUCTION 
1.1 Structure of BODIPY® Dyes 
Modern medicine continues to advance without bound, especially with the development of 
new technologies and novel techniques for bioimaging and disease therapies, and with such 
progression comes the need for new fluorophores capable of being excited and emitting in the red 
to near-infrared (IR) region of the visible spectrum.1 The optimal “biological window” of 600 – 
850 nm allows for minimal interference from endogenous chromophores, such as heme, and 
optimal light penetration through tissues with reduced light scattering and diminished damage to 
the tissues being imaged.2-5 These fluorophores can no longer possess a single use, and the demand 
for dual purpose theranostic agents is on the rise. Although numerous nonradioactive fluorophores, 
including rhodamines, cyanines and fluorescein (Figure 1.1), are on the market for facile 
modification and use, the difluoro - boraindacene family of dyes has garnered much attention for 
their seemingly unlimited versatility.  
 
Figure 1.1: Generic structure of common fluorophores including BODIPY. 
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Boron dipyrromethene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene, hereafter referred to 
as BODIPY, is formed from the complexation of a dipyrromethene ligand with a disubstituted 
boron moiety, typically in the form of BF2, achieved using boron trifluoride diethyl etherate.
6-8 
The dipyrromethene ligand is formed from the linking of the α-position of two pyrroles via a 
methine bridge. Complexation of the dipyrromethene ligand with the BF2 unit forms a rigid 
tricyclic system and prevents cis/trans isomerization of the dipyrromethene, allowing for the 
conjugation of π-electrons along the carbon-nitrogen backbone which leads to unusually high 
fluorescence quantum yields.9 The BODIPY fluorophore, once complexed with BF2 can be 
compared to a “constrained” cross-conjugated cyanine dye possessing fixed planarity of the 
fluorophore’s conjugated π-system.10 The resultant zwitterionic species possesses an overall 
neutral charge. 
Several approaches have been accepted in the systematic naming the BODIPY core. The 
first utilizes the similarity in BODIPY’s structure to that of s-indacene, it’s all-carbon tricyclic 
analog (Figure 1.2).6 Following this identification system, the 3- and 5- carbons are referred to as 
alpha and the 1, 2, 6 and 7 are denoted as beta, parallel to that of pyrrole.11 The C-8 position is 
referred to as the meso-position, following the accepted labeling of porphyrinic systems.7 
 
 
Figure 1.2: Naming and numbering of BODIPY based on s-indacene. 
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Analysis of single crystalline BODIPY chromophores units identifies a three-ring fused 
framework, as shown in Figure 1.3, exhibiting strong π-electron delocalization across the nine 
carbons and two nitrogens making up the central six-membered ring and the two flanking five-
membered pyrrolic rings.12 This π-conjugation is disrupted by the B-N bonds, indicating the BF2 
moiety plays very little to no role in the system’s extended π-delocalization. The mean bond length 
between N1-C3 depicts double bond character, whereas the N1-C4 indicates single bond character. 
The central boron atom displays a distorted tetrahedron BF2N2 configuration as noted by the N1-
B1-N2 and F1-B1-F2 bond angles.
13 The BODIPY fluorophore is isoelectronic with heptamine 
cyanine possessing 12π electrons delocalized over eleven atoms, rather than the monomethine 
cyanine dye with 6π electrons equally distributed over five atoms the BODIPY more closely 
resembles.14 
The monoclinic unit cell of the BODIPY fluorophore consists of four molecules stacked 
head-to-tail, an arrangement that aids in optimizing π–π interactions between adjacent hydrophobic 
BODIPY molecules and countering the variability of the fluorine atoms’ dipole moments.15 The 
slight polarization of the heteroatoms generates electronically diverse reaction sites of the 
BODIPY carbon core, favoring both nucleophilic and electrophilic reactions. Such electronic 
diversity across a single molecular structure opens the door for countless structural modifications 
on the core.16 
Known affectionately as “porphyrin’s little sister,” these fluorescent molecules bear 
outstanding optical properties compared to traditional fluorophores such as rhodamines and 
fluorescein.6 Like porphyrins, BODIPY and its derivatives absorb strongly visible region, have 
relatively sharp emission peaks, possess high fluorescence quantum yields, and high molar 
absorption coefficients (in the range of 40,000 to 80,000 M-1 cm-1), and have relatively small 
4 
 
Stokes’ shift (around 10 nm).6, 9 Other favorable properties of BODIPY as imaging agents include 
negligible triplet-state formation of non-halogenated BODIPYs (due to a slow rate of intersystem 
crossing (ca. 106 s-1)), resistance toward self-aggregation, and fluorescence lifetimes in the 
nanosecond range.1 Additionally, most BODIPY dyes exhibit thermal and photostability in solid 
and solution phases, are highly soluble in most organic solvents, and are insensitive to solvent 
polarity and pH.7, 17, 18 
 
 
 
 
 
 
 
Figure 1.3: The crystal structure of unsubstituted BODIPY elucidated by X-ray analysis with 
atoms labelled and 50% probability displacement ellipsoids.19 
 
The BODIPY absorption profile shows a strong, narrow absorption band in the visible 
region signifying the S0-S1 (π-π*) transition with a shoulder of high energy around 480 nm 
assigned to the 0 - 1 vibrational translation. A broad, much weaker band around 350 nm denotes 
the S0-S2 (π-π*) transition.20 Upon excitation to either the S1 or S2 states, an equally narrow 
emission band of mirror image to the absorption spectra is observed from the S1 state. Most 
BODIPYs emit at wavelengths less than 600 nm, routinely providing yellow to green emissions 
(500 nm – 590 nm).6, 21 Unsubstituted BODIPY typically absorbs near 500 nm and emits around 
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510 nm. Small Stokes’ shifts are routinely seen and indicate a modest change in the core structure 
following S0-S1 transition and vibrational relaxation.
22 
Addition of functionality at any position of the aromatic core alters the photochemical 
profile to varying degrees, dependent upon the groups added. The BODIPY core can be easily 
modified to bear desired functionalities at the α-, β-, and meso - positions as well as through 
substitution of the fluorines. As seen in Figure 1.4, the addition of functional groups to the 
BODIPY core can have varying effects dependent upon the placement and symmetry of the 
substituent.23, 24 Symmetrical BODIPYs 1 and 3 appear to produce more red-shifted absorptions 
compared to either equally substituted asymmetric counterpart. However, greater substitution of 
the BODIPY core does not necessarily produce a larger bathochromic shift, as depicted upon the 
comparison of the penta-substituted BODIPY 4 to the tetra-substituted BODIPY 3. 
 
 
Figure 1.4: The effect of substituents on the absorption wavelength of simple BODIPYs.23, 24 
 
Red to NIR shifts are typically achieved though facile modification to the BODIPY core, 
extending the degree of π-delocalization. In addition, the emissive behavior of BODIPY 
fluorophores are greatly influenced by steric and electronic interactions of substituents. Rotation 
  
             EtOH      EtOH           EtOH             THF 
            ΦF 0.81      ΦF 0.70        ΦF 0.80          ΦF 0.56 
       λabs = 507 nm                   λabs = 499 nm  λabs = 505 nm     λabs = 500 nm 
       λem = 520 nm                    λem = 509 nm                 λem = 516 nm      λem = 510 nm 
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or rigidity of pendant components, as well as their electron-donating or withdrawing effects on the 
conjugated core greatly influences both the brightness and absorptive and emissive properties of 
BODIPY.25 
Increasing development of facile synthetic modifications had led to an outpouring of 
research dedicated to functionally diverse BODIPY dyes. Many of the techniques used in 
modification of the spectroscopic characteristics and functional properties of these versatile 
fluorophores to develop multi - purpose fluorescent probes will be discussed within the pages of 
this dissertation. 
 
1.2 Synthetic Methodologies 
The first BODIPY was synthesized by Treibs and Kreuzer in 1968 by accident through the 
combining of 2,4-dimethylpyrrole and acetic anhydride in the presence of BF3
.OEt2, and was 
initially developed for use as tunable laser dyes.26 Immediately following its discovery, little work 
was done on this photo-stable substitute for fluorescein.6 It was not until the late 1980s that the 
potential of BODIPY in many areas, especially in cellular imaging, was recognized.  Work on 
BODIPYs boomed in the mid-1990 and has increased significantly since. Despite their initial lack 
of interest, study of these compounds has led to exuberant research interest in recent decades in 
many different applications which take advantage of their readily amended optical profiles 
yielding numerous patents and review articles.1, 6, 7, 9, 22 Extensive research surrounding the 
reactivity of the BODIPY core has produced methodologies for synthesizing amphiphilic and 
longer-wavelength absorbing and emitting fluorophores for a plethora of applications including as 
fluorescent labels for biomolecules and cellular imaging, light-emitting devices, drug delivery 
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agents, photosensitizers, fluorescent switches, chemosensors, energy transfer cassettes, and solar 
cells. 
 
1.2.1 Synthesis of the BODIPY Core 
Various methodologies derived from the well-known chemistry of pyrroles and 
dipyrromethanes have been utilized in the synthesis of these fluorophores. Incorporation of readily 
available pyrroles with highly electrophilic carbonyl compounds yields a variety of 
dipyrromethene ligands. Complexation with BF2 in the presence of a non-nucleophilic base, 
typically a secondary or tertiary amine, affords the BODIPY fluorophore in moderate, yet 
reproducible yields. 
Although literature boasts countless reports on the ease of synthesizing highly substituted 
BODIPY cores, the synthesis of the unsubstituted parent fluorophore remained a challenge. The 
highly unstable dipyrromethene precursor made producing the “naked” core in appreciable yields 
difficult. Not until recently, through the simultaneous work of three independent research groups, 
was a route to producing this compound established. The first synthetic route was reported by 
Bruce and co-workers (Scheme 1.1, Route A),19 in which the highly reactive precursor 
dipyrromethane 6 was oxidized to the dipyrromethene. To control side reactions, the DDQ 
oxidation was carried out at -78°C under inert conditions followed by subsequent in situ 
complexation with BF3
.OEt2 with the aid of DBU to form the target compound in 5-10% yield. 
The parent BODIPY was characterized by 1H-, 13C-, 11B-, and 19F-NMR and single crystal X-ray 
analysis. 
Applying a classic one-pot synthetic approach of combining pyrrole-2-carbaldehyde 7 and 
pyrrole 8 in the presence of an acid catalyst followed by complexation of BF2 in the presence of a 
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base, Wild and co-workers16 were able to synthesize the desired BODIPY 5 in 8% yield (Route 
B). Extensive column chromatography was employed in order to produce product of pure quality. 
The resultant BODIPY displayed the characteristic green fluorescence with a maximum 
absorbance wavelength of 503 nm and a fluorescence maximum wavelength of 512 nm. Over the 
course of experimentation it was noted that BODIPY exhibits high photostability (τ = 7.2 ns) but 
readily decomposes above 50°C, as a result of lacking substitution. 
 
 
Scheme 1.1: Synthesis of the unsubstituted BODIPY 5. 
 
The most efficient route was penned by Pena-Cabrera and co-workers (Route C),15 
producing the target parent BODIPY in an impressive 98% yield. The mild reaction between 8-
thiomethyl BODIPY 9 and trimethylsilane with the aid of a stoichiometric amount of copper(I) 
thienyl-2-carboxylate (CuTc) and a catalytic amount of palladium in THF stirred at 55°C for 45 
minutes, afforded the desired BODIPY 5 which exhibits quantum yields up to 94% in both polar 
and non-polar solvents. 
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1.2.2 Synthesis of Symmetric BODIPY Dyes 
Syntheses of 8- or meso- substituted BODIPYs are found most frequently in literature and 
involve preparation of the dipyrromethene ligand by acid-catalyzed condensation of two pyrroles 
with an acid chloride, anhydride, or aryl-aldehyde. Reaction with an aldehyde affords the 
dipyrromethane rather than the dipyrromethene and must be subsequently oxidized to generate the 
desired conjugated bipyrrolic system. In order to avoid forming pyrrolic chains longer than two 
units, the starting pyrrole must have only one α-position available for reaction.27 Once formed, the 
dipyrromethene ligand can be complexed to form the BODIPY by reacting with BF2
.OEt2 in the 
presence of a tertiary amine. Substituted BODIPYs, especially at the meso-position, show greater 
stability than their meso-unsubstituted counterparts. As described, this two/three step-one pot 
reaction has become standard practice for synthesizing meso-substituted BODIPYs. These 
relatively mild reaction conditions allow for the formation of BODIPYs bearing a large range of 
functional groups. With such diversity of functional groups tolerated by this synthetic method, the 
functionalized meso-substituent has served as a point of embellishment to build larger, specific 
function fluorophores for a variety of purposes, most extensively for use as bioimaging labels.28 
Most common syntheses of symmetrical BODIPYs involve condensation of an aryl-
aldehyde with two equivalents of an α-free pyrrole. An oxidation step is required to transform the 
dipyrromethane to a dipyrromethene unit before further complexation with BF2. The use of 
oxidizing agents such as DDQ (2,3-dichloro-5,6-dicyano-p-benzoquinone) and p-chloranil are 
common. However, use of such agents creates byproducts which must be separated by tedious 
chromatography. This method produces a symmetric structure bearing the aryl moiety at the meso-
position, Scheme 1.2.  
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Another common method of synthesizing symmetrical BODIPYs, also shown in Scheme 
1.2, involves the condensation of an acid chloride with two units of an α-free pyrrole. Unlike the 
synthesis involving aryl-aldehydes, there is no need for an oxidation step in forming 
dipyrromethene from the dipyrromethane, often resulting in larger yields with less purification 
required. 
 
 
Scheme 1.2: General procedure for the synthesis of symmetrical BODIPY via condensation of 
two pyrrole units with an activated carbonyl. 
 
Despite the addition of an aromatic substituent to an extended π-system, an aryl-moiety at 
the meso-position typically lies almost perpendicular to the BODIPY core, thus practically 
eliminating conjugation.6, 7, 13, 29 Due to the opposite orientation of the meso-substituent and the 
BODIPY core, the aryl-group participates little in electron conjugation which prevents it from 
having any significant effect on altering the absorption and emission wavelengths of the 
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fluorophore. Substituents at the 1,7-positions of the core prevent free rotation of the meso-group 
which reduces energy lost from excited states by non-radiative decay.7 Ortho-substituents on a 
phenyl ring located at the meso-position also prevent free rotation which increases the brightness 
of fluorescence. Although the meso-group often has little effect on the photophysical properties of 
BODIPY, variations in the meso-position yield structurally and functionally unique compounds. 
This also allows for selective groups to be introduced without affecting the optical properties of 
the dye. Such variations allow for these compounds to be used in many applications across many 
fields, from medicinal chemistry to materials chemistry to imaging and energy transfer.  
Acid anhydrides can also be used in synthesizing symmetrical BODIPYs. The use of the 
anhydride produces a free carboxylic acid which may be utilized in labeling biological molecules 
such as proteins, DNA, and lipids.17, 30  
Symmetric BODIPYs lacking a meso-substituent are obtained from condensation between 
a carbonyl-bearing pyrrole and an α-free pyrrole of equal substitution. An acid catalyst, typically 
p-toluenesulfonic acid or Montmorillonite clay, is required to generate the pyrrole carbinyl cation 
which condenses with a second α-free pyrrole to form a dipyrromethene that is complexed by 
BF2.
31, 32 In a modified approach reported more recently by Wu and Burgess,33 pyrrole-2-
carbaldehyde self-condenses in the presence of phosphorous oxychloride, via a dipyrromethenium 
cation and dichlorophosphate anion which readily complexes with BF2. This new method produces 
the desired meso-free BODIPY in much higher yields than the conventional approach. 
 
1.2.3 Synthesis of Unsymmetrical BODIPY Dyes 
Unsymmetrical BODIPYs can be formed from the acid-catalyzed condensation of a 
carbonyl-containing pyrrole and a dissimilar α-free pyrrole in similar protocol to that of acid 
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chloride condensation, Scheme 1.3.34 The condensation of a 2-carbonyl-pyrrole with an α-free 
pyrrole under catalytically acidic conditions typically affords the desired BODIPY in high yields 
when electron-rich pyrroles are used. When electron-deficient pyrroles are employed, self-
condensation of pyrrole-2-carboaldehyde are favored resulting in higher yields of the undesired 
symmetric BODIPY. 
 
 
Scheme 1.3: Common procedure for the synthesis of asymmetric BODIPY from carbonyl-
substituted pyrrole. 
 
The resultant dipyrromethene is usually isolated in its salt form, which readily reacts with 
BF3
.OEt2 in the presence of a tertiary amine to afford the desired BODIPY. This method allows 
for the formation of BODIPYs bearing different functional moieties on the left and right 
hemispheres facilitating further functionalization and bioconjugation. 
 
1.3 Derivatization of the BODIPY Platform 
In addition to their outstanding photophysical properties, these intrinsically electron-rich 
compounds are relatively easy to synthesize and derivatize due to their variable reactivity to 
numerous reaction types. Functionality may be added to nearly every position of the formed 
BODIPY core, as well as, being incorporated via commercially and synthetically accessible 
substituted pyrroles in their initial synthesis. The absorption and fluorescence properties of 
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BODIPY are highly influenced by the extent of electron delocalization around the core and also 
through conjugated substituents, and as such, may be tuned to have particular photophysical 
characteristics. However, there is still a lack of strategy for incorporation of function groups that 
allow for facile conjugation to biomolecules. 
Many research groups, including Vicente,29, 35, 36 Burgess,37 Ziessel,8 Boens and Dehaen,1, 
38 Nagano,39 Akkaya,40 O’Shea,41 Rurack and Daub,42 and Carreira43 are intensively exploring 
strategies for modifying the optoelectronic properties as well as the function of these dyes, 
including i) electrophilic substitutions at the 2,6-positions, ii) addition of functionalized styryl 
groups at the 3,5-positions via electrophilic methyl groups, iii) nucleophilic substitution at the 3,5-
positions, iv) Palladium-mediated cross couplings with halo-derivatives, v) replacement of the 
meso-carbon with nitrogen, vi) fusion of aromatic rings to the pyrrolic units,  vii) replacement of 
pyrrole with isoindole or indole derivatives and viii) nucleophilic substitution of fluorine at the 
boron center. Halogens typically located at the 2, 3, 5 and 6 positions are capable of undergoing 
metal-mediated cross-couplings. Examples of Suzuki,44-46 Sonagashira (Scheme 1.4),36, 44, 47 
Heck48, and Stille49 couplings can be found in literature. 
 
Scheme 1.4: Sonagashira couplings of halogenated BODIPYs. 
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1.3.1 Modification at the C8-Position 
Functionalization at the C-8 position or meso-position occurs most readily compared to 
substitution at the pyrrolic positions. Functionality at this position is incorporated during the 
synthesis of the dipyrromethane via acid-catalyzed condensation of pyrrole with a specifically 
substituted aryl-aldehyde or acyl-chloride.50 This point of variability remains the most utilized for 
its versatility in incorporating utility groups such as ion capture ligands,1, 6, 51 donor-acceptor 
groups,52-54 chiral auxiliaries,55, 56 water solubilizing groups,5, 18 and biomolecules57 for 
applications as pH probes, chemosensors, light-harvesting devices and biological labels (Figure 
1.5, structures 10 to 13). 
The effect of electron-rich or electron-deficient groups at the meso-position has been 
studied extensively by Boens and co-workers.1, 38, 58 Notably, the meso-substituent of aryl- or alkyl- 
type has very little effect on the optoelectronic properties of the BODIPY. Since this group favors 
orienting itself orthogonally to the BODIPY core, it does not extend the electron conjugation of 
the system. Although conjugation is unaffected by this group, the compound’s fluorescence 
efficiency is impacted by the free rotation of the meso-substituent. Incorporation of substituents at 
the 1,7-positions of the core sterically impedes this rotation and increases the fluorescence 
quantum yield. 
Exchange of the meso-carbon for nitrogen generates an analogous class of compounds 
referred to as aza-BODIPYs (Figures 1.5, structures 14 and 15, and Figure 1.6). Despite the 
predecessor dipyrromethene having been in chemical existence for some time, the synthesis and 
use of aza-BODIPYs has only recently garnered attention. Like BODIPY, aza-BODIPY has high 
molar extinction coefficients and moderate fluorescence quantum yields (ca. 0.20 - 0.40). 
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Incorporation of the lone pair on the nitrogen greatly influences the HOMO-LUMO energy 
gap through stabilization.6 This enhanced stability creates a red-shift in the absorption and 
emission profiles into the 650 - 850 nm range.59 Aza-BODIPYs can be synthesized from nitroso-
bearing pyrroles, via Michael addition products from chalcones and formamide, and from cyanide 
Michael addition products and ammonia.60,61,62 This class of BODIPY has found use as 
photosensitizers,49, 63 near-IR emitting chemosensors and imaging probes,43, 64-66 and as fluorescent 
labels.67, 68 
 
 
Figure 1.5: Chemical structures of various meso-substituted BODIPYs from literature: 10,58 11,69 
12,70 13,58 14,71 and 15.43 
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Figure 1.6: Structure comparison of BODIPY and aza-BODIPY dyes. 
 
1.3.2 Functionalization of the 1, 3, 5, 7-Positions 
Due to the electron density concentrated within the nine carbons and two nitrogens of the 
BODIPY core, methyls located at the 1, 3, 5, and 7-positions are strongly nucleophilic, with the 
3,5-methyls bearing the most nucleophilic behavior, and can be easily deprotonated under mild 
basic conditions. Most commonly, the in situ deprotonated anionic methene is added to an 
electron-rich aromatic aldehyde by way of a Knoevenagel condensation to generate a styryl group 
(Figure 1.7, 16, 17).72-74 Although the tetra-styryl BODIPY has been synthesized by activation and 
subsequent condensation of the 1, 3, 5, and 7-methyls,75 extension of π-conjugation and addition 
of functionality is most frequently accomplished through the 3,5-methyls. Addition of conjugation 
at the 3,5-positions generally produces a greater bathochromic shift (ca. 50 - 100 nm) than adding 
conjugation through the 2,6-positions, displaying the greatest shift when all four methyls have 
converted to styryl groups. 
Conjugation with highly decorated aryl-aldehydes offers a convenient approach for adding 
pendent functionalities that is easily controllable through simple modification to reaction 
conditions. Extension of the π-system, typically through the 1, 3, 5, and 7-positions effects the 
absorption and emission profile of the BODIPY system most drastically, although addition at the 
2,6-positions does have an effect as well. Incorporation of electron-donating groups immediately 
adjacent to the core creates a red-shift in the absorption and emission maxima.7 
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Furthermore, good leaving groups, such as chlorines or iodines occupying the 3,5- 
positions allows electron-deficient BODIPYs to undergo nucleophilic substitution reactions (as 
shown by structure 18). Various nucleophiles, including carbon, nitrogen, oxygen, and sulfur, have 
been used to add functionality or to extend conjugation and red-shift the emission profile of the 
BODIPY.17 The presence of halogens at the 3,5-positions also allows the use of palladium-
mediated couplings for the incorporation of ethynyl, ethenyl, and aryl-substituents for use in long 
wavelength BODIPY-based (19) fluorescent biosensing material and biolabels. 
 
Figure 1.7: Chemical structures of 1,3,5,7-modified BODIPY dyes: 16,76 17,75 18,77 19.78 
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1.3.3 Functionalization of the 2, 6-Positions 
Electronic mapping study of resonance structures of the BODIPY core show that the 2 and 
6-positions bear the least positive charge and are the least electrophilic, Figure 1.8. As such, they 
readily undergo electrophilic aromatic substitution reactions. 
 
 
Figure 1.8: Resonance delocalization of positive charge over the BODIPY core. 
 
Despite there only being a few electrophilic substitution reactions reported, including 
halogenation (Br, Cl and I),39 nitration (via nitric acid),79 sulfonation (by way of chlorosulfonic 
acid, Figure 1.9, 20),17, 80, 81 and most recently formylation,50 they have been extensively employed. 
The use of sulfonate groups to improve-water solubility of the typically lipophilic core without 
impacting the BODIPY’s optical properties is seen frequently in literature reports of BODIPYs 
with biological purposes. 
The introduction of halogens, usually Br or I, at these positions causes a bathochromic shift 
in the absorption and emission spectra and fluorescence quenching in comparison to the parent 
dye. This can be attributed to an heavy atom effect.7 Subsequent reaction occurs readily at these 
positions while leaving the BF2 chelate intact. This type of modification is usually used as a 
precursor to palladium-catalyzed couplings, including Suzuki,82 Stille,78 Sonagashira (e.g. 21),83 
and Heck couplings.84 
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Figure 1.9: Chemical structures of 2,6-functionalized BODIPYs from literature: 20,30 21.85 
 
1.3.4 Boron Center 
To date, few attempts have been made to substitute the fluorines of the boron difluoride 
chelate. Functionalization at this position has become an increasingly more popular target and 
more manuscripts are being published to that effect. Incorporation of alkyl groups,86 large aryl 
groups,87 ethynyl groups and ethynyl aryl moieties,8, 21, 88-91 and alkoxy groups92 can be found in 
literature (Figure 1.10, structures 22-24). Replacement of the fluorines by carbon, ethynyl, and 
oxygen nucleophiles has led to a family of photostable, highly luminescent redox-active C-
BODIPYs, E-BODIPYs, and O-BODIPYs, respectively.7 Modification of the boron chelate has 
shown to enhance the stability and Stokes’ shift of the fluorophore. Substitution of fluorine 
requires the use of organometallic compounds, typically an organolithium or Grignard complex, 
in order to be accomplished. 
The grafting of large light-harvesting units onto the core through the boron chelate has 
been explored for use as rapid energy transfer cassettes by way of through-space energy transfer 
from the donor to the core acceptor that is facilitated by significant overlap of the donor’s emission 
spectra with the absorption spectra of the acceptor. Much like the meso-substituent, attachments 
through the boron center do not affect the photophysical properties of the fluorophore. These novel 
20 
 
donor-acceptor systems have found possible uses as molecular dyads, energy transfer cassettes, 
electroluminescent devices, photovoltaic and supramolecular assemblies. 87, 89, 93 
 
1.3.5 Ring Fusion 
In order to shift the absorption and emission profiles of BODIPY into the far red to near-
IR regions, an extended electron delocalization pathway is needed. As seen frequently in literature, 
this can be accomplished through the addition of styryl and thienyl groups, as already discussed.46 
Another way to achieve extended conjugation is through the fusion of benzene rings directly to 
the pyrrolic units.94-96 
 
Figure 1.10: Chemical structures of F-substituted BODIPYs from literature: 22,97 23,8 24.88 
 
Red and near-IR emitting dyes have become a valuable target for biological imaging. 
Fusion of aromatic rings onto the BODIPY core has been recently utilized in achieving dyes with 
longer wavelengths. Strategies involving the use of aryl-fused pyrroles, 2-acetyl phenols,91 and 
retro Diels-Alder syntheses of norbornane-derived pyrroles12, 98 have allowed for the formation of 
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these π-extensive systems, Figure 1.11, 25 to 27. Incorporation of various benzene and substituted 
benzene,91 indole and isoindole,99, 100 and larger aromatic systems101 fused to the BODIPY core 
has allowed for the development of red-shifted, brighter emitting fluorophores compared to their 
unconstrained analogs. 
All of these various ways of modifying the BODIPY core increase the versatility of these 
dyes immensely. Simple modifications allow for these compounds to be tailored to particular 
wavelengths or functions. The possible uses for these readily synthesized and functionalized small 
molecules are endless. 
 
Figure 1.11: Chemical structures of aromatic-fused BODIPYs from literature: 25,101 26,102 27.102 
 
1.4 Applications of BODIPY Dyes 
Most commonly, these fluorophores are used as tunable laser dyes,45 in biological labeling 
and imaging,30, 36 and as electroluminescent devices.53 Other current uses include donor-acceptor 
systems (energy transfer cassettes),54, 89, 93, 103 fluorescent chemosensors,29, 47, 100 electron transfer 
reagents,72 light-emitting and ion signaling devices,1  and photodynamic therapy (PDT) agents.104, 
105  
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Fluorescence microscopy has become an ever more valuable tool for imaging in living 
cells. In addition to providing high sensitivity and specificity, microscopy yields good spatial and 
temporal sampling ability, instruments are simple to operate, and the technique is minimally 
invasive to cells.1 Because light can traverse biological tissues, microscopy imaging makes it 
possible to visualize location and concentration of analytes contained within all parts of a living 
cell. BODIPYs have been used in bioimaging in many ways.  
 
1.4.1 Biological Applications 
In the biological realm, fluorescent dyes have demonstrated to be essential for use as 
reporting molecules for various intracellular analytes (metal ions and protons) and biomolecules 
including peptides, proteins, enzymes, nucleic acids, and lipid membranes. Particularly, 
fluorescent organic dyes have been employed as non-radioactive ligand as biomarkers in in vivo 
imaging and for biological processes.80 The advancement of bioanalytical and optical imaging 
techniques in recent years has created a need for dyes that fluoresce in the red and near-IR region 
of the visible spectrum. Advancements in DNA sequencing, nucleic acid detection, gel 
electrophoresis, in vivo imaging, vasculature mapping and tissue perfusion have driven such a 
demand.106 
 Working in the red/near-IR region has many advantages. Imaging in the 600- 900 nm 
region of the electromagnetic spectrum improves light penetration and helps to eliminate much of 
the light scattering caused by endogenous chromophores found within biological tissues. 
Chromophores such as lipids, hemoglobin, some amino acid side chains, and other chemicals 
present in living tissues absorb and scatter short wavelength visible light, drastically limiting its 
penetration depth to only a few millimeters, as displayed in Figure 1.12. By utilizing longer 
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wavelength absorbing and emitting fluorophores, the large amount of background noise caused by 
this tissue auto-fluorescence which obscures the detection and quantification of biological signals 
is mostly eliminated.9, 36 Advantageously, the absorption coefficient for near-IR light in tissues is 
much lower than shorter wavelength visible light which sanctions deeper penetration up to several 
centimeters.4 
In addition to greater penetration depth, light scattering is greatly reduced in the near-IR 
region due to the inverse fourth power of the wavelength proportionality to the scattering intensity. 
The result is a low signal to noise ratio of the near-IR radiation which corresponds to highly 
sensitive signal detection. Furthermore, employing long wavelength light shows low interference 
from Raman scattering and reduced sample degradation. Because of these advantages, the 600 - 
900 nm region of the electromagnetic spectrum has been deemed the “biological window.” With 
such imaging advantages paired with the availability of low-cost long wavelength lasers and 
red/near-IR detectors, an influx of research has surrounded the design, synthesis, and evaluation 
of novel red/near-IR fluorescent probes for a multitude of applications. 
 An ideal near-IR fluorescent dye should possess a number of desirable characteristics 
including high molar absorption coefficients, high fluorescence quantum yields, photo- and 
chemo-stability, good solubility in aqueous media, resistance toward self-aggregation, and facile 
synthetic and functionalization routes allowing for the construction and modification of fluorescent 
probes and indicators.1 
 The development of near-IR fluorescent organic dyes with greater photostability and 
fluorescence maxima based on porphyrin, phthalocyanine, cyanine, fluorescein, squaraine, and 
BODIPY platforms has made significant progress in recent decades (Table 1.1). Although strides 
have been made in this field, current dyes are not without limitations. Low fluorescence quantum 
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yields, limited solubility in aqueous media, and poor photo- and/or chemo-stability are some of 
the drawbacks of current fluorophores. 
 
 
Figure 1.12: Tissue autofluorescence in the mouse using various excitation/emission filters. a) no 
filter; b) blue/green filter; c) green/red filter; d) near-IR filter. GB: gall bladder, SI: small intestine, 
BI: bladder. Reprinted with permission from [107] Copyright (2002) Elsevier. 
 
 Currently, cyanine-based dyes form the largest group of long wavelength fluorophores for 
biological imaging purposes. However, only indocyanine green (ICG:cardiogreen) is FDA and 
EMA approved for medicinal near-IR imaging and has been used for many years as a non-toxic, 
minimal side effect angiographic contrast agent. Regrettably, ICG has a low quantum yield (0.3% 
in water and 1.2% in blood) like most cyanine-derived dyes, and lacks any pendent functionality 
for biomolecule conjugation.108 A newer, improved near-IR fluorescent imaging agent of greater 
promise, IRDye®800CW, has undergone extensive study. This dye bears a reactive N-
hydroxysuccinimide or maleimide group which allows it to be attached to targeting 
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biomolecules.109 Although this dye has been investigated in pre-clinical trials, it has yet to undergo 
clinical testing. 
 With so many dyes currently on the market with countless shortcomings, there has been a 
drive to develop a new class of readily modifiable near-IR dyes for various biological applications. 
The BODIPY-family of fluorophores has caught much interest as small, fluorescent molecules 
with potential applications as stains, indicators, and labels. Potently fluorescent BODIPYs 
inherently possess many of the desired characteristics of near-IR dyes such as strong, narrow 
spectral bandwidths (for multicolor imaging), high molar absorption coefficients (log εmax < 8.8), 
solvent polarity ineffectualness, and small Stokes’ shifts. Compared with positively charged 
rhodamines and cyanines, BODIPYs have an overall neutral charge and are relatively nonpolar.110 
With the lack of a charge on the BODIPY platform, the affinity for targeted analytes or receptors 
is enhanced. BODIPY has found many application in the biological imaging realm particularly as 
cellular stains, fluorescent analyte indicators for protons and metal ions, as labels for various 
biomolecules, and as enzymatic activity monitors. 
 
1.4.1.1 Cellular Stains 
Under the lens of a microscope, most biological samples, especially cells, appear relatively 
transparent. The most highly studied parts of the cell, the internal organelles, are so transparent 
that they are difficult to see even under the lens of a high powered microscope. Cellular stains are 
valuable tools for the visualization of the cell and its organelles. Organelle specific stains allow 
for microscopic imaging which provides greater understanding of cell morphology and function. 
Small, neutral dyes, such as BODIPYs, have gained favor as cellular stains for the ability to 
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permeate cell membranes and be retained within the cell depending on their designed reactivity 
and inherent hydrophobic nature. 
 
Table 1.1: Various commercially available NIR dyes for bimolecular conjugation. 
 
Dye Name 
(Manufacturer) 
 
 
Chemical Structure 
Absorption 
Maximum 
(nm) 
Emission 
Maximum  
(nm) 
 
 
ICG 
(Sigma Aldrich) 
 
 
 
800 
 
 
 
810 
 
 
 
 
 
IRDye®800CW 
NHS ester 
(LI-COR 
Biosciences) 
 
 
 
 
 
 
774 
 
 
 
 
 
 
789 
 
 
 
 
Dye 783 
NHS ester 
(Dyomics 
GmbH.) 
 
 
 
 
783 
 
 
 
800 
 
 
 
La Jolla Blue 
(Hyperion Inc.) 
 
 
 
 
680 
 
 
 
700 
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Table 1.1: (continued) 
 
Dye Name 
(Manufacturer) 
 
 
Chemical Structure 
Absorption 
Maximum 
(nm) 
Emission 
Maximum  
(nm) 
 
 
BODIPY 
630/650-X 
Succinimidyl 
ester 
(Life 
Technologies 
Inc.) 
 
 
 
 
625 
 
 
 
640 
 
 
BODIPY 
650/665-X 
Succinimidyl 
ester 
(Life 
Technologies 
Inc.) 
 
 
 
 
646 
 
 
 
664 
 
 
A number of cell-permeable BODIPY dyes, either conjugated to a biomolecule or designed 
as a target-specific reactive fluorophore, have found use both in vitro and in vivo intracellular 
imaging. The dyes utilized for imaging the organelles of greatest interest to cellular function, the 
Golgi apparatus, endoplasmic reticulum, mitochondria, lysosomes and nuclei, are designed in such 
a way that their optoelectronic properties are not altered once in the cellular and subcellular 
environments.37 Some of the best known commercially available for visualizing the endoplasmic 
reticulum and Golgi apparatus are the red fluorescent BODIPY TR-glibenclamide and BODIPY 
TR-ceramide, respectively, manufactured by Life Technologies, Inc, Table 1.2.  As one of the 
largest commercial producers of BODIPYs and holding several patents on BODIPY fluorophores, 
Life Technologies, Inc, also produces numerous yellow or green-fluorescent BODIPY conjugates 
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for live cell or fixed cell imaging and for flow cytometry including BODIPY FL-ceramide, 
BODIPY FL-C5-sphingomyelin, and BODIPY-brefeldin A conjugates. Low molecular weight 
neutral BODIPY dye conjugates are found to permeate living cells better than their charged 
conjugate counterparts. Staining of cells and their organelles using low concentrations of BODIPY 
fluorophores has shown to lack any toxic effects on the cells.106  
 
Table 1.2: Commercially available BODIPY-based cellular stains from Life Technologies Inc. 
Dye Name Chemical Structure Absorption 
Max (nm) 
Emission 
Max (nm) 
 
BODIPY 
FL-ceramide 
 
 
 
505 
 
 
520 
 
 
BODIPY 
FL-C5-sphingomyelin 
 
 
 
 
505 
 
 
 
520 
 
 
BODIPY-brefeldin A 
 
 
 
558 
 
 
568 
 
 
 
 
BODIPY 
TR-glibenclamide 
 
 
 
 
 
 
587 
 
 
 
 
 
615 
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1.4.1.2 Environmental Indicators 
Intracellular pH and metal ions have great impact on cellular function including numerous 
biological processes and disorders. The need for selective and sensitive fluorescent chemosensors 
has amplified and has led to extensive research interest over the recent decade. The design of many 
fluorescent sensors are based on one of two models; 1) fluorophore-spacer-receptor systems, or 2) 
intrinsic fluorescent probes, in which the receptor is a part of the π-electron system of the 
fluorophore and affects the absorption/emission profile.  
Photoinduced electron transfer (PET) and internal charge transfer (ICT) processes are the 
fundamental principles fueling the fluorophore-spacer-receptor systems. Alterations in either the 
fluorescence intensity or wavelength correspond to the binding of an analyte, either a proton or a 
metal, to the active site of the sensor. In both PET and ICT systems, the absence of an analyte in 
the binding site quenches the fluorescence due to PET or ICT in the excited state.111 
ICT sensors display a significant emission spectra shift and a moderate increase in 
fluorescence intensity when the analyte is bound. An analyte bound to a PET sensor, on the other 
hand, inhibits the PET which increases emission intensity without causing a shift in the optical 
spectra. Due to the greater sensitivity of fluorescence, interaction with an analyte is usually 
measured by the easily monitored “off/on” or less common “on/off” fluorescence switching.55 
BODIPY chemosensors have shown to have high potential for colorimetric and 
fluorometric assays.112, 113 Several reports of fluorescent BODIPY-based sensors have been 
published for the detection of metal cations and anions, protons, pH, and reactive-oxygen species.1 
The sensing and imaging of pH,114 K+,77 Ni2+,115 Cu2+,29 Zn2+,116 Hg2+,117 and other metal ions in 
living cells (Figure 1.13, 28-30) is crucial for monitoring important cellular processes. The 
detection of protons, sodium, calcium, potassium, and transition metal ions using crown ethers,77, 
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118 cryptand,119 podand,120 2,2’-dipyridyl,121, 122 calixarene123 and p-(N,N-dialkyl)aniline42-based 
PET sensors, respectively dominate the literature.  
 
1.4.1.3 Biological Labels 
A growing demand for the visualization and investigation of function of proteins, enzymes, 
and other biomolecules in living cells has brought BODIPYs to the forefront of labelling 
biomolecules with fluorescent markers. Due to their outstanding photophysical properties and low 
cellular toxicities,36 BODIPYs have become one of the most promising candidates for fluorescent 
labels and probes. Their small molecular size allows for BODIPYs to be attached to biomolecules 
without significantly influencing the biological function. 
 
 
Figure 1.13: BODIPY based fluorescent indicators1 for Ca2+, Na+, Cu2+, and Zn2 +. 
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To date, several reports describe BODIPY-based fluorescent labels to target specific 
biological compounds such as DNA, RNA, lipids, amino acids, nucleotides, polystyrene 
microspheres, dextran, and proteins.111, 124-127 To accomplish such conjugations, BODIPY probes 
are functionalized with reactive pendent groups such as carboxylic acids, sulphonic acids, 
polyethylene glycol moieties, polysaccharides, and oligonucleotides.5 Various proteins including 
β-amyloid plaques,128, 129 Aβ1-42 soluble oligomers,130 and neurofibrillary tangles (NFTs) tau 
proteins131 have been visualized via ligand-targeted BODIPYs. 
BODIPYs have also found employment in various analytical techniques due to their high 
peak intensity which make them among the most readily detectable fluorophores. Oligonucleotide 
conjugates of BODIPY have been used in gel electrophoresis and DNA sequencing since the small 
fluorophore induces minimal effect on DNA fragment mobility during electrophoresis.110 
In addition to be attached to DNA and proteins extracellularly, many fluorescent BODIPY 
probes are being engaged in live cell labeling of biomolecules. There are a few reports in literature 
in which BODIPY-based imaging probes have shown promise for both single and two photon 
microscopic imaging of living tissue.132 Raymer and colleagues57 reported a BODIPY-labeled 
derivative of Soraphen A capable of binding to acetyl-CoA carboxylase (ACC) providing the 
ability to identify ACC inhibitors that bind to the Soraphen A site (Figure 1.14, 31 and 32). In 
another report by Wolfbeis and co-workers,133 biomolecules such as sugars, amino acids, and 
nucleotides could be labeled in vivo using copper-free and copper-mediated click chemistry. 
BODIPY-based clickable fluorophores were designed for the labeling of azide modified surface 
glycans of Chinese hamster ovary (CHO) cells.  
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Figure 1.14: BODIPY-labeled Soraphen derivatives.57 
 
1.4.1.4 Enzyme Substrates 
Fluorescent tags are often employed in assessing enzyme activity through the measurement 
of fluorescence change when a fluorophore is conjugated to a substrate and when the fluorophore 
is cleaved by the enzyme. BODIPYs have been linked to fatty acids, triglycerides, phospholipids, 
glycolipids, cholesterol, and a number of other biological substrates for fluorometric assays for 
measuring enzymatic activities of proteases, phospholipases, chloramphenicol acetyltransferases, 
amylase, and other enzymes.7, 28, 134-140 Many of the homogeneous fluorometric assays for 
proteases which utilize BODIPY fluorophore are based on Fluorescence Resonance Energy 
Transfer (FRET).141, 142 The BODIPY is conjugated to a protease substrate which yields a non-
fluorescent reporter moiety due to the “self-quenching” phenomenon. Once the protease enzyme 
hydrolyses the conjugate into smaller fragments, fluorescence is restored due to a disruption of 
intramolecular FRET quenching. The fluorescence restoration can be quantified to correlate with 
enzyme activity. This simple off/on measure of fluorescence in relation of enzymatic cleavage has 
formed the basis of both simple and continuum assays for numerous proteases.  
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In 1997, Jones and co-workers141 reported a pair of BODIPY-casein conjugates for the 
assay of protease activity.  Using a BODIPY whose fluorescence was heavily quenched when 
conjugated with casein, they reported a direct correlation in fluorescence restoration with enzyme 
activity as the fluorophore was cleaved from the substrate. Due to the lack of effect of solvent 
polarity and pH on the fluorescence of BODIPY, these fluorophores have produced greater assay 
sensitivity, and surpass the highly used fluorescein as an enzyme activity monitor, whose 
fluorescence has shown to be greatly affected by the solvent in which it is contained. Just over a 
decade later, Saba and co-workers143 reported a BODIPY-labeled sphingosine-1-phosphate lyase 
(SPL) substrate capable of effectively measuring SPL activity in tissues and cells. This new ω-
labeled BODIPY-sphingosine-1-phosphate lyase (BODIPY-S1P, Figure 1.15, structure 33) 
replaced the standard radioactive SPL assay which employed the photolabile and toxic, polar 7-
nitro-benz-2-oxa-1,3-diazole (NBD-S1P, 34) fluorophore.  
 
 
Figure 1.15: Sphingosine labeled BODIPY-S1P and NBD-S1P.143 
 
1.5 Research Outlook  
Despite the innumerable reports of BODIPY synthetic methodologies and derivatizations, 
little has been accomplished in exploring the capacity that BODIPYs hold for therapeutic purposes, 
as near-IR probes, and for positron emission tomography (PET) and single photon emission 
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computed tomography (SPECT) for in vivo imaging. Most of the available long-wavelength 
BODIPY dyes and bioconjugates emit at close to 600 nm and few water-soluble BODIPYs suitable 
for in vivo imaging have been reported in literature. Knowing these shortcomings, the synthesis, 
characterization, and in vitro evaluations of novel BODIPY dyes as dual purpose bioimaging and 
therapeutic agents will be discussed in the subsequent Chapters of this dissertation. 
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CHAPTER 2: SYNTHESIS, SPECTROSCOPIC STUDIES, COMPUTATIONAL 
MODELING AND IN VITRO EVALUATION OF A SERIES OF MESO-ARYL-
BODIPYS [a] 
 
2.1 Introduction 
Meso-aryl substituted BODIPYs riddle the literature for their ease in synthesis and readily 
generated diversity due to the multitude of aromatic aldehydes available both commercially and 
via facile syntheses.1-3 Benefits surrounding the ability to modify and functionalize the meso-
substituent without effecting the photophysical properties of the BODIPY core make it highly 
favorable for conjugation to biomolecules and other targeting groups. Meso-aromatic groups have 
also been employed to influence the hydrophilicity and targeting ability of BODIPY since 
BODIPY is inherently lipophilic.4 
The addition of halogens at every pyrrolic position of the BODIPY platform has been 
explored for their effect on the optical properties of the fluorophore as well as for their ability to 
facilitate aromatic substitution and palladium-catalyzed cross coupling reactions.5-7, 8, 9 The 
addition of heavy atoms to the BODIPY core has the potential to generate effective 
photosensitizers for photodynamic therapy (PDT) via enhanced intersystem crossing from the 
singlet to the triplet excited state. This conversion controls the production of singlet oxygen, the 
main cytotoxic species produced in PDT, due to spin-orbit coupling by the “heavy atom effect”.7, 
10, 11, 13, 14 Furthermore, the absorption and emission profiles of halogenated BODIPYs are also 
expected to be red-shifted compared with their non-halogenated analogs. Halogens can be readily 
installed via a variety of methods, most commonly through the N-halo-succinimide (NBS, NCS, 
and NIS) halogenation of starting pyrroles, dipyrromethenes, and unsubstituted BODIPYs.12-14 
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BODIPYs bearing halogens at the 1, 3, 5, and 7-positions have shown fluorescence enhancement7 
compared to the 2,6-halo BODIPYs and undergo nucleophilic aromatic substitution reactions with 
a multitude of nucleophiles and palladium-catalyzed Suzuki, Stille, Sonagashira, and Heck 
couplings.2, 15 In contrast, halogenation at the 2,6-positions is typically utilized to induce 
intersystem crossing (ISC) and effect spectral changes, as well as for preliminary platforms for 
subsequent palladium-mediated couplings.10 
BODIPY is highly favored for its fundamental properties and applications is various 
disciplines, but has recently emerged as a non-porphyrin photosensitizer for PDT.10 Banfi and co-
workers,4 note that heavy atomic halogens, Br and I, when located at the 2,6-positions of the 
BODIPY induce not only a red-shift in the photophysical spectra, but also display inhibited 
fluorescence caused by enhanced ISC from the singlet excited state to the triplet state due to heavy 
atom effect. The heavy atom effect is defined by large, electron rich atoms, such as halogens, 
enacting influence over the rates of ISC. ISC in BODIPY has been shown to progress faster for 
iodine compared to bromine due to its larger spin-orbit coupling.16 Halogens enhance ISC without 
exerting much change on the electronic structure of BODIPY and yield photosensitizers that can 
undergo the necessary singlet excited state to triplet excited state conversion by way of relatively 
large spin orbit coupling constants of high nuclear charge atoms.17 
 
2.1.1 Photodynamic Therapy  
 PDT is an effective and FDA approved treatment for lung, esophogeal, and cutaneous 
cancers, age related macular degeneration, and Barrett’s esophogus.18 PDT is a relatively non-
invasive process that combines three independently non-toxic components, a photosensitizer 
(PS), light, and systemic or intracellular oxygen, in a manner that transfers energy from light 
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to the photosensitizer. The triplet state PS subsequently interacts with molecular oxygen to 
generate reactive oxygen species, including singlet oxygen, that induce cell apoptosis and 
necrosis.19, 20 Treatment is initiated by administration of the photosensitizer either through 
intravenous injection or topical application for dermal treatments. After a latent period in 
which the photosensitizer is allowed to selectively accumulate within tumor cells, usually 24 
- 96 hours depending on the photosensitzer and cancer type, the tumor is selectivly irradiated 
with light of a specified wavelength in order to effectivley excite the photosensitizer, Figure 
2.1. 
 
 
Figure 2.1: General overview of photodynamic therapy.21 
 
Following activation of the photosensitizer by light, typically achieved by a laser source, 
the photosensitizer is excited from the ground state (1PS) to the short-lived excited singlet state 
(1PS*),19 Figure 2.2. From this singlet state, energy is released via fluorescence which allows for 
the clinical photodetection of the photosensitizer in vivo. The short-lived singlet state may undergo 
intersystem crossing by way of an electron spin conversion to the longer-lived triplet excited state. 
It is this triplet excited state that has the capacity to interact with various components intracellularly 
to generate reactive oxygen species that lead to cell death. More specifically, the photosensitizer 
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can generate reactive oxygen species of two types.18 Type I reactive oxygen species are produced 
indirectly through the transfer of protons or electrons from the photosensitizer to substrates within 
the cell to form radicals which then go on to interact with oxygen to produce toxic oxygenated 
species. On the other hand, the photosensitizer can directly transfer its excitation energy to triplet 
oxygen, the most abundant and stable form of oxygen, which reacts to form singlet oxygen (Type 
II), the most damaging of oxygen species. ISC of the singlet excited state to the triplet excited state 
of the photosensitizer allows ground state triplet oxygen to overcome spin forbidden triplet state 
to singlet state transformation.17 The triplet state photosensitizer and triplet oxygen are coupled to 
return the photosensitizer to the ground state and send oxygen to the reactive singlet state in an 
overall spin-allowed fashion. Both Type I and Type II oxygen species are formed simultaneously. 
The ratio in which each is produced depends upon the photosensitizer, the concentration of 
systemic and intracellular oxygen, and, for Type I species, the binding affinity of the 
photosensitizer to the substrate.  
 
 
Figure 2.2: Jablonski diagram of singlet oxygen generation caused by energy transfer from 
an excited photosensitizer.22 
 
 PDT efficacy depends upon several factors including the type of photosensitizer, the 
F = Fluorescence 
Ph = Phosphorescence 
S0 = Ground state 
S1 = First excited state 
T0 = Triplet ground state 
ISC = Intersystem crossing 
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drug concentration and its intracellular localization, the light dose, and the dose rate. The 
greatest factor determining how well PDT works is the concentration of oxygen surrounding 
the photosensitizer. Without oxygen, the photosensitizer would simply lose its excitation 
energy via non-radiative decay pathways, ie. fluorescence and phosphorescence. 
 Singlet oxygen is a highly reactive species with a very short half-life (< 0.04 µs). As a 
result, it can only diffuse 0.01 – 0.02 µm, therefore, only cells that are immediately adjacent 
to the location of the photosensitizer will be affected. Localization of the photosensitizer as 
close to the targeted tumor cell is therefore essential for treatment to be efficacious.  
 Due to its limited treatment scope, PDT can only be utilized as a local treatment of 
small size cancers and is not suited for systemic treatments of metastatic wide-spread cancers. 
PDT mediates tumor destruction in three ways: (1) reactive oxygen species direcly kill cancer 
cells; (2) through damage to the tumor’s vaculature thus cutting off its nutrient source; and (3) 
by eliciting an immune response to attack PDT-induced damaged tissues.19 
 PDT has many advantages over the most commonly utilized cancer treatment methods. 
PDT is typically completed as an outpatient therapy and requires a short (1 - 4 days) dwell 
period between injection with the photosensitizer and light treatment. Radiation therapy, on 
the other hand, requires approximately six to seven weeks of treatment to irradicate the tumor. 
Chemotherapy is extensively time intensive with treatments being administered for hours at a 
time over months. Although surgery is typically the quickest treatment method, the amount of 
time needed for healing can be prolonged. Clinical studies have shown PDT to be a more cost-
effective method of treatment and provides an increased life-expectancy. 
 Most PDT agents absorb between 630 nm and 680 nm. The therapeutic wavelength of 
light needed to excite these photosensitizers produces a narrow limit of light penentration. 
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Since light treatment must be focused, normal healthy tissues around and below the tumor are 
spared, which allows for faster rebuilding of damaged tissues without scarring. Although some 
ulceration at the treatment site typically occurs following irradiation, the long term damage to 
normal tissues is minimal, unlike the extensive damage caused to healthy tissues by radiation 
and chemotherapy. 
 
2.1.2 Photosensitizers 
To date, four clinically approved photosensitizers are available to treat a variety of cancer 
types across the globe. In the U.S., two porphyrin-based macrocycles and a porphyrin precursor 
(Figure 2.3) have been FDA-approved for use as photosensitizers and several other porphyrinoids 
are under investigation for the PDT treatment of various neoplastic and non-malignant conditions 
in dermatology, ophthalmology, and cardiology.23, 24 Current PDT agents fall short in their ability 
to treat a broad range of cancer types, with one of the greatest drawbacks being their effective 
depths of treatment penetration. Photofrin® (porfimer sodium, registered trademark of Pinnacle 
Biologics, Inc.) is a first generation photosensitizer and was approved in 1993 for the treatment of 
esophageal and lung cancers.18 Photofrin was the first photosensitizer to be approved for PDT and 
is still the most widely used PDT agent. Although Photofrin is used as an effective PDT agent, it 
suffers several inadequacies. Photofrin exists as a mixture of mono, di, and oligomers and the 
therapeutic composition is difficult to replicate.25 Despite having an absorption near the desired 
therapeutic window (650 – 800 nm), its weak absorption at 630 nm causes a need for greater light 
doses of 100 – 200 J/cm2 for tumor control. Furthermore, Photofrin has a long retention time within 
the body leading to skin sensitivity lasting four to twelve weeks. 
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a)  
b)     c)  
 
Figure 2.3: Molecular structures of FDA approved photosensitizers: a) Photofrin,26 b) ALA, 
and c) protoporphyrin IX. 
 
ALA, or 5-aminolevulinic acid, a second generation photosensitizer, was approved in 1999 
for the treatment of cutaneous cancer lesions, oral, and digestive cancers.18 Although ALA has no 
photosensitizing abilities itself, it is a natural precursor of heme and forms protoporphyrin IX in 
vivo which has shown to possess photosensitizing properties. ALA has several advantages over 
Photofrin including a more rapid clearance from the body (one to two days of photosensitivity). 
However, ALA is strongly hydrophilic and is not readily internalized by cells. As such, the methyl 
ester of ALA has been synthesized and studied and has shown to have better uptake thus increasing 
its effectiveness. 
 Highly effectual “ideal” photosensitizers must possess a unique set of characteristics 
including preferential accumulation in target tissue, a triplet state of adequate energy (ET ≥ 95 kJ 
mol-1) for efficient energy transfer, high quantum yields of the triplet state (ΦT > 0.4), long triplet 
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state lifetimes (τT = 1 μs), high photostability, high absorption coefficients at the therapeutic 
excitation window (650 nm - 800 nm), and low dark but high phototoxicity.19, 20  
 
2.1.3 Radioiodine Imaging 
 The use of isotopically and radioactively labeled heavy atoms, such as 123I, 124I, and 131I, 
can allow iodinated BODIPYs to be utilized in various bioimaging applications. Radioactive 
isotopically labeled iodine has been effectively used in single photon emission computed 
tomography (SPECT) and positron emission tomography (PET) imaging studies.27, 28 Iodine-120 
and 124I (t1/2 = 81 minutes and 4.18 days, respectively) are the only radioisopes of iodine to possess 
favorable PET qualities.29 However, because of their low positron emission abundance, high 
positron energies, and lengthy synthetic protocol, radioiodine isotopes have yet to be adopted for 
widespread application in habitual PET imaging. Conversely, 123I and 131I (t1/2 = 13.2 hours and 
8.05 days, respectively) have been significantly employed as SPECT radiotracers for long term in 
vitro studies and radioimmunoassays. Iodine-123 nuclei have been successfully used in nuclear 
medicine including blood flow, myocardial, and thyroid scintigraphy and for uptake measurements 
in tumors.30 The use of radioactively labeled iodine has gained popularity in bioimaging for its 
longer half-life (ca. 13 h) compared with other commonly used radio agents, including fluorine.31 
Numerous SPECT radiotracers have gained FDA approval and are frequently utilized in clinical 
diagnostics for a large portion of patients in need of imaging. SPECT imaging is favorable for 
imaging endogenous peptides and antibodies, and, provides a means for measuring the slow kinetic 
processes of these ligands facilitated by the relatively long half-life of the most common isotopes 
utilized.  
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In order to be suitable for radioimaging compounds must possess specific targeting 
abilities. Incorporation of targeting moieties, as seen with DHEA, cholesterol, and cyclooctyne-
BODIPY conjugates,32-34 can be easily accomplished by amending the BODIPY scaffold, via the 
starting pyrroles or through post-synthetic modifications. With such targeting capabilities 
incorporated, radioiodine-labeled BODIPYs have the potential for use in SPECT and PET. 
As of yet, no radioiodine-labelled BODIPYs have been published for use as SPECT 
radiotracers. An ideal radiopharmaceutical should possess characteristics to provide detectable 
diagnostic particles with minimal biological effect to the cells or tissues. Radiopharmaceuticals 
should have a relativley short half-life, maintaining radioactivity for only the necessary length of 
time needed to complete the diagnostic study, produce suitable radionucleotide emissions of 
desired energy, have high target to normal tissue ratio, possess a high target uptake, effeciently 
clear from blood and non-target tissue while lingering in target tissues for effective image contrast, 
and be inexpensive and relativley easy to produce.  
 
2.1.4 Research Prospective 
In order to broaden the effective scope of PDT, development of photosensitizers capable 
of treating a range of cancer types in various states of the disease must be explored. This chapter 
details the synthesis of a series of eleven photo-stable meso-aryl-BODIPYs from 2,4-
dimethylpyrrole and various aryl aldehydes. Furthermore, iodination at the 2,6-positions yielded 
the corresponding diiodo-BODIPY derivatives with high yield and selectivity. These 3,5-
dimethyl substituted BODIPYs can undergo Knoevenagel condensation reactions with aldehydes 
to give mono- and di-styryl functionalized long wavelength absorbing BODIPY dyes, within the 
biological window suitable for PDT.35-37  BODIPY-based dyes can be synthesized with extended 
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π-systems for excitation within the therapeutic window, however their high phototoxicity/low 
dark toxicity requirement and the structural features that optimize tumor cell uptake and 
cytotoxicity remain poorly understood. In this study the effects of the meso-aryl substituents on 
the spectroscopic and cytotoxic properties of a series of eleven BODIPYs and their 2,6-diiodo 
derivatives were investigated. 
 
2.2 Results and Discussion 
2.2.1 Syntheses  
Although functionalization can be achieved at nearly every position of the BODIPY core, 
incorporation of various aryl aldehydes via condensation with two pyrroles affords the simplest 
and most direct route to add functionality and diversity to this group of fluorophores. Following 
the classic three-step, one-pot strategy often employed in BODIPY synthesis eleven meso-aryl 
BODIPYs (1 - 11) were synthesized from commercially obtained 2,4-dimethylpyrrole and one of 
eleven different aryl aldehydes (Scheme 2.1).38  
 
Scheme 2.1: Synthesis of BODIPYs 1 - 11 from 2,4-dimethylpyrrole and an aryl aldehyde. 
 
 The synthesis of meso-aryl BODIPYs began with condensation of two pyrrole units with 
an aryl aldehyde in dichloromethane. An acid catalyst, either TFA or BF3·OEt2, is required to 
promote the condensation through protonation or chelation to the carbonyl oxygen, thus enhancing 
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the partial positive charge on the carbonyl carbon and ensuring nucleophilic attack by pyrrole.  In 
all syntheses reported herein, BF3·OEt2 facilitated this conversion to the desired dipyrromethanes. 
After stirring under inert argon conditions for 48 hours, the resultant dipyrromethanes were 
subsequently oxidized using 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) to afford the more 
stable dipyrromethenes.  Once formed, the dipyrromethenes were first deprotonated under basic 
conditions using Et3N before being exposed to excess BF3·OEt2 to deliver the BF2-complexed 
BODIPY structures. Following aqueous work-up, extraction with dichloromethane, and removal 
of any remnant water with Na2SO4, the BODIPYs were purified by silica gel column 
chromatography using a 30:70 mixture of DCM and petroleum ether as eluent. Recrystallization 
afforded the target compounds as red-orange, bright red, or deep red crystals in 18 to 58% yields, 
shown in Table 2.1.  
 All aldehydes used in these syntheses were acquired commercially with the exception 5’-
bromo-[2,2’-bithiophen]-5-carbaldehyde, compound 12, used in the synthesis of BODIPY 10. 
Bromo-bithiophene 12 was prepared through facile bromination of [2,2’-bithiophen]-5-
carbaldehyde in one step using bromine and sodium bicarbonate to obtain a yellow solid in 64% 
yield, Scheme 2.2.39  
 
 
Scheme 2.2: Synthesis of 12 from [2,2’-bithiophen]-5-carbaldehyde. 
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Table 2.1: R-group identification and corresponding percent yields of BODIPYs 1 - 11. 
BODIPY R % Yield 
1  22 
2  58 
3  23 
4  25 
5  23 
6  19 
7  20 
8  20 
9  18 
10  30 
11  52 
   
 With several pyrrole options available from both commercial producers and relatively 
straightforward synthetic routes, choosing one for the syntheses detailed herein required some 
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strategy. Therefore, 2,4-dimethylpyrrole (also known as Knorr pyrrole) was selected for its 
potential to offer multiple reactive points for later modification. The methyl groups of the pyrroles 
resided at the 1,3,5, and 7-positions of the BODIPY core are quite acidic in nature, particularly the 
3,5-dimethyls, allowing for facile extension of π-conjugation via use of the well-developed 
Knoevenagel condensation with aryl aldehydes in order to develop near-IR bioimaging dyes. In 
addition to bearing acidic properties, the 1,7-dimethyls enhance steric hindrance of meso-aryl 
group, limiting its rotational ability which increases the BODIPY’s fluorescence quantum yield. 
Finally, the 2,6-positions were left unoccupied to easily add functionality, by way of halogens, 
nitro or sulfonate groups, and to potentially extend conjugation via subsequent metal-mediated 
couplings. 
 The 2,6-positions of the BODIPY core can behave rather nucleophilically.  By resonance, 
these positions bear the least positive charge of the potentially reactive sites of the nine-carbon, 
two-nitrogen core.  As such, they readily undergo electrophilic substitution, most commonly seen 
in literature with the incorporation of halogens,11  nitro,40 or sulfonate groups.41 
 With this knowledge in hand, BODIPYs 1 - 11 underwent iodination in the  presence of 
iodine and iodic acid in 1:1 ethanol/dichloromethane heated to 60 °C for 2 hours to yield red 
crystalline diiodo-BODIPYs 1a - 11a in 65-94% yield after column chromatography using DCM 
for elution (Table 2.2).7, 10 
 Synthesis and evaluation of a series of meso-aryl BODIPYs and diiodo-meso-aryl 
BODIPYs allowed for the investigation of the effect halogenation had on the photophysical and 
cytotoxic properties, while at the same time exploring how the nature of the meso-aryl groups 
influences intracellular localization of the BODIPYs. Previous work has shown that substitution, 
especially meso-substitution with an aryl moiety, increase the photostability of the BODIPY 
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core.42, 43 Additionally, halogenation at the 2,6-positions is reported to create a bathochromic shift 
in the absorption and emission profiles of the BODIPY, as well as enhances intersystem crossing 
from the singlet excited state to the triplet state due to the heavy atom effect, and consequently 
induces phototoxicity through the production of singlet oxygen in vitro and in vivo.7, 10, 11 However, 
if halogenation is carried out at the 3,5-positions or at the BODIPY meso-phenyl or meso-thienyl 
substituents there is little to no significant effect the cytotoxicity of the compounds. 
 
Table 2.2: Percent yields of diiodo BODIPYs 1a - 11a. 
BODIPY % Yield 
1a 91 
2a 84 
3a 93 
4a 94 
5a 86 
6a 71 
7a 79 
8a 84 
9a 91 
10a 65 
11a 90 
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All BODIPYs were characterized by 1H- and 13C-NMR, HRMS and, in the case of 3, 7, 1a, 
2a, and 9a, by X-ray crystallography. Analysis of the NMR spectra shows the anticipated 2-fold 
symmetry of the BODIPY. Single peaks for the 2,6-hydrogens, the 1,7- and 3,5-dimethyl groups 
observed on the 1H-NMR spectra and the occurrence of signals for only half of the BODIPY core’s 
carbons in 13C-NMR specify a plane of symmetry extending through the boron and carbon-8. The 
observed upfield shift of the 1,7-dimethyls (at approximately 1.6 ppm) compared with the 3,5-
dimethyls (at approximately 2.5 ppm) is likely caused by shielding incurred by the meso-aryl 
groups. The departure of the 2,6-hydrogens (at ~ 6.0 ppm) in the 1H-NMR spectra indicated 
complete iodination; additional evidence was provided by the shift from 120 to 85 ppm of the 
carbon atoms bearing these hydrogens in 13C-NMR. 
 
2.2.2 X-ray Crystal Structure Determinations  
Confirmation of the absolute configuration of several of the BODIPYs were obtained from 
analysis of X-ray crystal structures. Single crystals of four BODIPYS, two β-free and two di-iodo, 
suitable for X-ray analyses were recrystallized from dichloromethane, acetone, or chloroform-d 
and their molecular structures are shown in Figure 2.4. X-ray analyses reveal the expected 
approximate two-fold symmetry of all five compounds, with two conformers of BODIPYs 7 and 
9a being elucidated (only one of each is shown in Figure 2.4). The refinement details and cell 
parameters are reported in the experimental details Section 2.4.3. 
The occurrence of two conformers suggests that the meso-thienyl group has greater 
rotational freedom compared with the phenyl substituent located at the same position. The nine-
carbon two-nitrogen BODIPY core shows high rigidity resulting in planarity that allows for strong 
π-electron delocalization between the adjacent pyrrole rings. However, no π-electron 
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delocalization is seen between the meso-aryl substituent and the core, due to their orthogonal 
orientation to one another in the molecule’s most relaxed form. This positioning reduces the steric 
strain on the meso-aryl group caused by the 1,7-dimethyl groups.44 The boron displays nearly 
tetrahedral geometry with the two fluorines also lying perpendicular to the BODIPY core. 
In comparison to previously reported boron-dipyrromethene compounds, the BODIPY 
cores of 1a, 3, 7 and 9a adopt expected bond lengths, planarity, and orthogonal dihedral angles of 
the F atoms relative to the C9N2B (excluding peripheral H atoms and substituents) aromatic 
framework.45, 46 The dihedral angles of the meso-substituents are also nearly 90° out-of-plane of 
the BODIPY core in the four crystal structures (1a 88.01(5)°; 3 78.60(4)°; 7 two partially occupied 
orientations: 82.8(2)° and 84.19(11)°; 9a two independent molecules 82.83(3)° and 89.54(2)°). 
Intermolecular halogen-halogen bonding exist in the iodinated BODIPYs 1a (F...I 3.108(2) Å) and 
in 9a (F...Br 2.903(1) and 2.971(1) Å; I...Br 3.598(1) and 3.717(1) Å). Intramolecular hydrogen 
bonding (C—H 0.98 Å, H···F 2.51 Å, C···F 3.1982(16) Å, C—H···F 127°) between the F atoms 
with an H atom of a methyl group (on the BODIPY core’s α-carbon site) is present in BODIPY 3.   
For BODIPY 7, the average structure contains two partially occupied orientations. The 
orientations can be modeled using static (positional) disorder with a refined occupancy ratio of 
0.824(2):0.176(2) for two of the thiophene atoms (S and one of the C atoms). In Figure 2.4, only 
one of the two orientations is shown. The crystal structure of BODIPY 3 has been previously 
reported in literature and Cambridge Structural Database (CCDC 712038) based on room 
temperature measurements.47 Other close matches can be found for two other crystal structures (1a 
and 7) determined in this study.  These close matches (CCDC 812643 and 856179) have been 
characterized by others and are extensions of 1a (with a meso-mesityl group, instead of a phenyl) 
and 7 (with additional quinolin-2-yl on the thiophene's other α-carbon atom).48, 49 
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a)   b)  
   
c)  d)  
Figure 2.4: Molecular structures of BODIPYs 1a (a), 3 (b), 7 (c), and 9a (d) from X-ray crystal 
structure determinations. Ellipsoids are drawn at the 50% probability level. 
 
2.2.3 Spectroscopic Investigations  
The spectroscopic properties of BODIPYs 1 - 11 and 1a - 11a were evaluated in 
dichloromethane and tetrahydrofuran, and the results obtained are summarized in Table 2.3 and 
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also shown in Figures 2.5 - 2.10. Little to no solvent effect was observed for these two solvents in 
the absorption and emission maxima wavelengths. Such lack of influence by the polarity of the 
solvent indicates that the permanent dipole moments of the BODIPYs do not change between the 
ground state and the excited state.50 The synthesized β-free, meso-aryl BODIPYs display 
absorptions between 499 nm and 517 nm and emission bands between 507 nm and 530 nm (Table 
2.3). BODIPYs 1 - 11 show typical fluorescence of a simple alkyl substituted BODIPY in the 
green/yellow spectral region with fluorescence quantum yields in the range of 0.03 – 1.0. The 
meso-thienyl- and pentafluorophenyl BODIPYs exhibited the largest red-shifted profiles and the 
lowest quantum yields of this series of compounds due to the presence of the sulfur and five 
fluorines, respectively, which impact the conjugation of the BODIPY π-system. 
Incorporation of iodines onto the BODIPY core, as in compounds 1a - 11a, causes a shift 
in the absorption and emission profiles to longer wavelengths, into the orange/red spectral region, 
and decrease the fluorescence quantum yields, as previously observed (Table 2.4).7, 10, 11 The trend 
observed in the β-free BODIPYs is also seen in their diiodo analogs with absorption and emission 
profiles becoming more red-shifted with the incorporation of thienyl- and pentafluorophenyl- 
groups.  
All compounds displayed high extinction coefficients, in the order of 23,000 to 118,000 
M-1 cm-1 (log ε values between 4.34 and 5.07), and Stokes’ shifts in the range 5 - 20 nm. BODIPYs 
7 - 11 and 7a - 11a, bearing meso-thienyl and pentafluorophenyl substituents, displayed greater 
red-shifted absorptions and emissions (by 13 - 41 nm) compared with the other meso-phenyl 
BODIPYs 1 - 6 and 1a - 6a. The electron-withdrawing effects of the sulfur and the five fluorine 
atoms on the meso-substituent of BODIPYs 7 - 11 and 7a - 11a tend to stabilize the lowest 
unoccupied molecular orbital (LUMO) via delocalization of the electron density.51 This causes a 
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decrease in the energy of the LUMO, decreasing the HOMO (highest occupied molecular orbital) 
- LUMO gap, and therefore increasing the absorbance and emission maxima wavelengths. 
 
Table 2.3: Absorption and emission spectral properties of meso-aryl BODIPYs 1 – 11 in DCM 
and THF (in parentheses) at room temperature. 
BODIPY Φf Absorption      
λmax (nm) 
Emission  
λmax (nm) 
Stokes’ 
 shift (nm) 
 
log ε 
1 0.63 (0.79) 501 (501) 511 (509) 10 (8) 
 
4.98 (4.84) 
2 1.00 (0.99) 502 (501) 510 (510) 8 (9) 
 
4.78 (4.86) 
3 0.97 (0.73) 499 (499) 507 (507) 8 (8) 
 
4.66 (4.60) 
4 0.94 (0.93) 501 (501) 510 (509) 9 (8) 
 
4.90 (4.92) 
5 0.56 (0.43) 503 (502) 513 (512) 10 (10) 
 
4.80 (4.81) 
6 0.84 (0.53) 503 (502) 513 (511) 10 (9) 
 
4.84 (4.90) 
7 0.11 (0.09) 513 (513) 520 (520) 7 (7) 
 
4.73 (4.84) 
8 0.03 (0.04) 515 (515) 523 (520) 8 (5) 
 
4.34 (4.57) 
9 0.12 (0.10) 516 (516) 524 (524) 8 (8) 
 
5.07 (4.89) 
10 0.06 (0.06) 516 (515) 522 (524) 6 (9) 
 
4.66 (4.76) 
11 0.91 (1.00) 517 (516) 530 (528) 13 (12) 
 
4.57 (4.77) 
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     (a)       (b) 
Figure 2.5: Normalized absorbance spectra of BODIPYs 1 - 6 (a) and 7 - 11 (b) in dichloromethane. 
(a) BODIPYs 1 (dark blue), 2 (red), 3 (green), 4 (purple), 5 (light blue), 6 (orange). (b) BODIPYs 
7 (dark blue), 8 (red), 9 (green), 10 (purple), 11 (light blue). 
 
 
 
           
(a)       (b) 
Figure 2.6: Normalized emission spectra of BODIPYs 1 - 6 (a) and 7 - 11 (b) in dichloromethane. 
(a) BODIPYs 1 (dark blue), 2 (red), 3 (green), 4 (purple), 5 (light blue), 6 (orange). (b) BODIPYs 
7 (dark blue), 8 (red), 9 (green), 10 (purple), 11 (light blue). 
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(a)       (b) 
 
Figure 2.7: Normalized absorbance spectra of BODIPYs 1 - 6 (a) and 7 - 11 (b) in tetrahydrofuran. 
(a) BODIPYs 1 (dark blue), 2 (red), 3 (green), 4 (purple), 5 (light blue), 6 (orange). (b) BODIPYs 
7 (dark blue), 8 (red), 9 (green), 10 (purple), 11 (light blue). 
 
           
   (a)       (b) 
Figure 2.8: Normalized emission spectra of BODIPYs 1 - 6 (a) and 7 - 11 (b) in tetrahydrofuran. 
(a) BODIPYs 1 (dark blue), 2 (red), 3 (green), 4 (purple), 5 (light blue), 6 (orange). (b) BODIPYs 
7 (dark blue), 8 (red), 9 (green), 10 (purple), 11 (light blue). 
 
It was also observed that the fluorescence quantum yields for the meso-phenyl BODIPYs 
1 - 6 and 11 (0.4 < ΦF < 1.0) were greater than for the meso-thienyl BODIPYs 7 - 10 (0.04 < ΦF < 
0.12). Due to the smaller size of the meso-group, the thienyl substituent has greater freedom of 
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rotation, which increases the amount of energy lost to non-radiative decay. This spinning motion 
increases the energy of the system which, in turn, decreases the number of photons that become 
excited and relax via fluorescence. Negligible effects were caused by the change of solvent.  
Nevertheless, these results suggest that the meso-phenyl BODIPYs with appropriate 
functionalization may serve as significantly brighter fluorophores in aqueous media than the meso-
thienyl derivatives. Furthermore, incorporating a longer chain group in the meso-position increases 
the degree of rotational freedom, which also decreases the fluorescence quantum yield as indicated 
by the results obtained for BODIPYs 7 (ΦF = 0.09 - 0.11) and 8 (ΦF = 0.03 - 0.04).  
 
Table 2.4: Absorption and emission spectral properties of 2, 6-diiodo-BODIPYs 1a - 11a in 
DCM and THF (in parentheses) at room temperature. 
BODIPY Φf Absorption      
λmax (nm) 
Emission  
λmax (nm) 
Stokes’ 
 shift (nm) 
 
log ε 
1a 0.05 (0.04) 534 (533) 550 (546) 16 (13) 
 
4.97 (4.92) 
2a 0.07 (0.05) 535 (534) 549 (547) 14 (13) 
 
4.89 (4.94) 
3a 0.06 (0.04) 531 (531) 546 (546) 15 (15) 
 
4.84 (4.83) 
4a 0.05 (0.04) 534 (532) 546 (546) 12 (14) 
 
4.96 (4.88) 
5a 0.05 (0.04) 537 (536) 554 (555) 17 (19) 
 
4.82 (4.77) 
6a 0.04 (0.03) 537 (536) 554 (553) 17 (17) 
 
4.81 (4.84) 
7a 0.04 (0.03) 548 (548) 561 (561) 13 (13) 
 
4.37 (4.68) 
8a 0.01 (0.01) 551 (550) 565 (566) 14 (16) 
 
4.59 (4.60) 
9a 0.03 (0.02) 553 (553) 570 (571) 17 (18) 
 
5.07 (5.05) 
10a 0.01 (0.01) 552 (551) 569  (571) 17 (20) 
 
4.87 (4.81) 
11a 0.04 (0.03) 558 (557) 576 (571) 18 (19) 
 
4.80 (4.76) 
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 (a)       (b) 
 
Figure 2.9: Normalized absorbance spectra of BODIPYs 1a - 6a (a) and 7a - 11a (b) in 
dichloromethane. (a) BODIPYs 1a (dark blue), 2a (red), 3a (green), 4a (purple), 5a (light blue), 
6a (orange). (b) BODIPYs 7a (dark blue), 8a (red), 9a (green), 10a (purple), 11a (light blue). 
 
   
   (a)       (b) 
Figure 2.10: Normalized absorption spectra of BODIPYs 1a - 6a (a) and 7a - 11a (b) in 
tetrahydrofuran. (a) BODIPYs 1a (dark blue), 2a (red), 3a (green), 4a (purple), 5a (light blue), 6a 
(orange). (b) BODIPYs 7a (dark blue), 8a (red), 9a (green), 10a (purple), 11a (light blue). 
 
  
Addition of bromine onto the meso-thienyl group has only a slight effect on the 
fluorescence quantum yield, as observed for BODIPYs 7 (ΦF = 0.11) and 9 (ΦF = 0.12) in 
dichloromethane. This result suggests that addition of heavy atoms, such as bromine, onto the 
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meso-substituent has little effect on the fluorescence quantum yield, while incorporation of iodines 
at the 2,6-positions of the BODIPY core, and of meso-thienyl groups, significantly decrease the 
fluorescence quantum yields. With the exception of the fluorines on the meso-pentafluorophenyl-
BODIPY 11, the quantum yields significantly declined with halogenation at the 2,6-positions (1a 
- 11a, 0.01 < ΦF < 0.07). 
   
2.2.4 Computational Analysis 
Computational modeling was accomplished to confirm the symmetric nature of the 
BODIPYs previously shown by NMR and X-ray. No symmetry constraints were initially used in 
the calculations and the initial geometries were not symmetric, however, the optimized geometries 
of BODIPYs are nearly symmetric (e.g. C2 for BODIPY 3 and Cs for BODIPY 7). The BODIPY 
core and meso-substituent form angles between 89.9° and 90.1°, elucidating perpendicular 
geometry. 
The effect of the orthogonal relationship on the HOMO - LUMO gap energy of all 
BODIPYs and the meso-group rotational barrier of BODIPYs 1 - 11 were examined 
computationally (details of the theoretical level are given the Experimental section). The calculated 
HOMO - LUMO gaps are listed in Table 2.5, along with the HOMO and LUMO energies. Indeed, 
it was observed that the LUMO decreases gradually for BODIPYs 5 – 11 in agreement with the 
observed spectral properties. However, this is not the sole effect determining the gap. In addition 
to LUMO lowering, the HOMO varies substantially. Therefore, the combination of the HOMO 
and LUMO effects determine the observed trend. In general, the computational models predict that 
the BODIPYs will be grouped into four groups: BODIPYs 1 - 6 with gaps around 3.0 eV, 
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BODIPYs 7 - 11 and 1a - 6a with gaps around 2.9 eV, and BODIPY 7a - 11a with significantly 
lower gap of 2.7 eV (see Figure 2.11).  
 
 
Figure 2.11: Experimentally observed absorption wavelengths versus the theoretically calculated 
HOMO - LUMO gap. 
 
 
This theoretical prediction is in exceptional agreement with the experimentally determined 
red-shifts of the meso-thienyl-BODIPYs 7 - 10 and 7a - 10a and the meso-pentafluorophenyl-
BODIPY 11 and 11a. In general, the diiodo substitution at the 2,6-positions lowers both the 
HOMO and LUMO, with a slightly greater effect on the LUMO. Overall, a slight lowering of the 
HOMO-LUMO gap is observed with all diiodo BODIPYs, which agrees well with the 
experimentally observed red-shifts when compared with their β-free analogs. 
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Table 2.5: Theoretically calculated energies of HOMO (a.u.), LUMO (a.u.), HOMO - LUMO 
gap, Eg (eV), and meso-group rotational barrier, Erot (kcal/mol) in vacuum and in 
dichloromethane (in parentheses), for BODIPYs 1 - 11 and 1a - 11a. 
 
BODIPY HOMO LUMO Eg Erot 
1 0.2072 0.0976 2.98 20.3 (19.7) 
 2 0.2028 0.0931 2.98 21.0 (20.6) 
3 0.2048 0.0948 2.99 21.7 (21.2) 
4 0.2068 0.0973 2.98 24.2 (18.6) 
5 0.2107 0.1013 2.98 20.5 (20.2) 
6 0.2112 0.1020 2.97 25.3 (25.0) 
7 0.2090 0.1030 2.88 15.3 (14.4) 
8 0.2093 0.1035 2.88 13.6 (12.5) 
9 0.2124 0.1073 2.86 15.8 (15.2) 
10 0.2113 0.1058 2.87 14.1 (13.3) 
11 0.2189 0.1134 2.87 33.0 (33.0) 
1a 0.2159 0.1106 2.87  
2a 0.2117 0.1061 2.87  
3a 0.2136 0.1076 2.88  
4a 0.2152 0.1094 2.88  
5a 0.2188 0.1139 2.85  
6a 0.2195 0.1147 2.85  
7a 0.2175 0.1157 2.77  
8a 0.2173 0.1155 2.77  
9a 0.2204 0.1190 2.76  
10a 0.2222 0.1222 2.72  
11a 0.2260 0.1253 2.74  
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 The rotational freedom of the meso-substituent in vacuum and in dichloromethane was 
studied computationally at the B3LYP/6-31+G (d, p) level for BODIPYs 1 - 11. The rotational 
energy barriers of the meso-aryl group are recorded in the last column of Table 2.5. For most 
compounds, there is a clear correlation between the rotational barrier and the fluorescence quantum 
yield (Figure 2.12).  
 
 
Figure 2.12: Theoretically calculated meso-aryl group rotational barrier (in vacuum and in 
dichloromethane) versus the experimentally observed quantum yield. 
 
  The meso-thienyl group in BODIPYs 7 - 10 can readily rotate, as noted with a barrier of 
only 14 - 16 kcal/mol, which explains the decline in quantum yield observed for this series of 
compounds. Heavy atom substitution of the BODIPY core does not have significant effect on the 
rotational barrier, in agreement with the negligible changes observed in the quantum yield. Taking 
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the solvent into account slightly lowers the rotational barriers but the effect is small and the 
tendency remains very similar. 
BODIPYs 1 and 5 demonstrate intermediate rotational barriers and intermediate 
fluorescence quantum yields. As observed experimentally, possessing a meso-phenyl group with 
substituents at the meta-position (OCH3 or tBu, 2 and 3, respectively) hinders the group’s rotation 
and results in significantly higher quantum yields, compared with substituents at the para-position 
(5 and 6). BODIPYs 2, 3, 4, and 6 experience rotational barriers of 20 - 24 kcal/mol, which is 
comparable to the kinetic energy at room temperature. The C6F5-substituted BODIPY 11 deviates 
from the relationship to the highest extent probably due to the strong electron-withdrawing 
character of the present fluorines. Still, it displays the highest rotational barrier and a large 
fluorescence quantum yield. 
 
2.2.5 In vitro Studies 
2.2.5.1 Time-Dependent Cellular Uptake. The results acquired from time-dependent cellular 
uptake of BODIPYs 5, 7, 8, 10, 1a, 2a, 4a, 6a, and 10a at a 10 µM concentration in human 
HEp2 cells, obtained over a 24 hour period, are shown in Figure 2.17.  Signif icant differences 
were seen with alteration of the meso-aryl group and with the incorporation of iodines. With 
the exception of BODIPY 10a, the diiodo-BODIPYs were internalized less effectivly than the 
β-free BODIPYs. Amongst the β-free BODIPYs, those bearing a meso-thienyl group (7, 8, and 
10) accumulated only slightly less than their meso-phenyl counterpart 5. By possessing groups 
that enhance the polar hydrophilicy of the molecule, the sulfur in the thiophene rings and the 
methyl ester on 5, the BODIPYs have greater affinity for hydrogen bonding, and bearing  
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partial charges enhances the ability of these BODIPYs to interact with the cellular membrane 
thus attributing to greater uptake. 
 
 
Figure 2.17: Time-dependent uptake of meso-aryl-BODIPYs 1a (black), 2a (blue), 4a (yellow), 
5 (light purple), 6a (purple), 7 (light green), 8 (dark green), 10 (pink) and 10a (red) at 10 μM 
by human HEp2 cells  
 
On the other hand, the diiodo-BODIPYs did not follow any specific trend in their 
internalization. BODIPY 10a showed remarkably higher cellular uptake than any other 
BODIPY tested. Incorportion of iodines onto the scaffold of BODPY 10 significantly enhanced 
the uptake of this compound, with four times more compound be internalized by cells. This 
result was rather interesting since similar diiodo-BODIPYs as well as meso-thienyl BODIPYs 
were difficult to solubilize in aqueous media and required prolonged sonificiation to dissolve.  
Nevertheless, this remarkably high cellular uptake may attribute to the high dark and 
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phototoxicity observed for BODIPY 10a. Likewise, BODIPYs 2a and 4a were the least 
accumulated within HEp2 cells, presumeably due to a noticeable decrease in solubility of 
diiodo-BODIPYs in aqueous media. However, they were also highly phototoxic, which might 
be due to their binding to certain protein lipophilic sites.52  
 
2.2.5.2 Cytotoxicity. The in vitro cytotoxicity of a select group of β-free BODIPYs (5, 7, 8 
and 10) and of all 2,6-diiodo-BODIPYs were investigated in human HEp2 cells using the Cell 
Titer Blue assay, the results of which are summarized in Table 2.6.  The cells were exposed to 
increasing concentration of BODIPY up to 400 µM. For photoxicity studies, the cells 
containing internalized BODIPY were irradiated with 1.5 J/cm2 of broad spectrum light. 
Working stock solutions were prepared by dissolving and adequate amount of BODIPY in 96% 
DMSO and 4% Cremophor. The dose-dependent survival curves are shown in Figures 2.13 - 
2.16 and the toxicity results are summarized in Table 2.6. Results are expressed as IC50  values, 
the concentration of dye (in µM) necessary to kill 50% of the cells. All but one BODIPY (10a, 
IC50 = 8 μM) were found to be non-toxic in the dark, with determined IC50 values above 400 
μM. Upon exposure to a low light dose (1.5 J/cm2) all of the β-free BODIPYs investigated 
showed low cytotoxicity (IC50 > 80 μM) in agreement with previous investigations.10, 43 Among 
the 2,6-diiodo-BODIPYs, 1a, 2a, 4a, 6a, 7a and 10a showed IC50 values between 3.5 and 28 
μM, while all others showed IC50 > 200 μM. 
This is a surprising result, since the 2,6-diiodo-BODIPYs previously investigated are 
reported to have high phototoxicity,10, 11 attributed to the “heavy atom effect,” and cleary 
shows the effect of the meso-aryl groups. In particular, BODIPYs 2a, 4a and 10a bearing meso-
dimethoxyphenyl or bromo-bithienyl substituents show the highest phototoxicity (IC50 = 3.5 –  
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7.5 μM at 1.5 J/cm2); among these, BODIPYs 2a and 4a are the most promising for PDT 
applications due to their high dark/phototoxicity ratio (> 50).  
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Figure 2.13: Dark toxicity of compounds, 5 (black), 7 (red), 8 (green), and 10 (blue) toward 
HEp2 cells using the Cell Titer Blue assay. 
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Figure 2.14: Dark toxicity of compounds, 1a (black), 2a (blue), 4a (yellow), 6a (purple), 7a 
(green) and 10a (red) toward HEp2 cells using the Cell Titer Blue assay. 
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Figure 2.15: Phototoxicity of compounds, 5 (black), 7 (red), 8 (green), and 10 (blue) after 
exposure to 1 J/cm2 light dose toward HEp2 cells using the Cell Titer Blue assay.  
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Figure 2.16: Phototoxicity of compounds, 1a (black), 2a (blue), 4a (yellow), 6a (purple), 7a 
(green) and 10a (red) toward HEp2 cells using the Cell Titer Blue assay  after exposure to 1 
J/cm2 light dose. 
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Table 2.6: Dark, phototoxicity (at 1.5 J/cm2 light dose), and comparative singlet oxygen quantum 
yields (relative to methylene blue) of selected BODIPYs toward HEp2 cells using the Cell Titer 
Blue assay. 
 
 
BODIPY 
Dark toxicity 
IC50 (µM) 
Phototoxicity 
IC50 (µM) 
 
ΦΔ 
 
5 > 400 >100 0.18 
 
7 >300 >100 0.10 
 
8 >400 >100 0.29 
 
10 >300 82 0.38 
 
1a > 400 27 0.76 
 
2a >400 4 0.40 
 
3a >400 >200 0.32 
 
4a >400 7.5 0.38 
 
5a >400 >200 0.27 
 
6a >400 28 0.31 
 
7a >400 14 0.02 
 
8a >400 >200 0.27 
 
9a >400 >200 0.10 
 
10a 8 3.5 0.34 
 
11a >400 >200 0.19 
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BODIPY 10a’s inherently high phototoxicity is likely attributed to is substantial dark-
toxicity, and can be eliminated as a potential PDT or bioimaging agent. On the other hand, 
BODIPYs 3a, 5a, 8a, 9a and 11a showed no dark/photo cytotoxicities and could therefore find 
application as radioiodine-labeled imaging agents for SPECT and PET, provided they are 
deemed to possess specific cellular targeting attributes not yet investigated.  
 
2.2.5.3 Intracellular Localization. The preferential sites of BODIPYs 5, 7, 8, 10, and 1a - 
11a localization within cells were evaluated by fluorescence microscopy upon exposure of 
HEp2 cells to 10 µM concentration of BODIPY for 6 hours, Figures 2.18 – 2.22. Overlay 
experiments were carried out using organelle specific fluorescent trackers, LysoSensor Green 
(lysosomes), MitoTracker Green (mitochondria), ER Tracker Blue/white (endoplasmic 
reticulum), and BODIPY FL C5 Ceramide (Golgi). Fluorescence patterns for cells containing 
tracker and cells containing localized BODIPYs  5, 7, 8, 10, and 10a are shown in Figures 2.18 
- 2.22 and the results are summarized in Table 2.7. These results show preferential localization 
of the β-free BODIPYs primarily in the mitochondria and endoplasmic reticulum. The diiodo-
BODIPY 10a showed preference for internalization within the lysosomes and Golgi.  
Preliminary results (not shown) reveal that all the phototoxic BODIPYs (1a, 2a, 4a, 6a, 7a 
and 10a) localized subcellularly partly within mitochondria, the cell “power house”.53  In 
particular, the role played by mitochondria in apoptosis, the process of programmed cell death, 
makes these cellular organelles highly desirable targets for PDT.54 These results are in agreement 
with a previous study10 that shows preferential localization of a meso-propionate-2,6-diiodo-
BODIPY in the mitochondria of HSC-2 cells. 
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Figure 2.18: Subcellular localization of BODIPY 5 in HEp2 cells at 10 µM for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence. 
Scale bar: 10 µm. 
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Figure 2.19: Subcellular localization of BODIPY 7 in HEp2 cells at 10 µM for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence. 
Scale bar: 10 µm. 
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Figure 2.20: Subcellular localization of BODIPY 8 in HEp2 cells at 10 µM for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence. 
Scale bar: 10 µm. 
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Figure 2.21: Subcellular localization of BODIPY 10 in HEp2 cells at 10 µM for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence. 
Scale bar: 10 µm. 
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Figure 2.22: Subcellular localization of BODIPY 10a in HEp2 cells at 10 µM for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence. 
Scale bar: 10 µm. 
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Table 2.7: Major (++) and Minor (+) Subcellular Sites of Localization for BODIPYs 5, 7, 8, 10, 
and 10a in HEp2 Cells. 
 
Compound Lysosomes ER Golgi Mitochondria 
5 + + + + + + 
7 + + + + + 
8 + + + + + 
10 + + ++ + + + 
10a + + + + + + 
 
2.2.6 Singlet Oxygen Generation Studies 
The singlet oxygen quantum yields were determined for compounds 5, 7, 8, 10, and 1a - 
11a by measuring the change in absorbance of a known singlet oxygen acceptor, 1,3-
diphenylisobenzofuran (DPBF), in the presence of photosensitizer produced singlet oxygen.10, 55 
The change in the 410 nm absorbance of DPBF (at an initial concentration of 50 μM in DMSO) 
was measured in 15 minute intervals over the course of an hour. The photosensitizer and DPBF 
were subjected to a long-pass filtered light source of > 500 nm to effectively excite the 
photosensitizer and to minimize the photobleaching of DPBF, which would have caused an 
underestimation of the singlet oxygen generation rate. Each photosensitizer was referenced to an 
equivalent concentration of methylene blue (ΦΔ = 0.52).  
Singlet oxygen quantum yields ranged from 0.1 to 0.76 (shown in Table 2.6), and generally 
correlated with the in vitro toxicity of the photosensitizer. BODIPYs 2a and 4a, which showed 
high phototoxicity values, also revealed to be moderate singlet oxygen generators (ΦΔ = 0.40 and 
0.38, respectively). Along with their key subcellular localization, such generation leads them to 
possess highly effective photosensitizer qualities. BODIPY 1a proved to be a good singlet oxygen 
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generator (ΦΔ = 0.76),56 however, due to its lipophilic nature, low cellular uptake likely prevents 
it from being an effective agent. In comparison, 10a, which possessed both high dark and 
phototoxicity, is a less effective singlet oxygen generator (ΦΔ = 0.34). Its greater cellular uptake 
and potential effect of the thienyl-meso substituent may play a larger role in its toxicity. 
 
2.3 Conclusions 
 A series of eleven photo-stable meso-aryl-BODIPYs, bearing both meso-phenyl and 
meso-thienyl groups, were synthesized and iodinated at the 2,6-positions to investigate the 
effect of the iodine atoms and the nature of the meso-aryl group on their photophysical 
properties and cytotoxicity. BODIPYs bearing meso-thienyl and meso-pentafluorophenyl 
substituents, showed the largest red-shifted absorptions and emissions due to their lower 
HOMO - LUMO gap, as determined computationally. The 2,6-diiodo-BODIPYs showed lower 
HOMO and LUMO energies compared with the corresponding non-iodinated derivatives. 
Furthermore, meso-thienyl BODIPYs showed drastically reduced fluorescence quantum yields 
due to the greater freedom of rotation of the small thienyl group. Addition of bromine onto the 
meso-substitutent had only a slight effect on the rotational barrier and the fluorescence 
quantum yields.  
 Studies in human HEp2 cells revealed that all BODIPYs with exception of 10a were 
non-toxic in the dark (IC50 > 400 μM). Upon light treatment (1.5 J/cm2) the β-free BODIPYs 
showed low cytotoxicity (IC50 > 80 μM) and five of the 2,6-diiodo BODIPYs (3a, 5a, 8a, 9a 
and 11a) showed no phototoxicity up to 200 µM. On the other hand, six of the 2,6-diiodo-
BODIPYs (1a, 2a, 4a, 6a, 7a and 10a) showed IC50 = 3.5 - 28 μM at 1.5 J/cm2, demonstrating 
the significant effect of both the 2,6-diiodo and the meso-aryl groups on the cytotoxic 
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properties of BODIPYs. BODIPYs 2a and 4a had the highest dark/phototoxicity ratio (> 50) 
and are the most promising for PDT. The high dark and phototoxicity observed for BODIPY 
10a is probably due to its very high cellular uptake, and preferntial accumulation within the 
cell mitochondria. The non-toxic diiodo-BODIPYs may find purpose as radio-iodine imaging 
agents with appropriate amendements to install radioactive isotope of iodine. BODIPYs 2a and 
4a that showed favorable qualities as PDT agents would better serve said purpose with a 
bathochromic shift of the BODIPY’s absorption and emission wavelengths into the near-IR, 
as will be explored in the following Chapter. 
 
2.4 Experimental  
2.4.1 General Information 
All reagents and solvents were purchased from either Sigma Aldrich or Alfa Aesar as 
reagent grade and used without further purification. Reactions were monitored by TLC using 0.2 
mm silica with UV indicator (UV254).  Column chromatography was performed using Sorbent 
Technologies 60Ȧ silica gel (230 - 400 mesh).  All 1H NMR and 13C NMR spectra were obtained 
using a Bruker DPX-400, AV-400, or DPX-250 spectrometer (400 MHz or 250 MHz for 1H, 100 
MHz for 13C) in deuterated chloroform as solvent with trimethylsilane as an internal indicator. 
Chemical shifts (δ) are reported in ppm with CDCl3 (1H: 7.27 ppm; 13C: 77.16 ppm) used as 
reference. Coupling constants (J) are reported in Hertz (Hz). High resolution electrospray 
ionization (ESI) and matrix assisted laser desorption/ionization (MALDI) mass spectra were 
obtained using an Agilent Technologies 6210 ESI-TOF Mass Spectrometer or a Bruker 
UltrafleXtreme MALDI-TOF/TOF. Melting points were determined using a MEL-TEMP 
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electrothermal instrument. 5’-Bromo-[2,2’-bithiophen]-5-carbaldehyde was synthesized in 64% 
yield as previously reported. 39  
 
2.4.2 Syntheses 
General Procedure for Synthesis of BODIPYs 1-11 
 In an oven dried flask, 2, 4-dimethylpyrrole (1 g, 10.5 mmol) and the corresponding aryl 
aldehyde (5.0 mmol) were dissolved in dry dichloromethane (DCM, 300 mL). Boron trifluoride 
diethyl etherate (BF3·OEt2, 0.15 mL) was added drop-wise and the mixture was stirred at room 
temperature under nitrogen atmosphere for 48 hours (until TLC revealed disappearance of the 
aldehyde). 2,3-Dichloro-5,6-dicyano-p-benzoquinone (DDQ, 1.2 g, 5.1 mmol) in DCM (5 mL) 
was added to the solution and stirred for 1 hour. Triethylamine (3.8 g, 37.5 mmol) was then added 
to the mixture and stirred for 30 minutes followed by the introduction of  BF3·OEt2 (6.2 mL, 50 
mmol) in DCM (10 mL) and stirred for 3 hours. The mixture was poured into water and the organic 
layer was extracted with DCM.  The organic layer was passed through a bed of anhydrous Na2SO4 
and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica 
gel flash chromatography using 30% dichloromethane in petroleum ether to yield the desired 
BODIPY. 
 
BODIPY 1: Obtained as a red solid (0.35 g) in 22% yield, mp: 168-169 °C; 1H-NMR (400 MHz, 
CDCl3) δ 7.49-7.48 (dd, J = 5.2, 1.4, 3H), 7.30-7.27 (dd, J=  7.2 and 2.2, 2H), 5.98 (s, 2H), 2.56 
(s, 6H), 1.38 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 155.83, 143.56, 142.14, 135.40, 131.84, 
129.53, 129.34, 128.35, 121.60, 14.98, 14.73; HRMS (ESI-TOF) m/z 325.1709 [M+H]+, calculated 
for C19H20BF2N2: 325.1688. The NMR data is in agreement with that previously reported.
57 
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BODIPY 2: Obtained as a red-orange solid (1.11 g) din 58% yield, mp = 162 °C (decomposes); 
1H-NMR (400 MHz, CDCl3) δ 6.55-6.54 (t, J = 2.0, 2H), 6.46-6.45 (d, J = 2.0), 5.99 (s, 2H3.80 
(s, 6H), 2.56 (s, 6H), 1.55 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 161.59, 155.46, 143.10, 141.33, 
136.57, 131.06, 121.08, 105.90, 100.92, 55.52, 14.54, 14.17; HRMS (ESI-TOF) m/z 385.1894 
[M+H]+, calculated for C21H24 BF2N2O2: 385.1899. The NMR data is in agreement with that 
previously reported.58 
 
BODIPY 3: Obtained as a red-orange solid (0.51 g) in 23% yield, mp = 115 °C (decomposes); 1H-
NMR (400 MHz, CDCl3) δ 7.48-7.47 (t, J = 1.8, 1H), 7.13-7.12 (d, J = 1.3, 2H), 5.98 (s, 2H), 2.56 
(s, 6H), 1.36 (s, 6H), 1.32 (s, 18H); 13C-NMR (100 MHz, CDCl3) δ 155.08, 151.96, 143.25, 143.17, 
133.97, 131.52, 122.08, 121.82, 120.99, 35.08, 31.40, 14.56, 14.12; HRMS (ESI-TOF) m/z 
437.2977 [M+H]+, calculated for C27H36BF2N2: 437.2940. The NMR data is in agreement with 
that previously reported.47 
 
BODIPY 4: Obtained a bright red solid (0.48 g) in 25% yield, mp = 182-183 °C. 1H-NMR (400 
MHz, CDCl3) δ 6.98-6.96 (d, J = 7.8, 1H), 6.83-6.80 (dd, J = 8.7 and 1.5, 2H), 6.79-6.78 (d, J = 
1.5, 1H), 5.98 (s, 2H), 3.94 (s, 3H), 3.84 (s, 3H), 2.54 (s, 6H), 1.47 (s, 6H); 13C-NMR (100 MHz, 
CDCl3) δ 155.38, 149.79, 149.50, 143.16, 141.58, 131.72, 127.13, 121.11, 120.42, 111.52, 111.07, 
56.11, 55.91, 14.57, 14.45; HRMS (ESI-TOF) m/z 385.1893 [M+H]+, calculated for 
C21H24BF2N2O2: 385.1899. The NMR data is in agreement with that previously reported.
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BODIPY 5: Obtained a bright red solid (0.44 g) in 23% yield, mp = 181-182 °C; 1H-NMR (400 
MHz, CDCl3) δ 8.19 (d, J = 7.9, 2H), 7.42-7.40 (d, J = 7.9, 2H), 5.99 (s, 2H), 3.97 (s, 3H), 2.56 
(s, 6H), 1.35 (s, 6H); 13C-NMR (100MHz, CDCl3) δ 166.47, 156.00, 142.88, 140.21, 139.95, 
130.80, 130.37, 128.39, 121.48, 52.40, 14.62, 14.51; HRMS (ESI-TOF) m/z 383.1746 [M+H]+, 
calculated for C21H22BF2N2O2: 383.1742. The NMR data is in agreement with that previously 
reported.60 
 
BODIPY 6: Obtained as a red solid (0.38 g) in 19% yield, mp = 172-173 °C; 1H-NMR (400 MHz, 
CDCl3) δ 7.66-7.64 (d, J = 8.2, 2H), 7.19-7.17 (d, J = 8.2, 2H), 5.99 (s, 2H), 2.55 (s, 6H), 1.41 (s, 
6H); 13C-NMR (100 MHz, CDCl3) δ 155.91, 142.92, 140.03, 133.96, 132.45, 131.19, 129.84 
123.27, 121.47, 14.65, 14.61; HRMS (ESI-TOF) m/z 403.0780 [M+H]+, calculated for 
C19H19BBrF2N2: 403.0793. The NMR data is in agreement with that previously reported.
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BODIPY 7: Obtained a red solid (0.33 g) in 20% yield, mp = 190-191 °C; 1H-NMR (400 MHz, 
CDCl3) δ 7.51-7.50 (d, J = 5.0, 1H), 7.15-7.12 (t, J = 4.4, 1H), 6.99-6.98 (d, J = 3.2, 1H), 6.00 (s, 
2H), 2.55 (s, 6H), 1.58 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 156. 07, 143.50, 134.63, 134.00, 
132.40, 127.81, 127.61, 127.41, 121.50, 14.65, 13.55; HRMS (ESI-TOF) m/z 331.1306 [M+H]+, 
calculated for C17H18BF2N2S: 331.1252. The NMR data is in agreement with that previously 
reported.62 
 
BODIPY 8: Obtained a dark red solid (0.42 g) in 20% yield, mp = 157 °C (decomposes); 1H-NMR 
(400 MHz, CDCl3) δ 7.23-7.22 (d, J = 3.5, 1H), 7.22-7.21 (d, J = 3.5, 1H), 7.21-7.20 (d, J = 3.5, 
1H), 7.06-7.04 (dd, J = 4.9 and 3.7, 1H), 6.90-6.89 (d, J = 3.5, 1H), 6.02 (s, 2H), 2.56 (s, 6H), 1.75 
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(s, 6H); 13C-NMR (100 MHz, CDCl3) δ 156.28, 143.44, 133.14, 128.65, 127.98, 125.02, 124.33, 
123.73, 121.58, 14.66, 13.95; HRMS (ESI-TOF) m/z 413.1116 [M+H]+, calculated for 
C21H20BF2N2S: 413.1129.  
 
BODIPY 9: Obtained a dark red solid (0.37 g) in 18% yield, mp = 167-168 °C; 1H-NMR (400 
MHz, CDCl3) δ 7.10-7.09 (d, J = 3.5, 1H), 6.77-6.76 (d, J = 3.9, 1H), 6.01 (s, 2H), 2.54 (s, 6H), 
1.69 (s, 6H); 13C-NMR (100MHz, CDCl3) δ 156.57, 143.34, 136.32, 132.11, 130.36, 128.43, 
121.75, 113.83, 14.65, 13.87; HRMS (ESI-TOF) m/z 409.0315 [M+H]+, Calculated for 
C17H17BBrF2N2S: 409.0357. 
 
BODIPY 10: Obtained as a dark red solid (0.74 g) from 5’-bromo-[2,2’-bithiophen]-5-
carbaldehyde39 (1.3658 g) in 30% yield, mp = 205 °C (decomposes); 1H-NMR (400 MHz, CDCl3) 
δ 7.14-7.13 (d, J = 3.5, 1H), 7.01-7.00 (d, J = 3.5, 1H), 6.97-6.96 (d, J = 3.9, 1H), 6.90-6.89 (d, J 
= 3.9, 1H), 6.03 (s, 2H), 2.56 (s, 6H), 1.73 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 156.42, 143.36, 
135.64, 133.70, 132.29, 130.75, 128.76, 124.41, 123.96, 121.64, 111.80, 14.67, 13.93; HRMS 
(ESI-TOF, negative ion) m/z 489.0089 [M+H]+, calculated for C21H17BBrF2N2S2: 489.0078. 
 
BODIPY 11: Obtained as a red solid (0.38 g) from pentafluorobenzaldehyde (0.39 g, 2 mmol) in 
52% yield, mp = 109 °C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 6.06 (s, 2H), 2.57 (s, 6H), 
1.62 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 157.78, 145.26, 142.77, 141.50, 139.44, 137.10, 
130.99, 122.73, 122.26, 14.76, 13.57; HRMS (ESI-TOF) m/z 415.1337 [M+H]+, calculated for 
C19H15BF7N2: 415.1216. The NMR data is in agreement with that previously reported.
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General Procedure for Iodination of BODIPYs 1-11 
 Iodic acid (2 equiv.) was dissolved in a minimal amount of water and added drop-wise to 
a solution of the BODIPY (1 equiv.) and iodine (2.5 equiv.) in a solution of 50:50 ethanol/DCM 
(~ 35 μM solution).  The resulting mixture was stirred at 60 °C for 2 hours. After cooling, the 
solvent was evaporated under vacuum and the resulting residue was purified by silica gel column 
chromatography using 50:50 hexanes/DCM for elution. 
 
BODIPY 1a: Obtained as a red solid (0.16 g) in 91% yield from 1 (0.1 g, 0.31 mmol), iodic acid 
(0.11 g, 0.62 mmol), iodine (0.10 g, 0.77 mmol), mp = 204-206 °C; 1H-NMR (400 MHz, CDCl3) 
δ 7.53-7.51 (dd, J = 5.2, 1.4, 3H), 7.27-7.24 (dd, J = 7.2 and 2.2, 2H), 2.65 (s, 6H), 1.39 (s, 6H); 
13C-NMR (100 MHz, CDCl3) δ 156.78, 145.37, 141.38, 134.74, 131.30, 129.54, 129.47, 127.79, 
85.65, 16.95, 16.04; HRMS (ESI-TOF) m/z 575.9461 [M]+, calculated for C19H17BF2I2N2: 
575.9543. The NMR data is in agreement with that previously reported.64 
 
BODIPY 2a: Obtained as a red solid (0.28 g) in 84% yield from 2 (0.2 g, 0.52 mmol), iodic acid 
(0.18 g, 1.0 mmol), iodine (0.17 g, 1.3 mmol), mp = 192-193 °C; 1H-NMR (400 MHz, CDCl3) δ 
6.60-6.59 (t, J = 2.0, 2H), 6.42-6.41 (d, J = 2.0, 1H), 3.81 (s, 6H), 2.65 (s, 6H), 1.57 (s, 6H); 13C-
NMR (100 MHz, CDCl3) δ 161.94, 156.84, 149.46, 145.42, 136.31, 131.12, 105.77, 101.45, 85.58, 
55.65, 16.88, 16.06; HRMS (ESI-TOF) m/z 636.9810 [M+H]+, calculated for C21H21BF2I2N2O2: 
636.9832. 
 
BODIPY 3a: Obtained as a red solid (0.37 g) in 93% yield from 3 (0.25 g, 0.57 mmol), iodic acid 
(0.2 g, 1.15 mmol) and iodine (0.18 g, 1.43 mmol); 1H-NMR (400 MHz, CDCl3) δ 7.54-7.53 (t, J 
93 
 
= 1.8, 1H), 7.08-7.07 (d, J = 1.3, 2H), 2.66 (s, 6H), 1.37 (s, 6H), 1.33 (s, 18H); 13C-NMR (100MHz, 
CDCl3) δ 156.40, 152.48, 145.35, 142.94, 133.76, 131.39, 122.46, 121.87, 85.45, 35.15, 31.40, 
16.69, 15.99; HRMS (ESI-TOF) m/z 688.0730 [M]+, calculated for C27H33BF2I2N2: 688.0794. 
 
BODIPY 4a: Obtained as a red solid (0.39 g) in 94% yield from 4 (0.25 g, 0.65 mmol), iodic acid 
(0.23 g, 1.3 mmol), iodine (0.21 g, 1.62 mmol), mp = 215-217 °C; 1H-NMR (400 MHz, CDCl3) δ 
7.02-7.01 (d, J = 7.8, 1H), 6.82-6.78 (dd, J = 8.7, 1.5, 2H), 6.75-6.74 (d, J = 1.5), 3.98 (s, 3H), 
3.87 (s, 3H), 2.65 (s, 6H), 1.49 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 156.70, 150.10, 149.97, 
145.37, 141.28, 131.62, 126.78, 120.33, 111.76, 111.81, 85.58, 56.18, 56.01, 17.07, 16.01; HRMS 
(ESI-TOF) m/z 635.9840 [M]+, calculated for C21H21BF2I2N2O2: 635.9754. The NMR data is in 
agreement with that previously reported.65 
 
BODIPY 5a: Obtained as a red solid (0.36 g) in 86% yield from 5 (0.25 g, 0.65 mmol), iodic acid 
(0.23 g, 1.31 mmol), iodine (0.21 g, 1.64 mmol), mp = 215 °C (decomposes); 1H-NMR (400 MHz, 
CDCl3) δ 8.24-8.20 (d, J = 7.9, 2H), 7.40-7.37 (d, J = 7.9, 2H), 3.99 (s, 3H), 2.65 (s, 6H), 1.37 (s, 
6H); 13C-NMR (100 MHz, CDCl3) δ 166.24, 157.34, 145.07, 139.81, 139.46, 131.34, 130.81, 
130.66, 128.24, 86.04, 52.53, 17.14, 16.12; HRMS (ESI-TOF) m/z 634.9663 [M+H]+, calculated 
for C21H20BF2I2N2O2: 634.9676. The NMR data is in agreement with that previously reported.
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BODIPY 6a: Obtained as a red solid (0.44 g) in 71% yield from 6 (0.25 g, 0.62 mmol), iodic acid 
(0.22 g, 1.24 mmol), iodine (0.2 g, 1.55 mmol), mp = 232 °C (decomposes); 1H-NMR (400 MHz, 
CDCl3) δ 7.71-7.68 (d, J = 8.2, 2H), 7.18-7.14 (d, J = 8.2, 2H), 2.65 (s, 6H), 1.44 (s, 6H); 13C-
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NMR (100 MHz, CDCl3) δ 157.27, 145.13, 139.64, 133.69, 132.80, 131.08, 129.66 123.91, 85.99, 
17.28, 16.09; HRMS (ESI-TOF) m/z 653.8638 [M]+, calculated for C19H16BBrF2I2N2: 653.8648. 
 
BODIPY 7a: Obtained as a red solid (0.6 g) in 79% yield from 7 (0.25 g, 0.76 mmol), iodic acid 
(0.27 g, 1.51 mmol), iodine (0.24 g, 1.9 mmol), mp = 186-187 °C; 1H-NMR (400 MHz, CDCl3) δ 
7.57-7.56 (d, J = 5.0, 1H), 7.19-7.17 (t, J = 4.4, 1H), 7.00-6.99 (d, J = 3.2, 1H), 2.65 (s, 6H), 1.59 
(s, 6H); 13C-NMR (100MHz, CDCl3) δ 157. 35, 145.65, 134.34, 133.75, 132.25, 128.20, 128.14, 
127.97, 86.17, 16.27, 16.11; HRMS (ESI-TOF) m/z 582.9173 [M+H]+, calculated for 
C17H16BF2I2N2S: 582.9185. 
 
BODIPY 8a: Obtained as a red solid (0.51 g) in 84% yield from 8 (0.25 g, 0.61 mmol), iodic acid 
(0.21 g, 1.21 mmol), iodine (0.19 g, 1.52 mmol), mp = 195-196 °C; 1H-NMR (400 MHz, CDCl3) 
δ 7.25-7.23 (t, J = 3.3, 1H), 7.21-7.20 (d, J = 3.9, 1H), 7.18-7.17 (d, J = 3.4, 1H), 6.91-6.89 (dd, J 
= 5.1 and 4.2, 2H), 2.66 (s, 6H), 1.74 (s, 6H); 13C-NMR (100MHz, CDCl3) δ 157.67, 145.50, 
141.83, 139.22, 137.88, 133.23, 129.13, 129.04, 128.09, 125.95, 125.41, 124.67, 86.28, 16.69, 
16.14; HRMS (ESI-TOF) m/z 663.8988 [M+H]+, calculated for C21H17BF2I1N2S2: 663.8984. 
 
BODIPY 9a: Obtained as a red solid (0.07 g) in 91% yield from 9 (0.05 g, 0.12 mmol), iodic acid 
(0.04 g, 0.24 mmol), iodine (0.04 g, 0.31 mmol), mp = 212 °C (decomposes); 1H-NMR (400 MHz, 
CDCl3) δ 7.15-7.14 (d, J = 3.4, 1H), 6.79-6.78 (d, J = 3.9, 1H), 2.65 (s, 6H), 1.71 (s, 6H); 13C-
NMR (100MHz, CDCl3) δ 158.18, 145.48, 136.18, 132.63, 130.65, 128.79, 114.84, 86.05, 16.63, 
16.15; HRMS (ESI-TOF) m/z 660.8246 [M+H]+, calculated for C17H15BBrF2I2N2S: 660.8290.  
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BODIPY 10a: Obtained as a red solid (0.25 g) in 65% yield from 10 (0.25 g, 0.51 mmol), iodic 
acid (0.18 g, 1.02 mmol), iodine (0.16 g, 1.27 mmol), mp = 198 °C (decomposes); 1H-NMR (400 
MHz, CDCl3) δ 7.17-7.16 (d, J = 3.5, 1H), 7.03-7.02 (d, J = 3.9, 1H), 6.99-6.98 (d, J = 3.9, 1H), 
6.90-6.89 (d, J = 3.5, 1H), 2.65 (s, 6H), 1.74 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 157.68, 
145.50, 139.38, 137.40, 133.20, 132.42, 132.16, 130.85, 129.13, 124.75, 124.14, 112.25, 86.32, 
16.68, 16.15; MS (MALDI-TOF) m/z 741.8490 [M+H]+, calculated for C21H16BBrF2I2N2S2: 
741.8089. 
 
BODIPY 11a: Obtained as a red solid (0.07 g) in 90% yield from 11 (0.05 g, 0.12 mmol), iodic 
acid (0.04 g, 0.24 mmol), iodine (0.04 g, 0.3 mmol), mp = 198 °C (decomposes); 1H-NMR (400 
MHz, CDCl3) δ 2.68 (s, 6H), 1.65 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 159.13, 145.11, 143.74, 
142.70, 139.65, 137.07, 130.89, 122.46, 87.05, 16.31, 16.20; HRMS (ESI-TOF) m/z 666.9130 
[M+H]+, calculated for C19H13BF7I2N2: 666.9150.  
 
2.4.3 X-ray Determined Molecular Structures  
 The crystal structures of BODIPYs 3, 7, 1a and 9a were determined at low temperature 
using MoK radiation on a Nonius KappaCCD (1a) diffractometer, CuK radiation on a Bruker 
Kappa Apex-II (3), or CuK (7) or MoK (9a) radiation on a Bruker Kappa Apex-II DUO 
diffractometer. For 7, the thiophene substituent was disordered into two orientations with 
0.824(2)/0.176(2) occupancies, and for 9a, there were two independent molecules in the 
asymmetric unit.   
Crystal data for 1a: C19H17BF2I2N2, M = 575.96, monoclinic space group P21/c, a = 11.4673 (15), 
b = 12.9564 (15), c = 17.3920 (15) Å,  = 130.446 (4)°, U = 1966.5 (4) Å3, T = 95 K, Z = 4. A 
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total of 16872 reflections were measured (Rint = 0.032). R = 0.031 for 6345 data points with I > 2 
(I) of 8604 unique data points and 239 refined parameters. 
Crystal data for 3: C27H35BF2N2, M = 436.38, monoclinic space group P2/c, a = 6.6395 (8), b = 
12.1074 (14), c = 15.139 (2) Å,  = 101.284 (10)°, U = 1193.5 (3) Å3, T = 90 K. A total of 9239 
reflections were measured (Rint = 0.042). R = 0.036 for 1887 data points with I > 2 (I) of 2097 
unique data points and 153 refined parameters. 
Crystal data for 7: C17H17BF2N2S, M = 330.20, monoclinic space group P21/c, a = 6.6059 (3), b = 
18.5456 (9), c = 12.7397 (6) Å,  = 92.791(2)°, U = 1558.89 (13) Å3, T = 90 K, Z = 4. A total of 
14155 reflections were measured (Rint = 0.035). R = 0.034 for 2762 data points with I > 2 (I) of 
2797 unique data points and 220 refined parameters.  
Crystal data for 9a: C17H14BBrF2I2N2S, M = 660.88, monoclinic space group P21/c, a = 21.871 
(2), b = 9.8112 (10), c = 19.478 (2) Å,  = 107.585 (5)°, U = 3984.3 (7) Å3, T = 100 K, Z = 8.  A 
total of 162,698 reflections were measured (Rint = 0.052). R = 0.029 for 19,684 data points with I 
> 2 (I) of 26,346 unique data points and 477 refined parameters. 
 
2.4.4 Steady-state Absorption and Fluorescence Spectroscopy  
The spectral properties of compounds 1-11 and 1a-11a were investigated using solutions 
prepared by dissolving an adequate amount of crystalline compound in either dichloromethane or 
tetrahydrofuran.  Stock solutions of concentrations ranging from 1.5x10-5 to 5x10-5 M were 
prepared and diluted to suitable concentrations for collection of absorbance and emission spectra. 
Absorption spectra were acquired using a PerkinElmer Lambda 35 UV/VIS Spectrometer. 
Measurements obtained for calculating the optical density, ε, were taken from prepared solutions 
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with concentrations between 7.5x10-6 and 2.5x10-5 M. These solutions provided absorption λmax 
between 0.5 and 1.0.  
Emission measurements were chronicled on a PTI QuantaMaster4/2006SE 
spectrofluorometer with the slit width set at 2 nm. Rhodamine 6G was used as a standard in 
calculating the fluorescence quantum yields (ΦF = 0.95 in ethanol). Fluorescence spectra were 
determined by subsequent dilution of solutions to between 1.5x10-6 and 8x10-6 M to achieve an 
optical density between 0.04 and 0.06 at the excitation wavelength, in order to minimize 
intermolecular reabsorption and inner-filter effects.66 Fluorescence emissions were recorded for 
all samples, including the standard, after excitation at 480 nm.  
The fluorescent quantum yields (Фexp) were calculated using the following equation: 67 
 
Ф𝑒𝑥𝑝 = Ф𝑟𝑒𝑓
𝐹𝑥[𝐴𝑠𝑡𝑑 ]𝑛
2
𝐹𝑠𝑡𝑑[𝐴𝑥]𝑛𝑠𝑡𝑑
2  
 
Фref is the fluorescent quantum yield of the standard, Fx is the area under the sample’s 
emission peak, Fstd is the area under the standard’s emission peak, Astd is the optical density at 
which the standard was excited, Ax is the optical density at which the sample was excited, n is the 
refractive index of the sample’s solvent, and nstd is the refractive index of the standard’s solvent. 
All measurements, both absorbance and emission, were acquired within 4 hours of solution 
preparation at room temperature (23 - 25 °C), using non-degassed samples and a 10 mm quartz 
spectrophotometric cuvette. 
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2.4.5 Computational Modeling 
 Electronic structure calculations of BODIPYs 1-11 and 1a-11a were carried out using the 
hybrid Becke’s Three Parameter DFT Functional.68, 69 All atoms except iodine were modeled using 
the 6-31+G(d,p) basis sets. For BODIPY’s 1a-11a the iodine atoms were treated using the Stevens-
Basch-Krauss (SBK)70-72 relativistic effective core potentials and the standard CEP-31G basis set. 
All structures were optimized without symmetry constraints. The Highest Occupied Molecular 
Orbital (HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO) were rigorously 
determined without any further approximations. Potential energy surface minima were confirmed 
with frequency calculations. Rotational energy barriers were determined by performing relaxed 
scans of the potential energy surface. All calculations were performed using the Gaussian 09 
program package.73 
 
2.4.6 Cell Studies  
 The human HEp2 cells used in this study were purchased from ATCC (derived from HeLa, 
cervical cancer, contamination). The HEp2 cells were maintained in a 50:50 mixture of 
DMEM:AMEM (Invitrogen) supplemented with 10% FBS (Invitrogen) and 1% antibiotic 
(Penicillin-streptomycin) and 5% CO2 at 37 °C. A 32 mM BODIPY stock solution was prepared 
by dissolving the compound in 96% DMSO and 4% Cremophor EL (a nonionic emulsifier). A 2 
mL of a 400 µM BODIPY solution containing 1.94% DMSO and 0.05% Cremophor EL was 
prepared by adding 15 µL DMSO, 1 µL Cremophor EL, and 25 µL of the 32 mM stock solution 
into 1960 µL medium. The final solution was sonicated to aid in BODIPY solubilization. 
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2.4.6.1 Time-Dependent Cellular Uptake. The HEp2 cells were plated at 15,000 cells per well 
in a Costar 96-well plate (BD biosciences) and grown overnight. The 10 µM BODIPY solution 
was prepared by diluting 400 µM stock solution with medium containing 5% FBS and 1% 
antibiotic. The cells were treated by adding 100 µL/well of the 10 µM BODIPY solution at time 
periods of 0, 1, 2, 4, 8, and 24 hours. The loading medium was removed at the end of the treatments. 
The cells were washed with 1X PBS, and solubilized by adding 0.25% Triton X-100 in 1X PBS. 
BODIPY standard curves at 10 µM, 5 µM,  2.5 µM, 1.25 µM, 0.625 µM and 0.3125 µM 
concentrations were obtained by diluting 20 mM BODIPY solution with 0.25% Triton X-100 in 
1X PBS. A cell standard curve was prepared using 10,000, 20,000, 40,000, 60,000, 80,000, and 
100,000 cells per well. The cells were quantified using the CyQuant Cell Proliferation Assay (Life 
Technologies). The compound and cell number were determined using a FluoStar Optima micro-
plate reader (BMG LRBTEH), with wavelengths 355/520 nm and 570/615 nm. Cellular uptake 
was expressed in terms of nM compound per cell. 
 
2.4.6.2 Dark Cytotoxicity. The HEp2 cells were placed in a 96-well plate as above, with BODIPY 
concentrations of 400, 200, 100, 50, 25, 12.5, and 0 µM, five repetitions for each concentration, 
and then incubated at 37 °C. After 24 hour incubation, the compound was removed by washing 
the cells with 1X PBS and replaced with media containing 20% Cell Titer Blue. The cells were 
incubated for an additional 4 hours at 37 °C. The viable cells were measured using fluorescence at 
570/615 nm using a FluoStar Optima micro-plate reader.  The dark toxicity was expressed in terms 
of the percentage of viable cells. 
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2.4.6.3 Phototoxicity. The concentrations of 200, 100, 50, 25, 12.5, 6.25, 3.125 and 0 µM were 
used for the phototoxicity experiments. The HEp2 cells were placed in 96-well plates as described 
above, and treated with compound for 24 hours at 37 °C. After the 24 hour treatment, the loading 
media was removed. The cells were washed with media, and then refilled with fresh media. The 
cells were placed on ice and exposed to 610 nm LP filter light from a 100 W halogen lamp filtered 
through a 610 nm long pass filter (Chroma) for 20 minutes. An inverted plate lid filled with cold 
water to a depth of 5 mm acted as an IR filter.  The total light dose was approximately 1.5 J/cm2. 
After exposure to light, the cells were returned back to the incubator for 24 hours. After 24 hour 
incubation, the medium was removed and replaced with medium containing 20% of Cell Titer 
Blue. The cells were incubated for an additional 4 hours. The viable cells were measured by 
fluorescence at 570/615 nm using a FluoStar Optima micro-plate reader. The phototoxicity was 
expressed in terms of the percentage of viable cells. 
 
2.4.6.4 Microscopy.  HEp2 cells were plated in a 6-well plate and allowed to grow overnight. The 
cells were then exposed to 10 µM of the compound at 37 °C for more than 6 hours before adding 
the organelle tracer (Invitrogen). The working concentrations of organelle tracers were as 
following: LysoSensor Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 
nM, and BODIPY FL C5 Ceramide 50 nM. The organelle tracers were diluted in growing medium 
and the cells were incubated concurrently with the compound and the tracer for 30 minutes. After 
adding the tracer for 30 minutes, the loading medium is removed and cells were washed with 1X 
PBS three times. Images were acquired using a Leica DMRXA2 microscope with a water 
immersion objective and a YFP filter cube (Chroma Technologies). 
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2.4.7 Comparative Singlet Oxygen Quantum Yield Measurements 
To each well of a 6-well plate was added 2 mL containing 50 μM of 1, 3-
diphenylisobenzofuran (DPBF) and 5 μM of photosensitizers in DMSO. The plate was irradiated 
using a 71 W filtered light source of >500 nm with a Schott glass 500 nm long-pass yellow filter 
for 1 hour. At 15 minute increments, 200 μL aliquots were removed from each of the six wells and 
the absorbance was measured at 410 nm. The rate of singlet oxygen generation was determined by 
the decrease in absorbance of DPBF over time. Control solutions of DPBF-DMSO (negative 
control) and DPBF-methylene blue-DMSO (reference standard) were irradiated under the previous 
mentioned conditions. Singlet oxygen quantum yields were determined using the following 
equation: 
𝛷∆(𝑈) =  𝛷∆(𝑆𝑡𝑑) 𝑥 
SU
SStd
 
 
ΦΔ(U) is the singlet oxygen quantum yield of the sample, ΦΔ(Std) is the singlet oxygen 
quantum yield of the standard (methylene blue, 0.52), SU is the slope of the plot of absorbance 
versus time of the sample, and SStd is the slope of the plot of absorbance versus time of the standard. 
 
2.4.8. Octanol-water partition coefficients 
The partition coefficients (log P) were measured at room temperature by 1 mg of BODIPY 
in 4 mL 1-octanol in a volumetric tube followed by addition of 4 mL of water. After vortexing for 
5 min, the phases were allowed to separate.74 An aliquot of 1 mL from each layer was removed 
and the absorbance was read on a Varian Cary 50 Bio UV/VIS spectrophotometer with 10 mm 
path length quartz cuvette. 
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CHAPTER 3: SYNTHESIS, SPECTROSCOPIC, AND IN VITRO EVALUATION OF 
NEAR-IR DIIODO-BODIPYS WITH MULTI-MODE IMAGING AND PDT 
APPLICATIONS 
 
3.1 Introduction 
 
Recent advances in the field of oncology have provided many new treatment methods that 
provide valuable improvements over traditional therapies.  The development of targeted therapies 
has allowed for more precise treatment of various cancers by limiting treatment to specified and 
targeted tissues. The combination of targeting moieties with innovative treatment methods creates 
cancer therapy options that have the potential to be less physically damaging to patients while still 
remaining effective. As such, anti-cancer agents that have both fluorescent and therapeutic 
properties are highly valuable and underappreciated. 
The exploration of BODIPY (difluoro boron dipyrromethene)-based bioimaging agents has 
blossomed as an active area of research in recent decades, producing a multitude of fluorescent 
dyes with a variety of purposes including use as labels for biomolecules such as DNA, peptides, 
and lipids,1-4 as well as for applications as enzyme substrate fluorescent tags,5, 6 as environmental 
indicators (pH and ion sensors),7-10 and as cellular stains.11 Despite their extensive investigation 
and applicability, only a few studies have been published detailing the photophysical and 
biological properties on near-IR BODIPYs for applications as PDT photosensitizers and as 
radioimaging agents, particularly for PET and SPECT. 
PDT is an under-utilized effective and FDA approved treatment for several forms of cancer 
and age related macular degeneration.  PDT is a tri-modal cancer treatment therapy combining a 
photosensitizer, light, and cellular oxygen to generate cytotoxic oxygen species, including singlet 
oxygen in particular, that induce apoptosis and necrosis.12, 13 PDT has many benefits including 
limited long-term side effects, relatively short treatment times, the option of multiple treatments 
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to be administered, and is non-invasive due to its limited area of exposure.14-16 Effective 
photosensitizers must possess properties favoring singlet oxygen generation including high 
quantum yields of photosensitizer triplet state (ΦT > 0.4), long lifetimes of the triplet state (τT = 1 
μs), and must possess adequate energy (ET ≥ 95 kJ mol-1) for efficient energy transfer to triplet 
oxygen.  In addition, target cell selectivity over normal cells, low dark toxicity, high photostability, 
and high absorption coefficients in the near-infrared fluorescence imaging range 630 nm-800 nm 
are highly sought after. Utilizing fluorophores that absorb and emit in this “ideal biological 
window” allows for the use of valuable long wavelength light sources which provide more 
effective imaging through the reduction of autofluorescence of intracellular chromophores, 
decreased light scattering, and deeper tissue penetration, all while maintaining low photo-damage 
to cells.17, 18  
Current PDT agents fall short in their ability to treat a broad range of cancer types, most 
notably as a result of their limited effective depths of treatment penetration. Photofrin® (registered 
trademark of Pinnacle Biologics, Inc.) and Visudyne® (registered trademark of Novartis AG) are 
PDT agents that have been FDA approved for the treatment of esophageal, digestive tract, 
genitourinary tract, and lung cancer, and age related macular degeneration, respectively. Although 
effective, both drugs have drawbacks that limit their utilization. The more commonly prescribed 
Photofrin® is delivered as a mixture of isomers, displayed a diminished absorption at the clinically 
prescribed excitation wavelength, and showed prolonged retention in the body, which is 
accompanied by patient photosensitivity for several weeks following treatment.19  In order to 
broaden the effective scope of PDT, development of photosensitizers with increased extinction 
coefficient within the therapeutic window, high phototoxicity, and solubility in biological media 
capable of treating a range of cancer types in various states of the disease must be explored. 
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BODIPY dyes have recently been shown to have potential as effective PDT 
photosensitizers.20, 21 Their remarkable photophysical properties, including high extinction 
coefficients, high fluorescence quantum yields, strong absorption profiles and bright emissions, as 
well as their known ability to permeate cells make them suitable for exploration as PDT agents.22, 
23 Recent studies have shown that some BODIPYs bearing heavy atoms, such as iodine or bromine, 
possess cytotoxic properties when exposed to light while others remain non-toxic.24-26 It is believed 
that the additional effects of the “spin-orbit couplings” of heavy atoms helps to enhance 
intersystem crossing from the excited singlet to the triplet state desired for producing singlet 
oxygen.27-29  As several reports have shown, incorporation of iodines at the 2,6-positions leads to 
enhanced intersystem crossing, whereas addition of at the 3,5-positions promotes fluorescence.30  
On the other hand, the discovery of non-toxic halogenated BODIPYs, specifically those 
bearing iodines and fluorines, have the potential to serve as radioactive bioimaging agents for PET 
and SPECT, in addition to fluorescence imaging, with the incorporation of radioisotopes of iodine 
and fluorine. Nuclear imaging allows for the translation of the pathophysiological status of the 
tissues being imaged without interference. PET and SPECT are non-invasive 3D nuclear imaging 
techniques that allow for the mapping of a radiotracer‘s uptake in vivo.28 PET most commonly 
utilizes 18F labeled radiopharmaceuticals (t1/2 = 109 minutes) and a 
18F-labelled glucose derivative 
has shown to have great success in clinical imaging. Only a handful of reports have been published 
detailing the synthesis and evaluation of 18F-bearing BODIPYs for PET/fluorescence dual 
modality imaging.31-33 
An ideal radiopharmaceutical should possess characteristics such to provide detectable 
diagnostic particles with minimal biological effect to the cells or tissues. Radiopharmaceuticals 
should have a relatively short half-life, maintaining radioactivity for only the necessary length of 
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time needed to complete the diagnostic study, produce suitable radionucleotide emissions of 
desired energy, have high target to normal tissue ratio, possess a high target uptake, efficiently 
clear from blood and non-target tissue while lingering in target tissues for effective image contrast, 
and be inexpensive and relatively easy to produce. 
We have recently discovered that 8-(3,5-dimethyoxyphenyl)-2,6-diiodo-1,3,5,7-
tetramethyl-BODIPY (1) was readily taken up by HEp2 cells and induced phototoxic properties 
while remaining non-toxic in the dark (IC50 = 4 µM at 1.5 J/cm
2).24 The less than ideal absorption 
and emission wavelengths (535 nm and 549 nm, respectively) prevented this compound from being 
considered as a PDT agent. Subsequent work to extend the conjugation of the BODIPY-scaffold 
and induce a bathochromic shift via a Knoevenagel condensation of the 3, 5-dimethyls with 
indolyl, phenyl, thienyl, and pyrrolyl-aldehydes is explored herein. The photophysical and 
biological properties of these near-IR compounds has also been evaluated. 
 
3.2 Results and Discussion 
3.2.1 Syntheses  
In the previous Chapter, the synthesis of phototoxic BODIPY 1 (BODIPY 2a in Chapter 
2) via condensation of 2,4-dimethylpyrrole with 3,5-dimethoxybenzaldehyde, followed by 
oxidation, boron complexation, and iodination using iodic acid, in 33% overall yield (4 steps), was 
detailed.24 Compound 1 was found to possess favorable qualities as a PDT agent, with sufficient 
internal cellular uptake and a high dark:phototoxicity ratio (> 100). The major drawbacks of this 
compound were the inability to differentiate the compound from the organelle trackers under the 
fluorescence microscope and the compound’s low solubility in aqueous media. An increase in the 
compound’s absorption and emission maxima (λmax = 535 and 549 nm, respectively, in 
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dichloromethane) into the near-IR would allow for the compound to be sufficiently viewed within 
cells. Incorporation of one or two polar styryl groups introduced through Knoevenagel 
condensation of the 3,5-dimethyls of 1 with polar aromatic aldehydes, as shown in Scheme 3.1, 
would effectively red-shift the absorption and emission wavelengths into the near-IR as well as 
promote water solubility. 
 
 
Scheme 3.1: Knoevenagel condensation of BODIPY 1 with aryl-aldehydes. 
 
The incorporation of the polar styryl groups, affording mono- and di-substituted styryl-
BODIPYs (2a-e and 3a-e respectively) in 15-40% yields was accomplished by condensing excess 
aldehyde with BODIPY 1 in refluxing toluene following the Knoevenagel strategy.34  The mixture 
was stirred over molecular sieves to remove the water formed over the course of the reaction. 
Production of water from the condensation hinders subsequent reactions in situ and thus must be 
removed with the aid of molecular sieves to promote product formation. To this mixture was added 
piperidine and acetic acid.  The mixture was stirred in the microwave under 400W power at 90°C 
for 1 hour for the production of 2a, 3a (38% and 40% yield) and 2b, 3b (40% and 26% yield).  
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Microwave-assisted syntheses and functionalizations of BODIPYs have been previously 
investigated34-36 and applied to Knoevenagel condensations.37 Heating under microwave 
irradiation allows for shorter reaction times, producing high yields and low decomposition of 
products, and recently has been utilized to functionalize BODIPY with aliphatic chains,35 and in 
the synthesis of an aza-dipirrin.36 It was noted that over the course of experimentation that 
concentration played a significant role in yields with a 20µM solution being ideal. Upon 
completion, the mixture was quenched with water. The aqueous layer was extracted with DCM 
and the combined organic layers were dried over Na2SO4. The solvent was removed under vacuum 
and the styryl-BODIPYs were purified by silica gel column chromatography to yield blue solid 
mono-styryl-BODIPYs and green solid di-styryl-BODIPYs. 
 Several attempts were made to synthesize the unsymmetrical mixed di-styryl BODIPY 4 
by condensing the mono-styryl 2a with tri(ethyleneglycol)benzaldehyde 8 or mono-styryl 2b with 
indole-3-carboxaldehyde, Scheme 3.2. Despite modifying reaction conditions, including the 
number of aldehyde equivalents used, temperature, microwave radiation versus bench-top 
heating/reflux, and the use of a Soxhlet extractor filled with calcium chloride to remove water from 
the refluxing toluene, BODIPY 4 could never be produced in greater than 4% yield and 
reproducibility was challenging. As such, BODIPY 4 could not be characterized by NMR but was 
identified by ESI-HRMS with m/z corresponding to [M+Na]+ found at 1036.1300. 
The aryl groups chosen to extend the π-conjugation of BODIPY 1, a triethylene glycol or 
a heteroatom aromatic group, were selected for their ability to increase the styryl-BODIPY 
solubility in aqueous media and enhance cellular permeability.32 Initially, indole-3-carbaldehyde 
was utilized with the intent of extending π-conjugation and increasing the wavelengths of 
absorption and emission of the styryl-BODIPY, and to enhance cellular uptake and biological 
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efficacy of the diiodo-BODIPY due to its resemblance to the naturally occurring amino acid 
tryptophan, a key component in the structure of many enzymes and proteins, and a precursor to 
the necessary biomolecules serotonin, melatonin, and niacin.38 We have also recently reported the 
synthesis and cytotoxicity properties of near-IR mono- and di-indolylstyryl-BODIPYs34, that 
showed high uptake by HEp2 cells with no detectable cytotoxicity in the absence or presence of 
light). This offered a direct comparison for the efficacy of iodination of BODIPYs 2a and 3a for 
their PDT applicability. 
 
  
Scheme 3.2: Synthesis of 4 from 2a and 2b. 
 
 Choosing an appropriate route for the synthesis of the water solubilizing 
tri(ethyleneglycol)benzaldehyde proved challenging.  Because BODIPY 1 is relatively water 
insoluble, incorporating polyethylene glycol (PEG) groups onto the fluorophore would enhance 
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delivery to target tissues by increasing water solubility, cell permeability, and serum life.39  
Creating our desired PEG group had its own challenges. Our synthesis began with the simple 
conversion of the terminal hydroxyl group of tri(ethyleneglycol)monomethyl ether into a sufficient 
leaving group, in this case a tosylate group was chosen, Scheme 3.3. The terminal hydroxyl group 
of commercially available tri(ethyleneglycol)monomethyl ether was converted into a tosylate 
group by treating the ether with KOH and p-toluenesulfonyl chloride giving compound 5.40 
Addition of compound 5 to commercially available 4-(hydroxymethyl)benzaldehyde dimethyl 
acetal using NaH in THF at room temperature readily yielded compound 6 in quantitative yield.41 
At this point, separation of the starting materials and product was feasible. Deacetalization proved 
to be more challenging. Compound 6 was treated with excess TFA to convert the acetal into the 
desired aldehyde 7.42 However, complete conversion from the acetal to the aldehyde was never 
achieved, despite numerous attempts under extended reaction times. Furthermore, separation of 
the starting material 6, from the aldehyde product 7 proved unmanageable.  
 
 
Scheme 3.3: Attempted synthesis of aldehyde 7. 
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 At this point, the decision was made to employ a different protecting group in hopes of 
easier purification and complete conversion to the desired aldehyde. The thiolane protecting group 
proved to be an ample choice. Synthesis of the PEG-moiety was carried out in 3 steps from 4-
hydroxybenzaldehyde using the previously synthesized tosyl-tri(ethyleneglycol)monomethyl 
ether 5, Scheme 3.4. The thiolane group was readily added to 4-hydroxybenzaldehyde in the 
presence of BF3·OEt2 in THF to produce compound 8 as a yellow solid in 81% yield. 
43 Compound 
5 from the previous synthesis was employed and readily added to compound 8 using K2CO3 in 
refluxing ACN to yield compound 9 in 93% as a light brown oil. 44 Removal of the thiolane group 
using mercury perchlorate in THF afforded aldehyde 10 as a colorless oil in 64% yield.45 
 
 
Scheme 3.4: Synthesis of tri(ethyleneglycol)benzaldehyde 10. 
 
It was noted over the course of experimentation that prolonged refluxed led to significant 
decomposition of both starting materials, BODIPY 1 in particular, and products; BODIPYs 2a and 
3a quickly decomposed (< 24 h) when left in solution or in crystalline form under ambient light, 
Figure 3.1 a/b, c/d, and Figure 3.2 a/b. For this reason, 5-nitroindole-3-carboxaldehyde was 
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prepared according to the literature from 5-nitroindole using POCl3,
46 and was condensed with 1 
by stirring in toluene at 60°C in the presence of p-TsOH and piperidine for 6.5 hours to yield 15% 
of the mono-nitroindolylstyryl product 2c and 22% of the di-nitroindolylstyryl BODIPY 3c after 
careful column chromatography.  
Incorporation of the electron-withdrawing nitro group on the indole-3-carboxaldehyde was 
hoped to enhance the stability of BODIPYs 2c and 3c relative to 2a and 3a. As expected, the 
addition of the nitro group did enhance the stability of the BODIPYs to an extent, Figure 3.1 g/h 
and Figure 3.2 e/f, however, significant decomposition was still observed with time for the 
indolylstyryl-BODIPYs 2a/3a and 2c/3c. 1H-NMR investigations of 2c and 3c in DMSO-d6 upon 
exposure to ambient light for up to 12 days were also conducted, Figure 3.3. Both compounds 
maintained stability up to 1 day, however decomposition was observed after that with new 
aromatic peaks becoming present over time, particularly for the di-substituted BODIPY 3c. The 
integration of the NMR signals corresponding to the nitroindolylstyryl group of BODIPY 3c 
detected at 9.1 (NH), 8.8, 8.4, 8.2, 7.8, 7.7, and 7.5 significantly decreased by day 12, while signals 
corresponding to what appears to be nitroindolyl derivatives were noted as time progressed. 
With only two of the six synthesized BODIPY possessing significant stability, the decision 
was made to explore other heteroatom aromatic aldehydes. The commercially available thiophene-
2-carboxaldehyde and the previously synthesized by the Vicente/Smith research group 5-
methylester-2,4-dimethyl-pyrrol-3-carboxaldehyde were condensed with BODIPY 1 in the 
presence of piperidine and p-TsOH. The mono- and di-thienylstyryl BODIPYs 2d and 3d were 
acquired after refluxing in toluene for 4 hours, in 19% and 25% yields, respectively. Over the 
course of experimentation and condition optimization, it was noted that the greater reactivity of 
the thiophene-2-carbaldehyde favored greater production of the di-styryl product over the mono 
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and careful monitoring of the reaction was required in order to return mono-styryl BODIPY 2d in 
sufficient yield. 
 
a)    b)  
 
c)    d)  
 
Figure 3.1. Time-dependent fluorescence spectra of 25 mM solutions of BODIPYs 1 (a: dark, b: 
light), 2a (c: dark, d: light), 2b (e: dark, f: light), 2c (g: dark, h: light), 2d (i: dark, j: light), 2e (k: 
dark, l: light) in DMSO at 0 min (blue), 4 hours (orange), 10 hours (grey), and 24 hours (yellow) 
after solution preparation at room temperature. Compounds were tested in the absence of light and 
after exposure to ambient light. The excitation wavelengths for BODIPYs were 1 (480 nm), 2a, 
2c, 2d, and 2e (540 nm), 2b (545 nm). 
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e)     f)  
 
g)    h)  
 
i)     j)  
(Figure 3.1 continued) 
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k)     l)  
(Figure 3.1 continued) 
 
The condensation of 5-methylester-2,4-dimethyl-pyrrol-3-carboxaldehyde with BODIPY 
1 required more time than most other BODIPYs, stirring at 60°C for 48 hours in the presence of 
piperidine and p-TsOH to yield 19% of the mono-pyrrolylstyryl 2e and 39% of the di-
pyrrolylstyryl 3e. The stability of these compounds was also examined as shown in Figure 3.1, i/j 
and j/k, and Figure 3.2 g/h and i/j. Notably, the thienylstyryl-BODIPYs 2d and 3d possessed 
similar stability to 2b/3b, whereas the pyrrolylstyryl-BODIPYs 2e and 3e decomposed within 24 
hours. 
The structures of all compounds were confirmed by 1H-NMR, 13C-NMR, HRMS (ESI-
TOF) or GCMS spectrometry, and UV/VIS and fluorescence spectroscopies. In the 1H-NMR, the 
ortho-phenyl hydrogens for all compounds appeared as doublets at ~ 6.5 ppm, while the para-
hydrogen presented as a triplet shifted slightly downfield at ~ 6.6 ppm. The styryl groups double 
bonds have a trans (E) configuration in all BODIPYs, as indicated by the coupling constants (J) of 
the alkene protons, between 16.2 - 17.1 Hz. 
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a)    b)  
c)    d)  
e)      f)  
 
Figure 3.2: Time-dependent fluorescence spectra of 25 mM solutions of BODIPYs 3a (a: dark, b: 
light), 3b (c: dark, d: light), 3c (e: dark, f: light), 3d (g: dark, h: light), and 3e (i: dark, j: light) in 
DMSO at 0 min (blue), 4 hours (orange), 10 hours (grey), and 24 hours (yellow) after solution 
preparation at room temperature. Compounds were tested in the absence of light and after exposure 
to ambient light. The excitation wavelengths for BODIPYs were 3a (660 nm), 3b (580 nm), 3c 
(635 nm), 3d (580 nm) and 3e (630 nm). 
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g)    h)  
 
i)        j)  
 
(Figure 3.2 continued) 
 
Significant differences were seen in chemical shifts of the 1,3,5,7-tetramethyls. Compound 
1’s tetramethyls displayed as two sets of equivalent protons, where the 1,7-dimethyls lie upfield 
(1.5 ppm) from the 3,5-dimethyls (2.5 ppm) due to meso-group shielding. Addition of one styryl 
group creates asymmetry in the BODIPY causing the remaining three methyls to appear as 
equivalent singlets at 2.7 ppm, 1.6 ppm, and 1.5 ppm. Return to symmetry through the 
incorporation of a second equivalent styryl group brought about a reappearance of a single signal 
for the 1,7-dimethyls at 1.6 ppm. Only slight changes in the chemical shifts of the styryl groups 
were observed in the 1H- and 13C-NMR spectra of the mono- versus di-styryl-BODIPYs. All 
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spectra were recorded in deuterated chloroform, with exception of 3c and 3e, which were obtained 
in DMSO-d6 and acetone-d6, respectively, as a result of their decreased solubility in chloroform 
and dichloromethane. 
 
a)  
b)  
Figure 3.3: Time-dependent 1H-NMR of BODIPY 2c (top) and 3c (bottom) in DMSO-d6. 
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3.2.2 X-ray Crystal Structural Determinations 
Single crystals of 1 and 3b suitable for X-ray analysis, Figure 3.4, were grown from slow 
evaporation of acetone. Exploration of the X-ray structures of 1 and 3b reveal the expected 
planarity and 2-fold symmetry of the eight carbon two nitrogen core that extended through the 2,6-
diiodo groups. The C9BN2 ring system exhibited mean deviation of 0.013 Å for 1 and 0.011-0.035 
Å for the four independent molecules of 3b. In both cases the iodine atoms lie less than 0.11 Å 
from these mean planes, and the methyl C atoms less than 0.06 Å. The meso-phenyl groups are 
roughly orthogonal to the core to reduce steric strain caused by the 1,7-dimethyls, forming dihedral 
angles of 79.97(2)° for 1 and 88.9(2)-90.0(2)° for the four independent molecules of 3b. The boron 
atom possesses tetrahedral geometry with the BF2 groups also lying perpendicular to the BODIPY 
core, forming dihedral angles of 89.23(4)° for 1 and 87.7(9)-89.3(10)° for 3b. Short intermolecular 
B-F...π interactions are observed between one pair of independent molecules in the crystal of 3b. 
The distances between the F atoms of one molecule and the centroids of the central ring of the 
C9BN2 ring system of another molecule are 2.750 and 2.767 Å. The polyether chains of 3b are 
very flexible, and the eight independent chains exhibit a wide variation of conformations in the 
solid. The trans (E) geometry of the styryl double bonds was confirmed by the X-ray structure of 
3b. 
  
3.2.3 Spectroscopic Investigations 
The spectroscopic characteristics of the BODIPYs were explored in dichloromethane, 
tetrahydrofuran, and DMSO and the results are summarized in Figures 3.5 – 3.7 and Table 3.1. 
Utilization of three solvents revealed a solvent influence on the solubility and optoelectronic 
profiles of all BODIPYs as solvent polarity increased as follows DCM < THF < DMSO. 
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Incorporation of one styryl group onto the BODIPY core, as seen in 2a-e, induced a pronounced 
red-shift of 59 – 98 nm in the absorption and 59 – 125 nm in emission compared to the 
tetramethylated BODIPY 1 in DMSO. Addition of a second styryl group created even greater red-
shifts compared to 1 of 126 – 189 nm for the absorption and 129 – 220 nm in the emission profile, 
due to further extension of the system’s π-conjugation. Additionally, the absorption and emission 
bands became broader with the increasing number of styryl substituents.   
 
       
Figure 3.4: Molecular structures of BODIPYs 1 and one of the four independent molecules of 3b, 
from X-ray crystal structure determinations. Ellipsoids are drawn at the 50% probability level. 
 
A stong Q-band absorption indicating the S0-S1 (π-π*) electronic transition is observed for 
all BODIPYs and is accompanied by a shoulder at slightly lower wavelength that is attributed to 
the vibrational transitions.37 This shoulder is more pronounced for the styryl-BODIPYs and in 
BODIPY 1 
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particular, for the distyryl-BODIPY 3a in DMSO. Additional broader and weaker absorption bands 
were noted in the absorption spectra of the styryl-BODIPYs which centered at 460 nm that are 
likely due to the S0-S2 transition.
37  
All BODIPYs displayed absorption maxima within the desired PDT biological window, 
between ca. 600 and 770 nm in DMSO with the longest wavelength absorptions belonging to the 
di-styryl-BODIPYs, in particular the di-indolylstyryl- 3a and 3c. Interestingly, incorporation of 
the styryl groups and corresponding extension of π-conjugation, which typically creates a 
reduction of fluorescence quantum yields, enhanced the fluorescence quantum yields of the styryl-
fluorophores 2a-c and 3a,b compared to 1 which lacks styryl groups. 
 
a)  
 
 
Figure 3.5: Normalized absorption spectra (a) and emission (b) of BODIPYs 1 (black solid), 2a 
(purple solid), 2b (blue solid), 2c (green solid), 2d (yellow solid), 2e (red solid), 3a (purple dash), 
3b (blue dash), 3c (green dash), 3d (yellow dash), and 3e (red dash) in DMSO at room temperature. 
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b)  
 
(Figure 3.5 continued) 
 
 
Figure 3.6: Normalized absorption spectra of BODIPYs 1 (black solid), 2a (purple solid), 2b (blue 
solid), 2c (green solid), 2d (yellow solid), 2e (red solid), 3a (purple dash), 3b (blue dash), 3c (green 
dash), 3d (yellow dash), and 3e (red dash) in DCM at room temperature. 
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Figure 3.7: Normalized absorption spectra of BODIPYs 1 (black solid), 2a (purple solid), 2b (blue 
solid), 2c (green solid), 2d (yellow solid), 2e (red solid), 3a (purple dash), 3b (blue dash), 3c (green 
dash), 3d (yellow dash), and 3e (red dash) in THF at room temperature. 
 
This effect was more pronounced in BODIPYs 2b and 3b, bearing the triethylene glycol 
groups, likely as a result of its higher solubility in the polar organic solvents.25, 44, 47 Characteristic 
of most BODIPYs encountered in literature, the styryl-BODIPYs displayed large extinction 
coefficients (log ε = 4.1-4.9) and Stokes’ shifts ranging from 11 nm to 43 nm with the greater 
enhancement observed for the mono-styryl BODIPYs. 
Concentration-dependent aggregation studies on the Q-band absorption maxima of all 
BODIPYs were carried out in DMSO, as shown in Figure 3.8, revealing strict correlation to the 
Beer- Lambert law with R2 values calculated at greater than 0.98, suggesting that aggregation did 
not occur with neither BODIPY 1 nor the styryl-BODIPYs aggregation in this solvent. 
Additionally observed were small to moderate red-shifts in λmax (1 - 25 nm) for the BODIPYs as 
solvent polarity increases from DCM (least polar) to THF to DMSO (most polar). This suggests 
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that the more polarized excited states of the BODIPYs find greater stabilization in the more polar 
solvent.37 
BODIPYs bearing 2,6-diiodo groups are expected to possess red-shifted absorptions and 
emissions compared to their unhalogenated counterparts, likely due to a comparatively reduced 
HOMO – LUMO gap.24, 26 Decreased fluorescent quantum yields are also observed as a result of 
a more favorable, competing energy release pathway from the excited S0 state. Intersystem 
crossing induced conversion of the excited singlet state to the excited triplet state via spin-orbit 
coupling created by the iodine’s heavy atom effect results in few excited electrons relaxing via 
fluorescence. 
 
3.2.4 In vitro Studies 
3.2.4.1 Cytotoxicity. In order to determine the efficacy of the synthesized BODIPYs as potential 
PDT agents, their concentration-dependent dark and photo (light dose ~ 1.5 J/cm2) cytotoxicities 
were investigated using the Cell Titer Blue assay in human carcinoma HEp2 cells, the results of 
which are summarized in Table 3.2 and Figures 3.9 and 3.10. All of the mono- and di-styryl-
BODIPYs were non-toxic in the dark (IC50 > 400 µM), with exception of mono-indolylstyryl-
BODIPY 2a, which showed low cytotoxicity (IC50 = 148 µM), likely as a result of its instability 
and suspected decomposition into toxic by-products. All the mono-styryl-BODIPYs were highly 
phototoxic when exposed to an approximately 1.5 J/cm2 light dose, with IC50 values between 2 
and 15 µM. The di-styryl-BODIPY were all non-cytotoxic with determined IC50 > 100 µM.  
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a)    b)   
c)    d)     
e)     f)      
Figure 3.8: Concentration-dependent absorption of BODIPYs 1 (a), 2a (b), 2b (c),* 2c (d), 2d (e), 
2e (f), 3a (g), 3b (h), 3c (i), 3d (j),* and 3e (k)* in DMSO at 3.125µM (green), 6.25 µM (orange), 
12.5 µM (grey), 25 µM (yellow), and 50 µM (blue). *Note: Absorbance at 50 µM extended beyond 
detectable limit. 
0
0.5
1
1.5
2
2.5
3
400 425 450 475 500 525 550 575 600
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
y=0.0509x - 0.1344
R2=0.9752
0
0.5
1
1.5
2
2.5
3
400 450 500 550 600 650 700 750
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
y=0.0498x + 0.0979
R2=0.9986
0
0.5
1
1.5
2
2.5
400 450 500 550 600 650 700
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
y=0.0414x + 0.0731
R2=0.9992
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
450 501 551 601 651
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
y=0.0275x + 0.0771
R2=0.9936
0
0.5
1
1.5
2
2.5
400 450 500 550 600 650 700
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
y=0.094x - 0.1494
R2=0.9934
0
0.5
1
1.5
2
2.5
3
450 500 550 600 650 700
A
b
s
o
rb
a
n
c
e
Wavelength (nm)
y=0.0484x + 0.1446
R2=0.9965
132 
 
 g)   h)     
i)      j)  
k)  
(Figure 3.8 continued) 
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Table 3.1: Absorption and emission properties of BODIPYs in dichloromethane, THF, and 
DMSO relative to rhodamine 6G (Φf = 0.95, EtOH for BODIPY 1) and methylene blue (Φf = 
0.03, MeOH for all other BODIPYs). 
BODIPY Solvent Abs λmax  
(nm) 
Log ε 
(M-1cm-1) 
Em λmax 
 (nm) 
Φf 
 
Stokes’ shift 
(nm) 
1 DMSO 538 3.55 551 0.03 14 
 CH2Cl2 618 4.64 661 0.19 43 
2a THF 627 4.76 668 0.20 41 
 DMSO 636 4.47 676 0.17 40 
 CH2Cl2 597 4.77 611 0.30 14 
2b THF 598 4.70 612 0.32 14 
 DMSO 601 4.17 624 0.52 23 
 CH2Cl2 599 4.08 610 0.40 11 
2c THF 598 4.06 610 0.30 11 
 DMSO 604 4.61 621 0.15 17 
 CH2Cl2 606 4.41 630 0.37 24 
2d THF 612 4.43 635 0.32 23 
 DMSO 622 4.46 651 0.19 29 
 CH2Cl2 606 4.85 628 0.21 22 
2e THF 611 4.90 632 0.22 21 
 DMSO 612 4.82 639 0.23 27 
 CH2Cl2 702 4.54 735 0.15 33 
3a THF 715 4.62 748 0.12 33 
 DMSO 727 4.39 771 0.10 44 
 CH2Cl2 664 4.75 687 0.24 23 
3b THF 664 4.80 684 0.19 20 
 DMSO 666 4.79 695 0.17 29 
 CH2Cl2 690 4.45 721 0.02 31 
3c THF 695 4.79 720 0.03 25 
 DMSO 712 4.87 748 0.02 36 
 CH2Cl2 670 4.59 682 0.02 12 
3d THF 670 4.60 680 0.01 11 
 DMSO 675 4.59 692 0.01 17 
 CH2Cl2 678 4.86 710 0.10 32 
3e THF 685 4.80 713 0.07 28 
 DMSO 693 4.96 731 0.07 38 
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Previous reports on similarly designed fluorophores indicate that the presence of electron-
donating alkoxyphenyl substituents at the meso-position and two iodides or bromides at the 2,6-
positions,24-26, 47 as in BODIPY 1, induces high phototoxicity with negligible dark cytotoxicity. 
Interestingly, despite possessing the same heavy atom bearing, 3,5-dimethoxyphenyl 8-substituted 
core, only the mono-styryl BODIPYs retain the phototoxic properties of BODIPY 1 whereas, the 
di-styryl BODIPYs lacked the phototoxicity, regardless of all being efficient singlet oxygen 
producers (see Table 3.2). Comparatively, the mono-styryl BODIPYs were more efficient singlet 
oxygen producers compared to their di-styryl analogs, with BODIPYs 2a and 2b, the most 
phototoxic of all BODIPYs, also possessing the highest singlet oxygen quantum yields. As a result 
of their unsymmetrical structures, the mono-styryl-BODIPYs may have more favorable cellular 
uptake and may bind to specific intracellular proteins, including the anti-apoptotic Bcl-2 proteins. 
On the other hand, the symmetric structure of the di-styryl-BODIPYs induces low or no 
phototoxicity, particularly for the most soluble derivatives, BODIPYs 3b, 3c and 3e.  
 
Table 3.2: Cytotoxicity (CellTiter Blue assay, 1.5 J/cm2), singlet oxygen quantum yields (relative 
to methylene blue) and partition coefficients in octanol-HEPES buffer (log P) of BODIPYs. 
 
BODIPY Dark toxicity  
(IC50, µM) 
Phototoxicity  
(IC50, µM) 
ΦΔ Log P 
2a 148 2.0  0.72 1.04 
2b > 400 3.8  0.78 0.72 
2c > 400 14.5  0.63 0.73 
2d > 400 5.0 0.55 1.50 
2e > 400 4.0 0.65 1.10 
3a > 400 >100 0.64 1.16 
3b > 400 >100 0.65 0.89 
3c > 400 >100 0.37 1.01 
3d > 400 >100 0.34 1.94 
3e > 400 > 100  0.43 1.88 
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Recent reports from Akkaya et al.26 and Ng et al.47 on several symmetric 3,5-distyryl-2,6-
diiodo or 2,6-dibromo BODIPYs described high phototoxicity of these compounds on K562 and 
HT20 cells, respectively. The most phototoxic di-styryl BODIPY reported in these studies 
contained five triethylene glycol chains (IC50 = 7 nM at 48 J/cm
2), to which the high phototoxicity 
was credited to its high cellular uptake and preferential localization within the ER of the cells. 
Similarly, unsymmetrical distyryl-2,6-diiodo-BODIPYs bearing three ethylene glycol groups and 
amine functionalities were also phototoxic to HT29 cells as a result, in part, to localization within 
mitochondria.25  
 
 
 
 
Figure 3.9: Dark toxicity of BODIPYs 2a (purple solid), 2b (blue solid), 2c (yellow solid), 2d 
(green solid), 2e (red solid), 3a (purple dash), 3b (blue dash), 3c (yellow dash), 3d (green dash), 
and 3e (red dash) at 10 µM by HEp2 cells. 
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Figure 3.10: Phototoxicity (1.5 J/cm2) of BODIPYs 2a (purple solid), 2b (blue solid), 2c (yellow 
solid), 2d (green solid), 2e (red solid), 3a (purple dash), 3b (blue dash), 3c (yellow dash), 3d (green 
dash), and 3e (red dash) at 10 µM by HEp2 cells. 
 
3.2.4.2 Time-Dependent Cellular Uptake. With toxicity results contrary to published findings 
on similar molecules, the cellular uptake was evaluated over a 24 hour period in an attempt to 
explain the cause of the observed phototoxicities, the results of which are shown in Figures 3.11 
and summarized in Table 3.2. As anticipated, all BODIPYs were efficiently internalized within 
cells. However, no distinct trend was observed for how quickly and efficiently mono-styryl versus 
di-styryl BODIPYs were taken up. Additionally, the extent of their uptake failed to correlate with 
the calculated partition coefficients (log P)48 in octanol-HEPES buffer pH = 7.4, shown in Table 
3.2, corresponding to their BODIPYs’ hydrophobic character. The di-styryl BODIPYs, 
nonetheless, did display higher hydrophobic character when compared to their mono-styryl 
counterparts.  
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Figure 3.11: Time-dependent cellular uptake of BODIPYs 2a (purple solid), 2b (blue solid), 2c 
(yellow solid), 2d (green solid), 2e (red solid), 3a (purple dash), 3b (blue dash), 3c (yellow dash), 
3d (green dash), and 3e (red dash) at 10 µM by HEp2 cells. 
 
In the first two hours of experimentation, BODIPYs 2b,e and 3a,d were taken up very 
quickly, however after 24 hours BODIPYs 2a-c and 3d,e had accumulated the greatest, while 2e 
was internalized the least. From eight to 24 hours, all BODIPYs except 2e and 3a continued to 
significantly accumulate.  
 
3.2.4.3 Intracellular Localization. The subcellular localization of all BODIPYs was investigated 
by fluorescent microscopy after six hours of uptake, Figures 3.12 – 3.19. For microscopic imaging, 
organelle-specific fluorophores BODIPY Ceramide (Golgi), LysoSensor Green (lysosomes), 
MitoTracker Green (mitochondria), and ER Tracker Blue/White (ER) were used in the overlay 
experiments. The purple and yellow/orange colors indicate co-localization of BODIPY and 
organelle tracker. All BODIPYs localized within the studied organelles. The preferential major 
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sites of localization for the mono-styryl-BODIPYs were the ER, lysosomes, and mitochondria, 
whereas the di-styryl-BODIPYs were found primarily in the Golgi and lysosomes, and in the ER 
and mitochondria to a lesser extent. This localization in key organelles, along with their 
unsymmetrical structure, may be responsible for the higher phototoxicities observed in the mono-
styryl-diiodo-BODIPYs. Accumulation of photosensitizers in important PDT targets, like the 
cellular ER and mitochondria, can induce rapid cell death due to photodamage to anti-apoptotic 
Bcl-2 proteins found in the membranes of the ER and mitochondria, and/or by direct mitochondrial 
photodamage.49 The mono-styryl-diiodo-BODIPYs may preferentially adhere better to anti-
apoptotic Bcl-2 proteins compared to their di-styryl analogs, leading to cell apoptosis and/or 
autophagy,50 and subsequent cell death. Previous studies detailing phototoxic BODIPYs that 
localize preferentially in the ER or mitochondria corroborate these findings.24-26, 47 
 
3.2.4 Singlet Oxygen Generation Studies 
Singlet oxygen generation studies were conducted on BODIPYs 2a-e and 3a-e by 
quantifying the absorbance variance of a documented singlet oxygen acceptor, 1,3-
diphenylisobenzofuran (DPBF), in the presence of photosensitizer generated singlet oxygen.29, 51 
The decrease in DPBF’s absorbance band at 410 nm (at a preliminary concentration of 50 μM in 
DMSO) was determined over the course of an hour, taking measurements at 15 minute intervals. 
The photosensitizer and DPBF were exposed to a long-pass filtered light source of >500 nm to 
efficiently excite the photosensitizer. An equivalent concentration of methylene blue (ΦΔ = 0.52) 
was utilized as a reference. 
  
139 
 
 
Figure 3.12: Subcellular localization of BODIPY 1 in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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Figure 3.13: Subcellular localization of BODIPY 2a in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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Figure 3.14: Subcellular localization of BODIPY 2b in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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Figure 3.15: Subcellular localization of BODIPY 2c in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
143 
 
 
Figure 3.16: Subcellular localization of BODIPY 2d in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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Figure 3.17: Subcellular localization of BODIPY 2e in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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Figure 3.18: Subcellular localization of BODIPY 3a in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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Figure 3.19: Subcellular localization of BODIPY 3b in HEp2 cells at 10 mm for 6 h. a) Phase 
contrast, b) overlay of the BODIPY fluorescence and phase contrast, c) ER tracker blue/white 
fluorescence, e) MitoTracker green fluorescence, g) BODIPY Ceramide, i) Lyso-Sensor green 
fluorescence, and d), f), h), and j) overlays of organelle tracers with the BODIPY fluorescence.  
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As previous in vitro studies in Chapter 2 indicated, BODIPYs bearing 2,6-iodines are 
expected to enhance production of singlet oxygen, the main cytotoxic species in PDT. Yet we have 
shown that the meso-substituent plays a significant role in determining which 2,6-diiodo-
BODIPYs are phototoxic to HEp2 cells.24 Since BODIPY 1 was both an efficient generator of 
singlet oxygen (ΦΔ = 0.40) and showed high phototoxicity, it was expected that they styryl-
derivatives of BODIPY 1 would also be good singlet oxygen generators. As anticipated, the 
comparative singlet oxygen quantum yields of the BODIPYs showed that all BODIPYs produced 
singlet oxygen (0.34 > ΦΔ > 0.78) but only the mono-styryl derivatives were phototoxic to HEp2 
cells (vide infra).  
 
3.3 Conclusions  
A series of five mono- and five di-styryl-diiodo-BODIPYs synthesized via Knoevenagel 
condensations on a 2,6-diiodo-1,3,5,7-tetramethyl-BODIPY (1) with indolyl-, 
tri(ethyleneglycol)phenyl-, thienyl-, and pyrrolyl-aldhydes in yields up to 40% upon microwave 
irradiation (90 oC for 1h at 400 W) yield far-red to near-IR fluorophores with absorptions and 
emissions in the ca. 600-770 nm region. Heteroaromatic and tri(ethyleneglycol)phenyl-styryl 
groups were introduced with the intent in inducing a red-shift in the the absorption and emission 
profiles of phototoxic BODIPY 1, as well as to increase its solubility and cellular permeability.  
The X-ray structure of polyether bearing-BODIPY 3b was obtained, which confimred the 
expected planarity and symmetry of the BODIPY core and corroborated the E configurations of 
the styryl groups with 1H-NMR. Incorporation of styryl groups resulted in extended π-conjugation 
of BODIPY 1, with the mono-styryl BODIPYs 2a-e producing 60 - 130 nm red-shifts in the 
absorption and emission bands, and 130 - 220 nm red-shifts were observed for the di-styryl-
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BODIPYs in DMSO. The indolylstyryl- and pyrrolylstyryl-BODIPYs decomposed upon light 
exposure, despite an attempt to increase stability through the incorporations of electron-
withdrawing groups (NO2, CO2Et). Conversely, both the mono- and di-tri(ethylene glycol)phenyl- 
and thienyl-styryl-BODIPYs were stable under similar light conditions.  
Although all BODIPYs generate singlet oxygen, the monostyryl-diiodo-BODIPYs were 
found to be better generators of singlet oxygen (ΦΔ = 0.55 - 0.78) and displayed high phototoxicity 
(IC50 < 15 µM at 1 J/cm
2) toward HEp2 cells. It is suggested that they lack of extended symmetry 
of the mono-styryl-BODIPYs and their preferential localization within the ER and mitochondria 
of cells, likely favoring their binding to intracellular proteins, such as the anti-apoptotic Bcl-2 
found in these organelles. On the other hand, the distyryl-diiodo-BODIPYs were weaker 
generators of singlet oxygen (ΦΔ = 0.34 - 0.65) and had no phototoxicity (IC50 > 100 µM at 1.5 
J/cm2). Consequently, BODIPYs 2a-e show the most promise for application as photosensitizers 
in PDT, whereas 3a-e are promising multi-mode agents for PET, SPECT, and near-IR fluorescence 
imaging.  
Particulary of interest among the phototoxic mono-styryl BODIPYs, 2a was found to 
strongly absorb at λmax 636 nm in DMSO, with high extinction coefficient (~ 29,000 M-1.cm-1), to 
be the most phototoxic among the BODIPYs investigated (IC50 = 2 µM at 1 J/cm
2 with dark to 
phototoxicity ratio of 74), probably as a result of efficient singlet oxygen generation (ΦΔ = 0.72), 
and is therefore particularly promising as a PDT photosensitizer. On the other hand, BODIPY 3b 
shows near-IR emission at λmax 697 nm in DMSO, with high fluorescence quantum yield (Φf = 
0.44) despite the 2,6-diiodides favoring intersystem crossing and singlet oxygen generation via the 
heavy atom effect, and is a promising dual near-IR fluorescent and PET or SPECT imaging probe 
upon istallation of radiofluorine, via exchange of one of the fluorides in the BF2, or radioiodine at 
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the 2 or 6 positions. BODIPYs 2a, the most far-red absorbing and emitting of the toxic mono-
styryl BODIPYs, and  3b and 3e, the most efficient singlet oxygen producers of the non-toxic di-
styryl-BODIPYs, will undergo in vivo evaluation in the near future. 
 
3.4 Experimental 
3.4.1 General Information  
Reagents and solvents were acquired from Sigma Aldrich and used without further 
purification. Reactions were monitored by TLC using 0.2 mm silica plates with UV indicator 
(UV254). Column chromatography was executed using Sorbent Technologies 60Ȧ silica gel (230 
- 400 mesh) or Merck neutral aluminum oxide (70 - 230 mesh). Merck TLC silica gel 60 glass 
plates were used for preparative thin layer chromatography. All 1H NMR and 13C NMR spectra 
were obtained using a Bruker AV-500, DPX-400, AV-400, or DPX-250 spectrometer (500 MHz, 
400 MHz or 250 MHz for 1H, 100 MHz for 13C) with samples dissolved in deuterated chloroform, 
acetone, or DMSO using trimethylsilane as an internal indicator. Chemical shifts (δ) are conveyed 
in ppm with CDCl3 (
1H: 7.27 ppm; 13C: 77.16 ppm), acetone-d6 (
1H: 2.05 ppm; 13C: 29.84 ppm), 
and DMSO-d6 (
1H: 2.50 ppm; 13C: 39.52 ppm) used as references. Coupling constants (J) are stated 
in Hertz (Hz). High resolution ESI mass spectra were obtained using an Agilent Technologies 
6210 ESI-TOF Mass Spectrometer. 
 
3.4.2 Syntheses 
BODIPYs 2a and 3a: BODIPY 1 (0.05 g, 0.08 mmol), indole-3-carbaldehyde (0.06 g, 0.4 mmol), 
and AcOH (0.4 mL) were dissolved in dry toluene over 4 Å molecular sieves (20 µM). To this 
solution was added piperidine (0.4 mL) and the mixture was stirred under 400 W microwave 
radiation at 90°C for 1 h. Upon cooling, the reaction was filtered to remove the sieves and the 
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filtrate was quenched with water and extracted with CH2Cl2. The combined organic layers were 
dried over Na2SO4 and the solvent was removed under vacuum.  The resulting residue was purified 
by silica column chromatography using 25% hexanes in CH2Cl2 (v/v) to 100% CH2Cl2to afford 
0.0225 g of a blue solid, 2a, in 38% yield and 0.028 g of a green solid, 3a, in 40% yield. 
Data For 2a: mp = 175°C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 8.51-8.47 
(d, J = 16.9, 1H), 8.13-8.11 (d, J = 7.3, 1H), 7.76-7.72 (d, J = 16.6, 1H), 7.56 (s, 1H), 7.41-7.39 
(d, J = 7.1, 1H), 7.31-7.27 (m, 2H), 6.60-6.58 (t, J = 2, 1H), 6.46-6.45 (d, J = 2, 2H), 3.19 (s, 6H), 
2.71 (s, 3H), 1.64 (s, 3H), 1.57 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.82, 154.95, 152.16, 
146.56, 143.39, 138.51, 137.07, 136.84, 133.86, 127.27, 125.56, 123.25, 121.56, 120.68, 116.16, 
115.07, 111.61, 106.21, 101.43, 69.55, 55.63, 53.80, 31.74, 29.28, 17.42, 16.72, 16.09; MS (ESI-
TOF) m/z Calculated for C30H26BF2I2N3O2: 763.0175; Found: [M]+: 763.0186. 
Data for 3a: mp = 195°C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 8.53-8.48 (d, J = 16.9, 
2H), 8.47 (s, 2H), 8.21-8.19 (d, J = 7.3, 2H), 7.89-7.84 (d, J = 16.6, 2H), 7.56 (s, 2H), 7.43-7.41 
(d, J = 7.1, 2H), 7.30-7.24 (m, 4H), 6.61-6.60 (t, J = 2, 1H), 6.51-6.50 (d, J = 2, 2H), 3.83 (s, 6H), 
2.64 (s, 3H), 1.65 (s, 6H); 13C-NMR (100 MHz, CDCl3) 167.71, 161.75, 137.13, 132.92, 132.33, 
130.91, 128.83, 127.14, 125.54, 125.03, 125.14, 121.64, 120.89, 116.45, 115.65, 111.55, 106.64, 
101.45, 55.64, 17.27; MS (ESI-TOF) m/z Calculated for C39H31BF2I2N4O2: 890.0598; Found: 
[M]+: 890.0639. 
 
BODIPYs 2b and 3b: BODIPY 1 (0.05 g, 0.08 mmol), aldehyde 8 (0.11 g, 0.4 mmol), and AcOH 
(0.4 mL) were dissolved in dry toluene over 4 Å molecular sieves (20 µM). To this solution was 
added piperidine (0.4 mL) and the mixture was stirred under 400 W microwave radiation at 90°C 
for 60 minutes. Upon cooling, the reaction was filtered to remove the sieves and the filtrate was 
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quenched with water and extracted with CH2Cl2. The combined organic layers were dried over 
Na2SO4 and the solvent was removed under vacuum.  The resulting residue was purified by silica 
column chromatography using CH2Cl2  to 25% Ethyl Acetlate in CH2Cl2 (v/v) to to afford 0.028 g 
of a blue solid, 2b, in 40% yield and 0.030 g of a green solid, 3b, in 26% yield. 
Data for 2b: mp = 63-65°C; 1H-NMR (400 MHz, CDCl3) δ 8.15-8.11 (d, J = 16.9, 1H), 7.60-7.57 
(d, J = 8.6, 2H), 7.57-7.52 (d, J = 16.6, 1H),  6.96-6.94 (d, J = 8.3, 1H), 6.60-6.59 (t, J = 2, 1H), 
6.45-6.44 (d, J = 2, 2H), 4.20-4.18 (t, J = 4.5, 2H), 3.90-3.88 (t, J = 4.6, 2H), 3.83-3.80 (s, 3H), 
3.76-3.71 (m, 2H), 3.69-3.66 (m, 4H), 3.58-3.56 (t, J = 4, 2H), 3.41 (s, 3H), 2.70 (s, 3H), 1.64 (s, 
3H), 1.59 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.89, 159.96, 156.72, 150.73, 146.17, 144.86, 
139.64, 139.04, 136.57, 131.97, 131.51, 129.63, 129.15, 116.59, 114.87, 106.02, 101.46, 85.98, 
82.19, 71.95, 70.89, 70.67, 70.59, 69.68, 67.55, 59.06, 55.63, 17.31, 16.87, 16.17; MS (ESI-TOF) 
m/z Calculated for C35H39BF2I2NaN2O6: 909.0856; Found: [M+Na]+: 909.0847. 
Data for 3b: mp = 131-134°C; 1H-NMR (400 MHz, CDCl3) δ 8.16-8.12 (d, J = 16.6, 2H), 7.61-
7.57 (d, J = 8.6, 4H), 7.59-7.57 (d, J = 16.6, 2H), 6.98-6.96 (d, J = 8.6, 4H), 6.61-6.60 (t, J = 2, 
1H), 6.46-6.45 (d, J = 2, 2H), 4.21-4.18 (t, J = 4.5, 4H), 3.91-3.88 (t, J = 4.6, 4H), 3.82 (s, 6H), 
3.78-7.75 (m, 4H), 3.72-3.66 (m, 8H), 3.58-3.55 (t, J = 4, 4H), 3.39 (s, 6H), 1.62 (s, 6H); 13C-
NMR (100 MHz, CDCl3) δ 161.86, 159.97, 150.53, 145.68, 139.12, 138.04, 136.86, 132.52, 
129.71, 129.25, 128.82, 116.76, 114.97, 114.30, 106.31, 101.45, 71.94, 70.88, 70.67, 70.59, 69.69, 
67.56, 59.07, 55.63, 17.35; MS (ESI-TOF) m/z Calculated for C49H57BF2I2NaN2O10: 1159.2062; 
Found: [M+Na]+: 1159.2065. 
 
BODIPYs 2c and 3c: BODIPY 1 (0.04 g, 0.063 mmol), 5-nitroindole-3-carboxaldehyde (0.06 g, 
0.315 mmol), and p-TsOH (0.005 g) were dissolved in dry toluene 20 mL. To this solution was 
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added piperidine (0.4 mL) and the mixture was stirred under nitrogen at 60°C for 6.5 hours. Upon 
cooling, the reaction was quenched with water and extracted with CH2Cl2. The combined organic 
layers were dried over Na2SO4 and the solvent was removed under vacuum.  The resulting residue 
was purified by silica column chromatography using CH2Cl2 to 10% EtOAc/ CH2Cl2 (v/v) to afford 
0.0095 g of a blue solid, 2c, in 15% yield and 0.0136 g of a green solid, 3c, in 22% yield. 
Data for 2c: mp = 140°C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 9.07 (s, 1H), 8.82 (s, 1H), 
8.41-8.38 (d, J = 16.8, 1H), 8.21-8.20 (d, J = 8.9, 1H), 7.80-7.77 (d, J = 16.8, 2H), 7.74 (s, 1H), 
7.49-7.47 (d, J = 9.2, 1H), 6.63-6.62 (t, J = 2, 1H), 6.48-6.47 (d, J = 2, 2H), 3.84 (s, 3H), 2.76 (s, 
3H), 2.20 (s, 3H), 1.67 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.92, 157.17, 154.77, 145.03, 
142.92, 139.64, 136.55, 130.26, 128.84, 127.99, 127.22, 125.22, 118.72, 118.31, 118.14, 118.02, 
117.78, 117.63, 111.57, 106.05, 101.48, 55.64, 17.23, 16.89, 16.19; MS (ESI-TOF) m/z Calculated 
for C30H25BF2I2N4O4: 808.0026; Found: [M]+:  808.0020. 
Data for 3c: mp = 170°C (decomposes); 1H-NMR (500 MHz, DMSO-d6) δ 12.45 (s, 2H), 8.91 (s, 
2H), 8.53-8.49 (d, J = 16.8, 2H), 8.16 (s, 2H), 8.09-8.06 (d, J = 8.9, 2H), 7.79-7.76 (d, J = 16.8, 
2H), 7.67-7.65 (d, J = 8.9, 2H), 6.68 (s, 3H), 3.80 (s, 6H), 2.08 (s, 6H); 13C-NMR (100 MHz, 
DMSO-d6) δ 161.95, 150.09, 147.42, 145.55, 142.27, 141.02, 137.51, 136.75, 133.05, 132.63, 
132.15, 124.66, 118.29, 116.96, 116.49, 115.79, 113.45, 106.65, 56.09, 17.24; MS (ESI-TOF) m/z 
Calculated for C39H29BF2I2N6O6: 980.0299; Found: [M]+: 980.0327. 
 
BODIPYs 2d and 3d: BODIPY 1 (0.02 g, 0.03 mmol), thiophene-2-carboxaldehyde (0.0035 g, 
0.03 mmol), and p-TsOH (0.0025 g) were dissolved in dry toluene over 4 Å molecular sieves (5 
µM). To this solution was added piperidine (0.1 mL) and the mixture was stirred at reflux for 4 
hours. Upon cooling, the reaction was filtered to remove the sieves and the filtrate was quenched 
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with water and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and 
the solvent was removed under vacuum.  The resulting residue was purified by careful silica 
preparatory plate chromatography using 1:1 DCM/Hexanes (v/v) to to afford 0.0048 g of a blue 
solid, 2c, in 19% yield and 0.0064 g of a green solid, 3c, in 25% yield. 
Data for 2d: mp = 165°C (decomposes); 1H-NMR (400 MHz, CDCl3) δ 8.29-8.26 (d, J = 16.2, 
1H), 7.47-7.44 (d, J = 16.2, 1H), 7.37-7.36 (d, J = 5.2, 1H), 7.30-7.29 (d, J = 3.4, 1H), 7.08-7.07 
(dxd, J = 3.8, 1.2, 1H), 6.60-6.59 (t, J = 2, 1H), 6.44-6.43 (d, J = 2, 2H),  3.81 (s, 3H), 2.70 (s, 3H), 
1.61 (s, 3H), 1.58 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.91, 157.51, 149.64, 145.80, 145.78, 
142.57, 139.77, 136.49, 131.81, 128.85, 128.06, 127.30, 117.99, 105.98, 101.47, 55.62, 17.23, 
16.91, 16.23; MS (ESI-TOF) m/z Calculated for C26H23BF2I2N2O2S: 729.9631; Found: [M]+: 
729.9656. 
Data for 3d: mp = 170°C (decomposes); 1H-NMR (500 MHz, CDCl3) δ 8.33-8.30 (d, J = 16.2, 
2H), 7.53-7.50 (d, J = 16.5, 2H), 7.40-7.39 (d, J = 4.9, 2H), 7.33-7.32 (d, J = 3.4, 2H), 7.10-7.08 
(dxd, J = 4, 2H), 6.61-6.60 (t, J = 2, 1H), 6.46-6.45 (d, J = 2, 2H), 3.82 (s, 6H), 1.62 (s, 6H); 13C-
NMR (100 MHz, CDCl3) δ 161.90, 149.95, 145.76, 142.66, 136.74, 132.97, 132.23, 129.01, 
128.13, 127.55, 118.06, 113.93, 106.27, 101.51, 83.62, 55.64, 17.33; MS (ESI-TOF) m/z 
Calculated for C31H25BF2I2N2O2S2: 823.9508; Found: [M]+:  823.9512. 
 
BODIPYs 2e and 3e: BODIPY 1 (0.04 g, 0.063 mmol), 5-methylester-2,4-dimethyl-pyrrol-3-
carboxaldehyde (0.061 g, 0.315 mmol), and p-TsOH (0.005 g) were dissolved in dry toluene (20 
mL) over 4 Å molecular sieves. To this solution was added piperidine (0.4 mL) and the mixture 
was stirred under nitrogen at 60°C for 48 hours. Upon cooling, the reaction was filtered to remove 
the sieves and the filtrate was quenched with water and extracted with CH2Cl2. The combined 
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organic layers were dried over Na2SO4 and the solvent was removed under vacuum.  The resulting 
residue was purified by silica preparatory plate chromatography using CH2Cl2 to 5% EtOAc/ 
CH2Cl2 (v/v) to afford 0.0098 g of a blue solid, 2e, in 19% yield and 0.024g of a green solid, 3e, 
in 39% yield. 
Data for 2e: mp = 160°C (decomposes); 1H-NMR (500 MHz, CDCl3) δ 8.90 (br s, 1H), 8.25-8.22 
(d, J = 16.9, 1H), 7.39-7.36 (d, J = 17.1, 2H), 6.59-6.58 (t, J = 2, 1H), 6.44-6.43 (d, J = 2, 2H), 
4.37-4.33 (q, J = 6.9, 2H), 3.81 (s, 3H), 2.65 (s, 3H), 2.56 (s, 3H), 2.54 (s, 3H), 1.62 (s, 3H), 1.56 
(s, 3H), 1.41-1.38 (t, J = 7, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.84, 161.58, 155.49, 151.94, 
146.50, 143.81, 138.94, 136.74, 133.99, 133.28, 131.96, 131.12, 128.26, 120.25, 118.21, 116.16, 
106.14, 101.40, 85.32, 81.84, 60.12, 55.61, 17.34, 16.75, 16.05, 14.52, 13.67, 11.47; MS (ESI-
TOF) m/z Calculated for C31H32BF2I2N3O4: 813.0543; Found: [M]+: 813.0538. 
Data for 3e: mp = 150°C (decomposes); 1H-NMR (500 MHz, acetone-d6) δ 10.83 (br s, 2H), 8.38-
8.34 (d, J = 16.9, 2H), 7.59-7.54 (d, J = 16.9, 2H), 6.71 (s, 3H), 4.31-4.25 (q, J = 6.9, 4H), 3.89 (s, 
6H), 2.81 (s, 3H), 2.77 (s, 3H),  2.60 (s, 3H), 1.65 (s, 6H), 1.35-1.29 (t, J = 7, 3H); 13C-NMR (100 
MHz, acetone-d6) δ 162.13, 160.64, 134.68, 132.43, 127.58, 127.15, 119.71, 118.54, 115.85, 
113.88, 106.28, 101.72, 76.34, 59.32, 55.20, 54.58, 48.21, 16.44, 13.92, 12.18, 12.13, 10.92; MS 
(ESI-TOF) m/z Calculated for C41H43BF2I2NaN4O6: 1013.1231; Found: [M+Na]+: 1013.1217. 
 
BODIPY 4: General Procedure: BODIPY, aryl-aldehyde (5 equivalents), and p-TsOH (0.005 g, 
0.03 mmol) were dissolved in dry toluene over 4 Å molecular sieves (20 µM). To this solution was 
added piperidine (0.2 mL) and the mixture was refluxed for 6.5 hours. After cooling to room 
temperature, the mixture was filtered to remove the molecular sieves and the filtrate was poured 
into water.  The aqueous layer was extracted with CH2Cl2 and the combined organic layers were 
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dried over Na2SO4. The solvent was removed under vacuum and the resulting residue was purified 
by silica gel column chromatography using 10% EtOAc in CH2Cl2 to elute to obtain the product 
as a green solid.   
From BODIPY 2a: BODIPY (0.0225 g, 0.03 mmol) and aldehyde 10 (0.0158 g, 0.06 mmol) 
afforded 0.0021 g of the title compound in 4% yield. 
From BODIPY 2b: BODIPY (0.054 g, 0.06 mmol) and indole-3-carboxaldehyde (0.018 g, 0.12 
mmol) provided 0.0014 g of the title compound in 2% yield.   
MS (ESI-TOF) m/z Calculated for C44H44BF2I2NaN3O6: 1036.1274; Found: [M+Na]+: 1036.1300. 
 
Compound 5: Triethylene glycol monomethyl ether (10.0 g, 61 mmol) and p-toluenesulfonyl 
chloride (12.77 g, 70 mmol) were dissolved in diethyl ether (75 mL) and cooled to 0°C.  Freshly 
ground potassium hydroxide (13.67 g, 244 mmol) was added in small portions so that the reaction 
temperature never climbed above 5°C.  The mixture was warmed and stirred at room temperature. 
After 3 hours, 10 mL of ice water was added and the mixture was transferred to a separatory funnel.  
The aqueous layer was extracted with diethyl ether and the combined organic layers were dried 
over Na2SO4. The solvent was evaporated under reduced pressure to yield a pale yellow liquid 
(17.5 g) in 90% yield.  
1H-NMR (400 MHz, CDCl3) δ 7.69-7.66 (d, J = 7.8, 2H), 7.25-7.22 (d, J = 7.8, 2H), 4.06-4.02 (t, 
J = 4, 2H), 3.58-3.55 (t, J = 4, 2H), 3.47 (m, 6H), 3.42-3.41 (t, J = 3.3, 2H), 3.24 (s, 3H), 2.33 (s, 
3H); 13C-NMR (100 MHz, CDCl3) δ 145.11, 133.26, 130.16, 128.11, 72.07, 70.81, 70.65, 69.70, 
68.79, 59.06, 21.75; MS (ESI-TOF) m/z Calculated for C14H23O6S: 319.1215; Found: 
[M+H]+:319.1206. The NMR data is in agreement with that already published.52 
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Compound 6: 4-(Hydroxymethyl) benzaldehyde dimethyl acetal (0.025 g, 0.14 mmol), sodium 
hydride (0.0046 g, 0.19 mmol), and compound 5 (0.0437g, 0.14 mmol) were placed in an oven 
dried 5 mL round bottom flask.41  The flask was then evacuated and filled with Nitrogen three 
times.  THF (2.5 mL) was added and the mixture was stirred at room temperature for 24 hours 
(until TLC revealed disappearance of the starting material). The reaction was quenched with water 
and diluted with 3 mL EtOAc.  The aqueous layer was washed three times with 3 mL EtOAc.  The 
combined organic layers were dried over Na2SO4 and the solvent was evaporated under reduced 
pressure.  The residue was purified by alumina column chromatography using 10% MeOH in 
dichloromethane as eluent yielding a pale yellow liquid in quantitative yield.  
1H-NMR (400 MHz, CDCl3) δ 7.64 (d, J = 7.4, 2H), 7.24 (d, J = 7.4, 2H), 5.24 (s, 1H), 3.98 (m, 
2H), 3.43 (m, 12H), 3.16 (s, 6H), 1.88 (s, 3H); MS (MALDI-TOF) m/z Calculated for C17H28NaO6: 
351.178; Found: [M+Na]+: 351.189 
 
Compound 7: Compound 6 (0.2 g, 0.6 mmol) was dissolved in DCM (5 mL) at room temperature 
in a round bottom flask equipped with magnetic stir bar.  TFA (1.4 g, 12.3 mmol) was added drop-
wise and the solution was allowed to stir for 6 hours.42  The mixture was poured into 15 mL of 
water.  The aqueous layer was extracted with ethyl acetate (3 x 10 mL).  The combined organic 
layers were dried over Na2SO4 and the solvent was evaporated under vacuum.  The residue was 
purified by flash chromatography using neutral alumina and 2% MeOH in dichloromethane as 
eluent yielding a pale yellow liquid in 67% yield.  
1H-NMR (400 MHz, CDCl3) δ 9.93 (s, 1H), 7.79 (d, J = 7.4, 2H), 7.46 (d, J = 7.4, 2H), 4.10 (t, J 
= 4.7, 2H), 3.60 (m, 6H), 3.51 (m, 6H), 3.31 (s, 3H); MS (ESI-TOF) m/z Calculated for C15H22O5: 
282.15; Found: [M+H]+: 283.16. 
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Compound 8: To a round bottom flask equipped with a magnetic stir bar was added 4-
hydroxybenzaldehyde (5.0 g, 41 mmol) and 1,2-ethanedithiol (4.4 g, 47 mmol) in THF (40 mL). 
The flask was purged and filled with argon before being cooled to 0°C. BF3·OEt2 (0.58 g, 4.1 
mmol) was added drop-wise. The solution was stirred at room temperature for 45 minutes. The 
mixture was then washed once with 10% aqueous NaOH and once with saturated NaCl before 
being passed through a bed of Na2SO4. The solvent was evaporated under reduced pressure and 
the resulting residue was purified by silica gel column chromatography using EtOAc to afford a 
yellow solid (6.6 g) in 81% yield, mp = 113-117°C.   
1H-NMR (400 MHz, CDCl3) δ 7.41-7.38 (d, J = 7.8, 2H), 6.79-6.76 (d, J = 7.8, 2H), 6.09 (s, 1H), 
5.62 (s, 1H), 3.53-3.43 (m, 2H), 3.39-3.29 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ 157.22, 130.76, 
129.32, 115.09, 55.90, 39.85; GC-MS m/z Calculated for C9H10OS2: 198.017; Found: [M+H]+: 
197.6. The NMR data is in agreement with that already published.40 
 
Compound 9: Compound 8 (4.9 g, 25 mmol), potassium carbonate (3.8 g, 27 mmol) and 
compound 5 (7.9 g, 25 mmol) were dissolved in acetonitrile (250 mL) and the mixture was refluxed 
for 24 hours. Upon completion, the reaction was cooled to room temperature, then quenched with 
water and diluted with 75 mL EtOAc. The aqueous layer was washed three times with EtOAc and 
the combined organic layers were dried over Na2SO4. The solvent was evaporated under reduced 
pressure and the resulting residue was purified by alumina column chromatography using 4:1 
hexanes/EtOAc as eluent to give a light brown liquid (7.96 g) in 93% yield.  
1H-NMR (400 MHz, CDCl3) δ 7.44-7.41 (d, J = 7.8, 2H), 6.86-6.82 (d, J = 7.8, 2H), 5.62 (s, 1H), 
4.13-4.09 (t, J = 4, 2H), 3.85-3.81 (t, J = 4, 2H), 6.72-6.63 (m, 6H), 3.58-3.43 (m, 4H), 3.37 (s, 
3H), 3.37-3.31 (m, 2H); 13C-NMR (100 MHz, CDCl3) δ 158.60, 132.02, 129.11, 114.56, 71.92, 
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70.81, 70.63, 70.54, 69.67, 67.50, 59.00, 56.04, 40.17; MS (ESI-TOF) m/z Calculated for 
C16H24O4S2: 367.1014; Found: [M+Na]+: 367.1028. 
 
Compound 10: To a solution of compound 9 (8.3 g, 24 mmol) in 5% aqueous THF (40 mL) under 
argon was added Hg(ClO4)2·3H2O (22 g, 48.5 mmol) in THF (25 mL). The mixture was stirred at 
room temperature for 1 hour following which the solution was filtered and the precipitate was 
washed three times with diethyl ether. The combined filtrate was washed three times with saturated 
Na2CO3 and twice with water before being passed through a bed of Na2SO4. The solvent was 
evaporated under reduced pressure and the resulting residue was purified by silica gel column 
chromatography using 4:1 EtOAc/MeOH to produce a colorless liquid (4.2 g) in 64% yield.   
1H-NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 7.74-7.72 (d, J = 7.8, 2H), 6.98-6.96 (d, J = 7.8, 2H), 
5.24 (s, 1H), 4.18-4.14 (t, J = 4, 2H), 3.85-3.81 (t, J = 2, 2H), 3.63-3.44 (m, 8H), 3.30 (s, 3H); 13C-
NMR (100 MHz, CDCl3) δ 190.54, 163.60, 131.63, 129.71, 114.94, 71.53, 70.43, 70.19, 70.08, 
69.25, 67.53, 58.49; MS (ESI-TOF) m/z Calculated for C14H20O5: 291.1208; Found: [M+Na]+: 
291.1229. The NMR data is in agreement with that already published.45 
 
3.4.3 X-ray Determined Molecular Structures 
Diffraction data were collected at 100 K on a Bruker Kappa Apex-II DUO diffractometer 
equipped with MoK radiation ( = 0.71073 Å). Refinement was by full-matrix least squares using 
SHELXL, with H atoms in idealized positions. Compound 3b has four independent molecules and 
large displacement parameters for its polyether chains. Isotropic atoms with heavily restrained 
refinement was necessary in these regions, and some disorder in the polyethers could not be 
modeled. 
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Crystal data for 1: C19H17BF2I2N2, M = 636.01, monoclinic space group P21/c, a = 7.0702 (3) Å, 
b = 16.8644 (7) Å, c = 18.4079 (8) Å,  = 92.838 (2)°, U = 2192.17 (16) Å3, T = 100 K, Z = 4, A 
total of 49862 reflections were measured (Rint = 0.027). R = 0.026 for 11738 data points with  I > 
2 (I) of 13815 unique data points and 277 refined parameters.  
Crystal data for 3b: C49H57BF2I2N2O10, M = 1136.57, triclinic space group P1, a = 12.2712(5), b 
= 19.5190(8), c = 22.4285(8) Å, α = 106.006(2)°,  = 101.516(2)°,  = 104.576(2)°, U = 4784.1(3) 
Å3, T = 100 K, Z = 4.  A total of 48,144 reflections were measured (Rint = 0.034). R = 0.060 for 
30,040 data points with I > 2 (I) of 48,144 unique data points and 1,953 refined parameters and 
2,097 restraints.  
 
3.4.4 Steady-state Absorption and Fluorescence Spectroscopy 
The spectroscopic properties of BODIPYs 1, 2a-e, and 3a-e were determined on solutions 
prepared by dissolving crystalline compound in dichloromethane, THF, or DMSO. Stock solutions 
(5x10-5 M) were prepared and diluted to appropriate concentrations for collection of absorbance 
and emission spectra. Absorption spectra were obtained on a Varian Cary 50 Bio UV/VIS 
Spectrophotometer. Measurements obtained for determining optical density were taken from 
solutions with concentrations between 1.2x10-5 and 5x10-5 M so that λmax was between 0.5 and 1.0. 
Fluorescence measurements were recorded on solutions with concentrations between 1.2x10-6 and 
2.5x10-5 M to attain an optical density at the excitation wavelength between 0.04 and 0.06 to 
minimize intermolecular reabsorption and inner-filter effects. Compounds were excited at 485 nm 
for 1, 530 nm for 2a, 2c, 2d, and 2e, 535 nm for 2b, 660 nm for 3a, 580 nm for 3b, 635 nm for 3c, 
580 nm for 3d, and 630 for 3e. Emission spectra were acquired on a PTI QuantaMaster4/2006SE 
spectrofluorometer with the slit width set at 3 nm for dichloromethane and THF and 5 nm for 
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DMSO. Rhodamine 6G and methylene blue were used as standards in calculating the fluorescence 
quantum yields (Φf = 0.95 in ethanol and Φf = 0.03 in methanol, respectively). All measurements, 
both absorbance and emission, were acquired within 4 h of solution preparation at room 
temperature (23 – 25 °C), using a 10 mm path length quartz spectrophotometric cell. 
 
3.4.5 Cell Studies 
All reagents and tissue culture media were purchased from Invitrogen. Human carcinoma 
HEp2 cells used in this study were purchased from ATCC and were sustained at 37°C and 5% CO2 
in a 50:50 mixture of DMEM:AMEM augmented with 10% FBS and 1% antibiotic (Penicillin-
streptomycin). A working BODIPY stock solution of 32 mM BODIPY was prepared by dissolving 
the compound with sonication in 96% DMSO and 4% Cremophor EL. 
 
3.4.5.1 Time-Dependent Cellular Uptake. The HEp2 cells were grown overnight in a Costar 96-
well plate plated at 15,000 cells per well.  The 32 mM stock solution was diluted to a 10 µM 
BODIPY solution through the addition of medium containing 5% FBS and 1% antibiotic to a 400 
µM stock solution.  The cells were exposed to the BODIPY in medium solution at 100 µL/well at 
time intervals of 0, 1, 2, 4, 8, and 24 hours. At the termination of the treatment, the loading medium 
was removed and the cells were washed with 1X PBS, and solubilized by adding 0.25% Triton X-
100 in 1X PBS.  Quantification of the cells was conducted using the CyQuant Cell Proliferation 
Assay (Life Technologies). BODIPY concentration was determined by reading fluorescence at 
355/670 nm (for 2a and 3a), 355/700 nm (for 2b), and 410/700 nm (for 3b) with a FluoStar Optima 
micro-plate reader (BMG LRBTEH). Cellular uptake is expressed in nM compound/cell. 
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3.4.5.2 Dark Cytotoxicity. The HEp2 cells were placed in a 96-well plate as above and allowed 
to incubate overnight. Following incubation, the cells were exposed to increasing concentrations 
of BODIPY, from 0 µM up to 400 µM, and then incubated at 37°C. After 24 hour incubation, the 
loading media containing compound was removed by washing the cells with 1X PBS. The media 
was replaced with media containing 20% Cell Titer Blue and the cells were incubated at 37°C for 
a subsequent 4 hours. Cell viability was determined by reading fluorescence at 570/615 nm with a 
FluoStar Optima micro-plate reader.  The dark toxicity is expressed in terms of the percentage of 
viable cells. 
 
3.4.5.3 Phototoxicity. The HEp2 cells were placed in 96-well plates as incubated as described 
above. Following incubation, the cells were exposed to increasing concentrations of BODIPY (0 
µM, 3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, and 100 µM) and then incubated for 24 hours 
at 37°C. After the 24 hour treatment, the loading media was removed, the cells were washed with 
1X PBS and refilled with fresh media. The cells were then exposed to a 600 W halogen lamp light 
filtered through a water filter (Newport) and then through a beam turning mirror (200 – 3000 nm, 
Newport) to generate an approximate light dose of 1.5 J/cm2. After a 20 minute exposure time, the 
cells were incubated for another 24 hours. Following incubation, the medium was removed and 
replaced with medium containing 20% of Cell Titer Blue and the cells were incubated for a 
subsequent 4 hours. Cell viability was determined by reading fluorescence at 570/615 nm with a 
FluoStar Optima micro-plate reader. The phototoxicity is expressed in terms of the percentage of 
viable cells. 
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3.4.5.4 Microscopy. HEp2 cells were plated in a 6-well plate and allowed to grow overnight. The 
cells were then exposed to 10 µM of the compound at 37°C for more than 6 hours before adding 
the organelle tracer (Invitrogen). The working concentrations of organelle tracers were as 
following: LysoSensor Green 50 nM, MitoTracker Green 250 nM, ER Tracker Blue/white 100 
nM, and BODIPY FL C5 Ceramide 50 nM. The organelle tracers were diluted in growing medium 
and the cells were incubated concurrently with the compound and the tracer for 30 minutes. After 
adding the tracer for 30 minutes, the loading medium is removed and cells were washed with 1X 
PBS three times. Images were acquired using a Leica DMRXA2 microscope with a  water 
immersion objective and DAPI, GFP, YFP, Texas Red, CY5, and TRITC filter cubes (Chroma 
Technologies). 
 
3.4.6 Comparative Singlet Oxygen Generation Studies 
To each well of a 6-well plate was added 2 mL containing 50 μM of 1,3-
diphenylisobenzofuran (DPBF) and 5 μM of photosensitizers in DMSO. The plate was irradiated 
using a 71 W filtered light source of > 500 nm with a Schott glass 500 nm long-pass yellow filter 
for 1 hour. At 15 minute intervals, 200 μL aliquots were removed from each of the six wells and 
the absorbance was measured at 410 nm. The rate of singlet oxygen generation was determined by 
the decrease in absorbance of DPBF over time. A control solutions of DPBF/methylene blue 
(reference standard) was irradiated under the previous mentioned conditions. Absorption spectra 
were chronicled using a Varian Cary 50 Bio UV/VIS Spectrophotometer. 
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3.4.7 Time-Dependent Fluorescence Studies 
The dark and photostability of all BODIPYs were assessed by measuring the change in 
fluorescence when excited at a compound specific wavelength (485 nm for 1, 530 nm for 2a, 2c, 
2d, and 2e, 535 nm for 2b, 660 nm for 3a, 580 nm for 3b, 635 nm for 3c, 580 nm for 3d, and 630 
for 3e). Solutions of 25 µM BODIPY were made by dissolving crystalline BODIPY in DMSO and 
were used immediately. For dark studies, the vials containing BODIPY solutions were covered in 
aluminum foil to minimize light exposure. To assess potential photo-induced decomposition, the 
compounds were exposed to ambient light, by keeping the BODIPYs in 20 mL scintillation vials 
on the bench top under 32 W fluorescent light from Sylvania OCTRON®/ECO® 4100K for a 
period up to 24 h. BODIPY decomposition is noted by a significant decrease in the compound’s 
emission over time. 
 
3.4.8 Octanol-HEPES buffer coefficients 
The partition coefficients (log P) were measured at room temperature by adding 0.5 mL of 
a BODIPY stock solution in DMSO (50 µM) to a 15 mL volumetric tube containing 4.0 mL of 
HEPES buffer (1 M, pH 7.4), followed by addition of 4.0 mL of 1-octanol. After vortexing for 5 
min, the phases were allowed to separate completely. An aliquot of 0.5 mL from each layer was 
diluted with 0.5 mL of methanol and the absorbance was read on an Agilent Technologies 8354 
UV-Vis spectrophotometer with 10 mm path length quartz cuvette. 
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CHAPTER 4: SYNTHESIS, SPECTROSCOPIC, AND IN VITRO EVALUATION OF 
NEAR-IR BODIPYS WITH MULTI-MODE IMAGING APPLICATIONS 
 
4.1 Introduction 
Fluorophores that allow for imaging using various modalities with minimal modification 
to the chemical structure are useful for imaging and three dimensional mapping of cancerous 
tissues and masses. Specifically, radioisotopic driven imaging techniques, including PET and 
SPECT, offer significant benefits to tumor mapping over other imaging techniques. BODIPYs 
hold substantial potential to serve as multi-modal imaging agents, due to their characteristic 
tunable fluorescence and their ability to undergo facile modifications via a variety of well-
established synthetic methodology to install desired radioisotopes, specifically radiofluorine and 
radioiodine. However, while optical imaging via fluorescence does allow for in vivo visualization 
over a broad scope from subcellular to whole body anatomical imaging, the limited optical 
transparency of tissues hinders its widespread application.1, 2 On the other hand, PET and SPECT 
are used clinically but are limited to macroscopic special and temporal imaging. Therefore, 
imaging agents that allow for seamless switching between fluorescence and radioimaging would 
be highly beneficial for multidimensional imaging. Improvements in the realm of PET agents that 
are capable of being visualized at the microscopic level, as well as the development of hybrid 
imaging probes that allow for the superimposition of signal maps to visualize the macro- and 
microscopic physiological events of cancers and other diseases,3 would fulfill many necessary 
improvements in clinical imaging and diagnosis. The development of hybrid optical/radioimaging 
probes has been hindered as a result of methodological limitations, proving the need for a synthetic 
strategy that enables generic access to these type of compounds. 
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To date, several reports have detailed methodology to install 18F on BODIPY via 
substitution of the boron chelate as shown in Scheme 4.1. Hudnall and Gabbai4 developed the first 
protocol, Route A, in which 1,3,5,7,8-pentamethyl BODIPY was first treated with TMSOTf and 
DMAP at elevated temperatures for an extended period of time to facilitate substitution of fluorine 
with DMAP. This reasonably stable, yet reactive intermediate was then treated with fluorine-18 
(half-life of 110 minutes) anions in DMF at 100°C to afford the radiofluorine labeled BODIPY. 
Despite the success of this method, the conditions required for this approach are likely to be 
incompatible with many functional groups. As a result, a few years later Hendricks and co-
workers5 noted that treatment of the same BODIPY with TMSOTf at 0°C afforded the triflyl-
substituted BODIPY almost instantaneously, Route B. This intermediate could be stabilized by 
adding a small amount of mild, non-nucleophilic base, such as diisopropylethylamine or 2,6-
lutidine, and would remain as the triflyl-BODIPY in solution at room temperature for a prolonged 
period of time. When desired, fluorine-18 anions could be introduced with rapid and complete 
conversion to the radiolabeled BODIPY. 
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Scheme 4.1: Fluoride exchange of BODIPY.4, 5 
Hendricks et al. went on to investigate the in vivo stability and found that the non-targeting 
18F-BODIPY did not display tissue-specific labeling and was eliminated from the system within 1 
hour. Additionally, their protocol was applied to BODIPYs bearing N-hydroxysuccinimide-ester 
moieties which demonstrated high stability under these conditions and allowed for clean TMSOTf 
activation and re-fluorination. 
Alternatively, simple nucleophilic substitution of a sufficiently labile leaving group at the 
terminal end of an appended spacer moiety, as shown in Scheme 4.2, would enable the streamlined 
production of a multitude of radioimaging agents. Kung et al.6 made use of a tosylated-alcohol 
terminated spacer or a bromine terminated spacer attached to dihydrotetrabenazine which 
underwent 18F-substitution via two radiofluorinating agents, [18F]KF/K22 and [18F]TBAF, to 
obtain the desired 18F-dihyrdotetrabenazine. It was noted that the reaction showed little preference 
in achieving the desired fluorinated product in terms of precursor (-OTs vs -Br), with both offering 
efficient production. Optimization of reaction time, temperature, and solvent were necessary to 
establish an effective protocol for fluorination, and may produce challenges if the same strategy is 
applied to BODIPY fluorophores with similar appendages. 
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Scheme 4.2: Fluorination via nucleophilic substitution.6 
In another approach, BODIPYs bearing highly electron deficient pentafluorophenyl 
moieties7 may undergo nucleophilic substitution of the para-fluoride to directly yield radiolabeled 
BODIPYs through the addition of radiofluorine or radioiodine containing salts, such as [18F]TBAF 
or Na124 I, or through substitution of a previously installed spacer moiety bearing a labile terminal 
leaving group as described previously. Several reports are available that detail the nucleophilic 
substitution of the p-fluoro phenyl moieties of porphyrins and porphyrin derivatives.8-10 
Bhupathiraju and Vicente11 have recently reported a tetrakis(pentafluorophenyl)porphyrin (TPPF) 
that underwent facile nucleophilic substitution of the para-fluorines with both sulfur and nitrogen 
nucleophiles, Scheme 4.3. With BODIPY possessing similar behavior to porphyrins in terms of 
reactivity, these substitutions could lead to facile attachment of radiolabeling moieties. Direct 
fluorination of the 2,6-positions of the BODIPY aromatic system may also be accomplished using 
N-fluorophyridinium triflate, a mild fluorinating agent, that has shown success in the meso-
perfluorination of porphyrins.12 
On the other hand, radioisotopes can possibly be installed via substitution of a 
trimethylstannyl derivative, as shown in Scheme 4.4.  Pandey et al.13, 14 successfully installed 
iodine-124 onto 3-(1’-m-iodobenzyloxyethyl)pyropheophorbide-a methyl ester by first reacting 
the pheophorbide derivative with hexamethylditin and bis(triphenylphosphine)palladium(II) 
dichloride, to give the trimethyltin derivative. This intermediate was then reacted with Na124I in 
acetic acid in the presence of 1,2,4,6-tetrachloro-3α,6α-diphenylglucouril to yield the desired 
radioiodine labeled pheophorbide derivative. The glucose and galactose conjugates of the 
pheophorbide derivative withstood the Na124I substitution of the trimethylstannyl-substituent, 
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displaying the mild nature of these reaction conditions in the presence of biomolecules and its 
future applicability to biomolecules conjugated to various radioisotope-ready fluorophores. 
 
Scheme 4.3: Nucleophilic aromatic substitution of pentafluoroporphyrin (TPPF).11 
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Nevertheless, to date, only a handful of BODIPY-based PET agents have been synthesized 
and there are no reports of radiolabeled BODIPY for SPECT. Through the combination of known 
protocols, including Knoevenagel condensation, which successfully extends π-conjugation to 
produce long wavelength BODIPYs with absorptions and emissions that extend into the far red 
and near-IR regions of the visible spectrum, with the previously discussed methods for introducing 
radioisotopes for PET and SPECT, a new strategy for the development of dual-modal imaging -
agents based on BODIPY will be explored herein. 
 
Scheme 4.4: Trimethylstannyl-mediated radiolabeling.13 
 
4.2 Results and Discussion 
4.2.1 Syntheses 
The synthesis of far red and near-IR mono- and di-styryl 2,6-diiodo-BODIPYs explored in 
Chapter 3 with varying cytotoxicities prompted the need to explore the potential of the non-toxic 
fluorophores as dual-modal fluorescence/radioimaging agents. None of the di-styryl-diiodo-
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BODIPYs (3a-e, Chapter 3) showed phototoxicity, IC50 > 100, when exposed to a light dose of 1.5 
J/cm2, however, the presence of iodines made these compound more susceptible to oxidation and 
tended to decompose when left in the presence of light for too long. As a result, near-IR dyes that 
lack iodines at the 2,6-positions of the BODIPY core were synthesized using the well-established 
Knoevenagel condensation protocol. 
For direct comparison to the previously synthesized compounds with the most red-shifted 
absorption and emission profiles (2a, 3a, Chapter 3), and with the greatest stability (2b, 3b, 
Chapter 3), mono- and di-indolylstyryl and para-methoxyphenylstyryl were synthesized from 
BODIPY 1, Scheme 4.5. Condensation of 1 with excess indole-3-carboxyaldehyde in refluxing 
toluene in the presence of piperidine and p-TsOH yielded mono-indolylstyryl-BODIPY 1a as a 
purple solid in 16% yield and di-indolylstyryl-BODIPY 1b as a blue solid in 12% yield.15  
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Scheme 4.5: Knoevenagel condensation of BODIPY 1 with formyl-indole and p-anisaldehyde. 
 
Similarly, the mono- and di-p-methoxyphenylstyryl-BODIPYs 2a and 3a were synthesize 
via condensation with excess p-anisaldehyde to afford the desired compounds as purple and blue 
solids in 12% and 6%, respectively. The low yields of these condensations are likely a result of 
the presence of water in the reaction mixture, both from water containing solvent and as a by-
product of the condensation. Even with the addition of 3Å molecular sieves, yields remained low. 
In order to improve yields, the reaction flask should be fitted with a Soxhlet extracted filled with 
calcium chloride, as described by Hao et al.,16 for the toluene to be dried over the course of the 
reaction. Removal of water from the starting solvents, by first drying over molecular sieves, would 
also improve the yield of both the mono and distyryl-BODIPYs. With such an excess of aldehyde 
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being employed, the reaction should favor formation of the more favorable greater red-shifted 
distyryl-BODIPYs. 
BODIPY 1a, 1b, 2a, and 2b were characterized by 1H-NMR, 13C-NMR, and high 
resolution ESI-MS. Comparison with the 1H-NMR data obtained from the diiodo-analogs revealed 
the same profile of peaks for the indolylstyryl- and p-methoxyphenylstyryl- aromatic protons, as 
well as the signals for the remaining 1,5,7- and 1,7-methyls found in the mono- and di-derivatives, 
respectively. Seven signals were visible in both 1a and 1b corresponding to the indolylstyryl 
substituent, observed at 8.4 (NH), 8.17/8.07 (di/mono), 7.87/7.75 (di/mono), 7.54, 7.53, 7.42, and 
7.30 ppm. The only notable difference between the diiodo- and iodine-free dyes was the presence 
of peaks corresponding to the β-hydrogens. The spectra of the mono-indolyl 1a revealed two 
equivalent peaks for these hydrogens at 6.6 and 6.0 ppm. These were identified through 
comparison to the starting BODIPY 1 and di-indolylstyryl-BODIPY 1b as the β-hydrogen on the 
styryl-bearing hemisphere (6.6 ppm) and the β-hydrogen on the methyl-bearing hemisphere (6.0 
ppm). With the return to symmetry in 1b the two β-hydrogen signals merged into one at 6.6 ppm.  
The geometry of the styryl-alkene were confirmed as the suspected trans (E) configuration 
through determination of the coupling constants (J) at 16.1 and 16.5 Hz. The division of the two 
equivalent tetramethyl peaks at 2.5 and 1.6 ppm in the starting material into three signals at 2.6, 
1.6, and 1.2 ppm confirmed the identity of the mono-indolylstyrl-BODIPY 1a. Condensation with 
the remaining 3/5-methyl to yield the di-indolylstyryl 1b was observed by loss of the signal at 2.6 
ppm and a doubling of the integration of the peak at 1.6 ppm, as expected. Finally, HR-MS via 
ESI-TOF confirmed the desired products with m/z found at 511.2253 (1a) and 638.2677 (1b). 
Likewise, 1H-NMR of BODIPYs 2a and 2b exhibited four aromatic signal in two 
equivalent sets corresponding to the styryl phenyl at 7.6/7.56 ppm (di/mono) and 6.98/6.92 ppm 
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(di/mono) and to the styryl alkene at 7.64/7.57 ppm (di/mono) and 7.24 ppm. Again, the trans (E) 
configuration of the styryl-alkene were confirmed with coupling constants (J) calculated at 16.3 
Hz. The β-hydrogen followed an identical pattern to that described for 1a,b with signals visible at 
6.6 and 6.0 ppm in 2a and 6.6 ppm in 2b. The three equivalent methyl groups of 2a were observed 
at 2.6, 1.6, and 1.5 ppm indicating loss of symmetry, and a return to symmetry in 2b with only a 
single signal visible at 1.6 ppm corresponding to the 1,7-dimethyls. The most noticeable difference 
between the starting BODIPY 1, 2a, and 2b was the appearance of a second methoxy peak at ~3.8 
ppm and its increase in integration from three to six with the addition of the second styryl arm. 
Confirmation of both BODIPYs was also achieved via high resolution ESI-TOF MS through 
identification of m/z peaks for 2a at 503.2320 and 2b at 621.2725. 
Attempts to iodinate the styryl-BODIPYs using the same protocol used to iodinate the 
tetramethyl-BODIPY derivatives with iodine and iodic acid in a 1:1 mixture of ethanol and DCM 
lead to decomposition, suggesting that the styryl arm alkenes are more nucleophilic than the 2,6-
positions of the BODIPY core. This demonstrates that radioiodine cannot be added to the 
styrylated BODIPY via electrophilic aromatic substitution. Additionally, there have been no 
reports to date of nucleophilic aromatic substitution of the 2,6-positions, the only remaining active 
sites, and efforts of this lab to accomplish this task have proved unsuccessful. Thus, another 
method for radiolabeling must be explored. The previously described fluoride substitution with 
fluorine-18 may be employed to convert 1a, 1b, 2a, and 2b into PET radiotracers and will be 
discussed in the following pages. 
In order to employ another tactic in hopes of securing a suitable route for labeling long 
wavelength absorbing and emitting BODIPYs, bromine-containing BODIPY 3a was synthesized, 
Scheme 4.6. BODIPY 3, bearing a meso-4-bromophenyl substituent, was condensed with excess 
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4-acetamidobenzaldehyde in refluxing toluene in the presence of piperidine and p-TsOH. It was 
hoped that the acyl-protected amine would mimic a conjugated biomolecule for the purpose of 
exploring the compound’s photophysical properties. Free amines located on both the meso-
substituent and conjugated through functionalized styryl groups are known to be highly basic and 
readily protonate to yield non-fluorescent dyes.17 The mono-styryl BODIPY 3a was the only 
isolated product from this reaction obtained in 16% yield. Trace amounts of the di product were 
visible by TLC but were not isolated. A large amount of the starting BODIPY 3 was returned 
unreacted even after exposure to excess aldehyde for 48 hours. This could be a result of low 
reactivity of the less electron-rich BODIPY, because of the electron-deficient aldehyde, the 
presence of water in the reaction mixture, or a combination of these effects. Future attempts to 
remove water from the reaction mixture using a calcium chloride filled Soxhlet extractor as 
described previously may effectively improve the yields of both the mono and di products. As a 
result of the low yields, only the mono-acetamidophenyl-BODIPY 3a was evaluated. 
Proton NMR characterization of 3a strongly resembled that of BODIPY 2a in the aromatic 
region and in regards to the 1,5,7-trimethyls. Two equivalent sets of two doublets corresponding 
to the equivalent the meso- and styryl-phenyl protons were identified at 7.66-7.65 and 7.21-7.19, 
as well as 7.38-7.36 and 7.12-7.11, respectively. The alkene protons were identified at 7.57-7.55 
and 7.21-7.18, with a coupling constant calculated at 16.3 ppm indicating trans (E) geometry, as 
with all styryl BODIPYs. The β-hydrogens were split into two singlets of identical integration with 
the hydrogen on the same side as the styryl arm lying downfield at 6.6 ppm compared to the 
hydrogen on the same side as the 3/5-methyl located 6.02 ppm. The alkane region of the spectra 
indicated four signals relating to the three core methyl groups at 2.6, 1.47, and 1.43 ppm and the 
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acetyl-methyl found downfield at 3.3 ppm. The molecular weight of BODIPY 3a was confirmed 
as the [M+H]+ by high resolution ESI-MS with an m/z identified at 548.1372.  
 
 
Scheme 4.6: Synthesis of BODIPY 3a. 
  
Additionally, a long wavelength BODIPY bearing the electron-deficient pentafluorophenyl 
substituent was synthesized with the hopes of later substitution of the para-fluorine with either 
radionuclei directly, via nucleophilic aromatic substitution, or through attachment of a pendent 
spacer with a terminal labile leaving group that could be subsequently substituted to yield the 
radiolabeled BODIPY. BODIPY 4 was synthesized from the condensation of 2,4-dimethylpyrrole 
and pentafluorobenzaldehyde as detailed in Chapter 2. The electron-deficient meso-
pentafluorophenyl substituent of BODIPY 4 decreases the electron density in the BODIPY core 
and, as a result enhances the acidity of the 3,5-dimethyl protons. Consequently, the di-p-
methoxyphenystyryl-BODIPY 4a was isolated as a green solid as the major product in 13% yield 
from the condensation of 4 with excess p-anisaldehyde in refluxing toluene in the presence of 
piperidine and p-TsOH, Scheme 4.7. The mono-p-methoxyphenylstyryl BODIPY was observed 
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as a faint blue spot with red fluorescence when exposed to long wavelength UV light by TLC but 
was not isolated by column chromatography. 
 
 
Scheme 4.7: Synthesis of BODIPY 4a from pentafluorophenyl-BODIPY 4. 
 
BODIPY 4a displayed a similar, yet simplified 1H-NMR spectra in terms of the number of 
signals in comparison to the previously synthesized fluorophores.  Because 4a lacks meso-phenyl 
hydrogens, the aromatic region contains fewer peaks than 2a and 3a, which are similarly decorated. 
However, despite fewer signals being present, there is a greater degree of overlap between the 
signals that are present. A multiplet found at 7.67-7.58 ppm contains a singlet corresponding to 
the two β-hydrogens, a doublet representing one set of four equivalent styrylphenyl-hydrogens, 
and a second doublet belonging to two styryl-alkene protons. The remaining set of four equivalent 
styrylphenyl-hydrogens is seen as a doublet at 7.08-7.06 ppm, whereas the remaining two alkene 
protons show up as a doublet at 6.99-6.98 ppm with a coupling constant of 16.1 Hz indicating 
trans (E) geometry. An m/z peak at 673.1859 from HR-MS matching the calculated value for the 
[M+Na]+ ion further confirmed the identity of 4a. 
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 Several attempts were made to apply the previously mentioned protocols for substituting 
the fluorine bound to the boron center, to install trimethyltin to the halogen bearing meso-phenyl, 
and to substitute the p-fluorine of meso-pentafluorophenyl BODIPY. The procedure for F-
substitution dictated by Hendricks et al.5 was modified with the intent of allowing for facile 
monitoring of the boron substitution via 11B-NMR, Scheme 4.8. Initial attempts were made on 
BODIPY 2a from Chapter 3 by dissolving the BODIPY in deuterated chloroform and acquiring 
the NMR spectrum of the –BF2 chelated structure.  
 
 
Scheme 4.8: Attempt to substitute boron with TMSOTF. 
 
This produced the expected triplet as the only signal visible.18 Next, one drop of diluted 
TMSOTf in the same solvent was added and the NMR tube was inverted several times to 
thoroughly mix the solution prior to obtaining the NMR spectrum. At this point it was noted that 
the fluorescence that was usually visible under ambient light had disappeared and insoluble 
particles had dropped out of solution. An attempt to acquire the NMR was made, but no signals 
were visible after acquiring an equivalent number of scans to the starting material. It was assumed 
that the starting material had decomposed when the TMSOTf was added, possibly through attack 
of the reactive double bond of the styryl arm. Nevertheless, potassium fluoride, dissolved in 
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deuterium oxide, was added in hopes that the addition of free fluoride ions would restore the 
structure, solubility, and fluorescence of the BODIPY. Regretfully, upon addition of KF, the 
solution remained non-fluorescent and the insoluble particles did not dissolve. 
Next, Pandey et al.’s13, 14 procedure for substituting an aromatic halide with trimethyltin 
with attempted on BODIPY 3 as a model system before subjecting the protocol to the more 
valuable 3a as shown in Scheme 4.9. BODIPY 3 and bis(triphenylphosphine)palladium(II) 
chloride were dissolved in 1,4-dioxane, the solution was degassed, and the flask was fitted with an 
Argon balloon. To this solution was added hexamethyldistannane and the mixture was stirred at 
60°C overnight. The solvent was then removed and the residue was purified by a short silica 
column using 50:50 DCM/hexanes as eluent to separate the single fluorescent band from the non-
fluorescent bi-products residing at the baseline. NMR of the fluorescent band showed unreacted 
starting material.  
 
 
Scheme 4.9: Attempted substitution of 3 with hexamethyldistannane. 
 
The primary differences between the halogenated BODIPY 3 and Pandey’s iodo-
pheophorbide derivative are the halogen being substituted, bromine versus iodine, the connectivity 
of the halogen on the halogen-bearing phenyl, and the conjugation of the system. First, iodine is a 
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more labile leaving group than bromine with its weaker carbon-halogen bond and may undergo 
the necessary oxidative insertion onto palladium more readily. Next, the phenyl ring containing 
the iodine that underwent substitution of the pheophorbide derivative was not conjugated with the 
pheophorbide macrocycle, whereas the bromine-bearing phenyl of the BODIPY is connected to 
the conjugated core. Although the meso-aryl substituent is known to lie perpendicular to the 
BODIPY core, direct connection of the two aromatic systems may make the carbon-bromine bond 
stronger than expected. Additionally, the bromine resides at the para-position of the phenyl on 
BODIPY, which imparts a greater effect on the electronics of the phenyl ring compared to the 
meta-iodine of the pheophorbide. Nevertheless, the simplest explanation may be that the palladium 
used to install the trimethyltin was not reduced to palladium(0) in situ as is required for the 
oxidative insertion to occur. Addition of a reducing agent, such as copper(I) iodide may facilitate 
this conversion. 
The final attempt to synthesize a near-IR BODIPY suitable for radioimaging involved the 
substitution of the para-fluorine of BODIPY 4a, Scheme 4.10. Assuming that the electron-
deficient meso-pentafluorophenyl would behave similarly to porphyrins bearing the same 
substituent,11 BODIPY 4a was subjected to nucleophilic substitution by an amine. The BODIPY 
and propargyl amine were dissolved in N-methyl-pyrrolidinone and the mixture was allowed to 
stir at 100°C. Propargyl amine was selected for its capacity to only undergo nucleophilic 
substitution at the amine and for possible subsequent “click” couplings with azides, if successful. 
After two hours, TLC showed a new, more polar blue spot below the green spot of starting material. 
The product was expected to be of similar polarity to the starting material and display no change 
in the fluorescence intensity. The new spot showed much brighter fluorescence under long 
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wavelength UV light, which suggests that the product was likely being converted to the mono-
styryl product. 
 
 
Scheme 4.10: Attempted nucleophilic substitution of BODIPY 4a. 
 
 Future work to furnish an efficient protocol for installing radioisotopes for PET and SPECT 
imaging is planned. The substitution of bromine with trimethyltin of BODIPY 3 with the addition 
of copper iodine to induce in situ reduction of palladium(II) will be attempted. Since the double 
bonds of the styryl arms of the long wavelength BODIPYs are reactive towards nucleophiles and 
electrophiles, as seen through failed attempts at nucleophilic substitution on the meso-phenyl and 
preliminary attempts to iodinate β-free styryl-BODIPYs resulting in decomposition, design of long 
wavelength BODIPYs via other routes is necessary. Preliminary work to synthesize a meso-
pentafluorophenyl BODIPY from a conjugated pyrrole has begun. The successful Suzuki coupling 
of benzyl 4-chloro-5-iodo-3-methyl-1H-pyrrole-2-carboxylate 5 with 4-methoxyphenyl boronic 
acid yielded pyrrole 6a or 6b after refluxing in toluene in the presence of 
tetrakis(triphenylphosphine)palladium(0) and 1M sodium carbonate, Scheme 4.11. NMR shows 
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only one product as a result of the coupling. Integration of the aromatic peaks suggests that only 
coupling with only one of the halogenated carbons occurred, rather than the desired di-coupling, 
and it is assumed that pyrrole 6a is the product obtained. Mass spectrometry is required to 
determine which product was produced, since NMR is inconclusive in that regard. Subsequent 
attempts to remove the benzyl protecting group with Pd/C under hydrogen atmosphere to liberate 
the free acid were unsuccessful.  
 
Scheme 4.11. Suzuki coupling of pyrrole 5 with 4-methoxyphenyl boronic acid. 
Additionally, ethyl 3,4-diethyl-1H-pyrrole-2-carboxylate 7 was condensed with 
pentafluorobenzldehyde in dichloromethane with the aid of boron trifluoride diethyl etherate to 
obtain the dipyrromethane 8, Scheme 4.12. Attempts to cleave the ethyl ester from both the pyrrole 
and the dipyrromethane by refluxing in lithium hydroxide doped 1:1 THF/H2O were unsuccessful. 
Further work is required to establish a protocol to remove the ethyl ester and substitute the 
remaining acid with iodine for future couplings towards the synthesis of long wavelength dyes 
with promise towards serving as multi-modal fluorescence/PET/SPECT imaging dyes. 
 
187 
 
 
Scheme 4.12: Synthesis of dipyrromethane 8. 
 
4.2.2 Spectroscopic Investigations 
The spectroscopic properties of BODIPYs 1a,b, 2a,b, 3a, and 4a were carried out in 
DMSO using methylene blue in methanol (ΦF = 0.03) as the standard and are summarized in 
Figures 4.1 - 4.2 and Table 4.1. DMSO was chosen as the sole solvent since it most closely 
resembles how BODIPYs behave in the polar environment of the body. Incorporation of the styryl 
groups produces a pronounced red shift in the absorbance and emission profiles compared to the 
1,3,5,7-tetramethyl BODIPYs, which absorb around 500 nm and emit around 510 nm. Addition of 
a single styryl arm produces approximately 70 - 100 nm red-shift as seen in BODIPYs 1a, 2a, and 
3a. Among the mono-styryl BODIPYs, the indolylstyryl BODIPY 1a produces the greatest red-
shift as a result of the extended π-conjugation compared to the phenylstyryl 2a and 3a. 
Phenylstyryl-BODIPYs bearing electron withdrawing groups on the styryl arm, as in the amide of 
3a, induce a slightly greater red shift (6 nm) than phenylstryryl-BODIPY 2a bearing an electron 
donating substituent.  The emission spectra also show the same trend, displaying 70 – 120 nm red-
shifts compared to the simple tetramethyl BODIPY. Incorporation of a second styryl group, 
BODIPYs 1b, 2b, and 4a, created an even greater red shift of 150 – 190 nm in the absorption and 
140 – 210 nm in the emission profile, due to greater extension of the fluorophore’s π-conjugation. 
The absorption bands also became broader with the addition of multiple styryl substituents. 
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Figure 4.1: Absorption (solid line) and emission (dashed line) of BODIPYs 1a (blue) and 1b 
(red) on the left and BODIPYs 2a (green) and 2b (yellow) on the right in DMSO. 
 
 
   
Figure 4.2: Absorption (solid line) and emission (dashed line) of BODIPY 3a (purple) on the left 
and BODIPY 4a (orange) on the right in DMSO. 
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Table 4.1: Absorption and emission properties of BODIPYs in DMSO relative to methylene blue 
(Φf = 0.03, MeOH). 
 
Compound λmax abs 
(nm) 
λmax em 
(nm) 
log ε ΦF Stokes' Shift 
(nm) 
1a 599 637 4.60 0.46 38 
1b 691 724 4.62 0.06 33 
2a 574 587 4.29 0.73 13 
2b 650 667 4.55 0.18 17 
3a 580 597 4.12 0.54 17 
4a 676 697 4.60 0.16 21 
 
 
All BODIPYs displayed the characteristic Q-band absorption for the S0-S1 (π-π*) 
electronic transition with a shoulder at slightly lower wavelength corresponding to the vibrational 
translations.19 Additionally, the styryl-BODIPYs displayed large extinction coefficients (log ε = 
4.12 – 4.62) and Stokes’ shifts of 13 - 38 nm, with the largest shift seen in the indolylstyryl-
BODIPYs 1a,b. Compared to the diiodo-styryl-BODIPYs discussed in Chapter 3, the β-free 
BODIPYs possessed larger fluorescence quantum yields of 0.46 – 0.73 for the mono-styryl-
BODIPYs and 0.06 - 0.18 for the di-styryl-BODIPYs. Quantum yields greater than 0.2 are 
desirable for fluorescence imaging to better distinguish the fluorophore from endogenous 
chromophores.  
 
4.2.3 In vitro Studies 
4.2.3.1 Cytotoxicity. In order to determine the efficacy of the synthesized BODIPYs as potential 
imaging agents, their concentration-dependent dark and photo (light dose ~ 1.5 J/cm2) 
cytotoxicities were investigated using the Cell Titer Blue assay in human carcinoma HEp2 cells, 
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the results of which are summarized in Figure 4.3. All of the BODIPYs were non-toxic in the dark 
(IC50 > 400 µM) with the exception of di-methoxyphenylstyryl-BODIPY 2b which was slightly 
toxic (IC50 ~ 150 µM). Furthermore, none of the BODIPYs were phototoxic when exposed to an 
approximately 1.5 J/cm2 light dose, with IC50 values greater than 100 µM. These results were as 
expected, in comparison to similar di-iodo-styryl-BODIPYs discussed in Chapter 3. 
 
4.2.3.2 Time-Dependent Cellular Uptake. The time-dependent cellular uptake of all BODIPYs 
at a 10 µM concentration were evaluated in HEp2 cells over a 24 hour period, and are shown in 
Figure 4.4. The mono-styryl BODIPYs 1a and 2a displayed similar uptake and were more 
internalized by cells than the di-styryl-BODIPYs 1b and 4a. The di-methoxyphenylstyryl-
BODIPY 2b was internalized the greatest, likely as a result of its more hydrophilic character from 
the four methoxy-substituents it contains. The cellular uptake of 3a produced interesting results, 
surpassing the standard used in concentration determining calculations. Consequently, the uptake 
of this compound bears repeating to accurately quantify this compound’s internalization. 
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Figure 4.3: Dark toxicity (left) and phototoxicity (right, 1.5 J/cm2) of BODIPYs 1a (black), 1b 
(green), 2a (pink), 2b (purple), 3a (blue), and 4a (red) at 10 µM by HEp2 cells. 
 
 
 
Figure 4.4: Time-dependent cellular uptake of BODIPYs 1a (black), 1b (green), 2a (pink), 2b 
(purple), and 4a (red) at 10 µM by HEp2 cells. 
 
4.3 Conclusions 
 A series of six styryl-BODIPYs were synthesized from β-free BODIPYs with the intent of 
producing long wavelength absorbing and emitting dyes of sufficient fluorescence quantum yield, 
that would readily undergo modification to include radioisotopes of fluorine and/or iodine for 
multi-modal near-IR fluorescence/PET/SPECT imaging. All of the BODIPYs displayed 
significantly red-shifted spectral profiles compared to their starting materials, with absorbances 
ranging from 570 nm to 690 nm. Although the di-styryl BODIPYs 1b, 2b, and 4a possessed the 
most long wavelength absorbances (> 650 nm), they were significantly less fluorescent than the 
mono-styryl BODIPYs 1a, 2a, and 3a, with ΦF of 0.06 – 0.18 and 0.46 - 0.73, respectively. 
Favorably, all BODIPYs were non-toxic in the dark (IC50 > 400 µM) with the exception of the 
mildly toxic 3a with an IC50 ~ 150 µM, and non-phototoxic (IC50 > 100 µM), making all 
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compounds potentially suitable as imaging agents. However, despite several attempts to modify 
the variously decorated BODIPYs to bearing potential radioisotopes, none suitable for multi-
modal imaging were acquired. Future endeavors are necessary to produce long wavelength 
absorbing and emitting dyes with high fluorescence quantum yields capable of undergoing late 
state modification to incorporate radioisotopes of fluorine and iodine. 
 
4.4 Experimental 
4.4.1 General Information 
Reagents and solvents were acquired from Sigma Aldrich and used without further 
purification. Reactions were monitored by TLC using 0.2 mm silica plates with UV indicator 
(UV254). Column chromatography was executed using Sorbent Technologies 60Ȧ silica gel (230 
- 400 mesh). Merck TLC silica gel 60 glass plates were used for preparative thin layer 
chromatography. All 1H NMR and 13C NMR spectra were obtained using a Bruker AV-500 or 
AV-400 (500 MHz or 400 MHz for 1H, 100 MHz for 13C) with samples dissolved in deuterated 
chloroform or acetone using trimethylsilane as an internal indicator. Chemical shifts (δ) are 
conveyed in ppm with CDCl3 (
1H: 7.27 ppm; 13C: 77.16 ppm) and acetone-d6 (
1H: 2.05 ppm; 13C: 
29.84 ppm) used as references. Coupling constants (J) are stated in Hertz (Hz). High resolution 
ESI mass spectra were obtained using an Agilent Technologies 6210 ESI-TOF Mass Spectrometer. 
 
4.4.2 Syntheses 
BODIPYs 1a and 1b: BODIPY 1 (0.1 g, 0.26 mmol), indole-3-carbaldehyde (0.11 g, 0.78 mmol), 
and p-TsOH (0.01 g) were dissolved in dry toluene (60 mL) over 3 Å molecular sieves. To this 
solution was added piperidine (0.4 mL) and the mixture was at reflux for 48 hours. Upon cooling, 
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the reaction was filtered to remove the sieves and the filtrate was quenched with water and 
extracted with CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was 
removed under vacuum.  The resulting residue was purified by silica column chromatography 
using 50:50 hexanes/CH2Cl2 (v/v) to afford 0.021 g of a purple solid, 1a, in 16% yield and 0.019 
g of a blue solid, 1b, in 12% yield. 
Data For 1a: 1H-NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 8.07-8.05 (d, J = 7.3, 1H), 7.75-7.70 (d, 
J = 16.1, 1H), 7.54 (s, 1H), 7.54-7.50 (d, J = 16.1, 1H), 7.42-7.39 (d, J = 6.2, 1H), 7.30-7.29 (m, 
2H), 6.66 (s, 1H), 6.56 (s, 1H), 6.51-6.50 (d, J = 2.2, 2H), 6.00 (s, 1H), 3.81 (s, 6H), 2.62 (s, 3H), 
1.62 (s, 3H), 1.26 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.50 153.13, 142.98, 140.96, 138.72, 
137.04, 136.89, 136.34, 130.88, 130.23, 126.24, 125.57, 123.21, 121.43, 120.50, 120.39, 117.23, 
115.93, 115.63, 111.49, 106.35, 105.42, 100.93, 55.58, 14.67, 14.57, 14.14; MS (ESI-TOF) m/z 
Calculated for C30H28BF2N3O2: 511.2243; Found: [M]+: 511.2253. 
Data for 1b: 1H-NMR (400 MHz, CDCl3) δ 8.39 (s, 2H), 8.17-8.16 (d, J = 7, 2H), 7.87-7.83 (d, J 
= 16.5, 2H), 7.54 (s, 2H), 7.53-7.48 (d, J = 16.5, 2H), 7.43-7.42 (d, J = 7, 2H), 7.31-7.29 (m, 4H), 
6.67 (s, 2H), 6.56-6.55 (m, 3H), 3.83 (s, 6H), 1.63 (s, 6H); 13C-NMR (100 MHz, CDCl3) 161.40, 
153.28, 141.24, 136.98, 128.99, 126.11, 125.60, 124.57, 123.10, 122.08, 121.24, 120.66, 116.76, 
116.23, 116.11, 111.52, 106.74, 100.97, 55.06, 53.75, 14.48, 14.15; MS (ESI-TOF) m/z Calculated 
for C39H33BF2N4O2: 638.2665; Found: [M]+: 638.2677. 
 
BODIPYs 2a and 2b: BODIPY 1 (0.15 g, 0.39 mmol), p-anisaldehyde (0.53 g, 3.9 mmol), and p-
TsOH (0.01 g) were dissolved in dry toluene (50 mL) over 3 Å molecular sieves. To this solution 
was added piperidine (0.4 mL) and the mixture was at reflux for 48 hours. Upon cooling, the 
reaction was filtered to remove the sieves and the filtrate was quenched with water and extracted 
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with CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was removed 
under vacuum.  The resulting residue was purified by silica column chromatography using 20% 
EtOAc in hexanes (v/v) to afford 0.024 g of a purple solid, 2a, in 12% yield and 0.015 g of a blue 
solid, 2b, in 6% yield. 
Data for 2a: 1H-NMR (400 MHz, CDCl3) δ 7.57-7.55 (d, J = 16.3, 1H) 7.56-7.54 (d, J = 8.7, 2H), 
7.23-7.19 (d, J = 16.3, 1H), 6.92-6.89 (d, J = 8.7, 2H),  6.60 (s, 1H), 6.56-6.55 (t, J = 2.1, 1H), 
6.49-6.48 (d, J = 2.3, 2H), 6.01 (s, 1H), 3.84 (s, 3H), 3.80 (s, 6H), 2.60 (s, 3H), 1.60 (s, 3H), 1.56 
(s, 3H); 13C-NMR (100 MHz, CDCl3) δ 161.57, 160.44, 154.68, 153.47, 142.63, 142.26, 139.64, 
136.78, 136.12, 129.35, 129.04, 121.00, 117.41, 116.99, 114.24, 106.19, 100.95, 69.53, 55.58, 
55.38, 53.75, 14.72, 14.49, 14.23; MS (ESI-TOF) m/z Calculated for C29H30BF2N2O3: 503.2318; 
Found: [M+H]+: 503.2320. 
Data for 2b: 1H-NMR (400 MHz, CDCl3) δ 7.64-7.61 (d, J = 16.3, 2H) 7.60-7.58 (d, J = 8.7, 4H), 
7.24-7.20 (d, J = 16.3, 2H), 6.98-6.93 (d, J = 8.7, 4H), 6.63 (s, 2H), 6.57-6.56 (t, J = 2.2, 1H), 
6.52-6.51 (d, J = 2.1, 2H), 3.86 (s, 6H), 3.81 (s, 6H), 1.61 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 
161.52, 160.38, 152.74, 141.77, 137.73, 136.93, 135.74, 132.84, 129.84, 129.77, 129.55, 129.06, 
128.67, 117.42, 117.23, 114.26, 114.08, 114.03, 113.95, 106.49, 100.96, 55.60, 55.39, 14.48; MS 
(ESI-TOF) m/z Calculated for C37H36BF2N2O4: 621.2736; Found: [M+H]+: 621.2725. 
 
BODIPYs 3a: BODIPY 3 (0.1 g, 0.25 mmol), 4-acetamidobenzaldehyde (0.4 g, 2.5 mmol), and 
p-TsOH (0.01 g) were dissolved in dry (50 mL) over 3 Å molecular sieves. To this solution was 
added piperidine (0.4 mL) and the mixture was at reflux for 48 hours. Upon cooling, the reaction 
was filtered to remove the sieves and the filtrate was quenched with water and extracted with 
CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was removed under 
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vacuum.  The resulting residue was purified by silica column chromatography using 1:1:1 
acetone/hexanes/CH2Cl2 (v/v) to afford 0.01 g of a purple solid, 3a, in 10% yield. 
Data for 3a: 1H-NMR (500 MHz, CDCl3) δ 7.66-7.65 (d, J = 8.2, 2H) 7.57-7.54 (d, J = 16.3, 1H), 
7.38-7.36 (d, J = 8.2, 2H), 7.21-7.19 (d, J = 8.2, 2H), 7.21-7.18 (d, J = 16.3, 1H), 7.12-7.11 (d, J 
= 8.2, 2H) 6.61 (s, 1H), 6.02 (s, 1H), 3.35 (s, 3H), 2.59 (s, 3H), 1.47 (s, 3H), 1.43 (s, 1H); 13C-
NMR (100 MHz, CDCl3) δ 168.24, 155.57, 153.20, 142.32, 138.66, 135.95, 135.91, 135.24, 
133.94, 132.40, 130.92, 130.02, 128.56, 128.32, 128.24, 123.26, 121.50, 119.99, 119.63, 117.77, 
46.20, 14.89, 14.73, 14.66; MS (ESI-TOF) m/z Calculated for C28H26BBrF2N3O: 548.1320; 
Found: [M+H]+: 548.1372. 
 
BODIPYs 4a: BODIPY 4 (0.1 g, 0.24 mmol), p-anisaldehyde (0.33 g, 2.4 mmol), and p-TsOH 
(0.01 g) were dissolved in dry toluene (50 mL) over 3 Å molecular sieves. To this solution was 
added piperidine (0.4 mL) and the mixture was at reflux for 48 hours. Upon cooling, the reaction 
was filtered to remove the sieves and the filtrate was quenched with water and extracted with 
CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was removed under 
vacuum.  The resulting residue was purified by silica column chromatography using 50:50 
hexanes/CH2Cl2 (v/v) to afford 0.021 g of a green solid, 4a, in 13% yield. 
Data for 4a: 1H-NMR (400 MHz, acetone-d6) δ 7.67-7.58 (m, 8H), 7.08-7.06 (d, J = 8.1, 4H),  
6.99-6.96 (d, J = 16.1, 2H), 3.89 (s, 6H), 1.79 (s, 6H); 13C-NMR (100 MHz, acetone-d6) δ 161.23, 
161.13, 137.92, 137.45, 129.26, 129.20, 129.16, 129.07, 128.75, 118.83, 118.51, 116.39, 116.27, 
114.60, 114.57, 54.91, 13.09; MS (ESI-TOF) m/z Calculated for C35H26BF7NaN2O2: 673.1873; 
Found: [M+Na]+: 673.1859. 
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4.4.3 Steady-state Absorption and Fluorescence Spectroscopy 
The spectroscopic properties of BODIPYs 1a,b, 2a,b, 3a, and 4a were determined on 
solutions prepared by dissolving crystalline compound in dimethylsulfoxide. Stock solutions 
(5x10-5 M) were prepared and diluted to appropriate concentrations for collection of absorbance 
and emission spectra. Absorption spectra were obtained on a Varian Cary 50 Bio UV/VIS 
Spectrophotometer. Measurements obtained for determining optical density were taken from 
solutions with concentrations between 1.2x10-5 and 5x10-5 M so that λmax was between 0.5 and 1.0. 
Fluorescence measurements were recorded on solutions with concentrations of 5x10-6 M to attain 
an optical density at the excitation wavelength between 0.04 and 0.06 to minimize intermolecular 
reabsorption and inner-filter effects. Compounds were excited at 540 nm for 1a, 650 nm for 1b,  
520 nm for 2a, 615 nm for 2b, 530 nm for 3a, and 600 nm for 4a. Emission spectra were acquired 
on a PTI QuantaMaster4/2006SE spectrofluorometer with the slit width set at 3 nm for 
dichloromethane and THF and 5 nm for DMSO. Methylene blue was used as a standard in 
calculating the fluorescence quantum yields (Φf = 0.03 in methanol). All measurements, both 
absorbance and emission, were acquired within 4 h of solution preparation at room temperature 
(23 – 25 °C), using a 10 mm path length quartz spectrophotometric cell. 
 
4.4.4 Cell Studies 
All reagents and tissue culture media were purchased from Invitrogen. Human carcinoma 
HEp2 cells used in this study were purchased from ATCC and were sustained at 37°C and 5% CO2 
in a 50:50 mixture of DMEM:AMEM augmented with 10% FBS and 1% antibiotic (Penicillin-
streptomycin). A working BODIPY stock solution of 32 mM BODIPY was prepared by dissolving 
the compound with sonication in 96% DMSO and 4% Cremophor EL. 
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4.4.4.1 Time-Dependent Cellular Uptake. The HEp2 cells were grown overnight in a Costar 96-
well plate plated at 15,000 cells per well.  The 32 mM stock solution was diluted to a 10 µM 
BODIPY solution through the addition of medium containing 5% FBS and 1% antibiotic to a 400 
µM stock solution.  The cells were exposed to the BODIPY in medium solution at 100 µL/well at 
time intervals of 0, 1, 2, 4, 8, and 24 hours. At the termination of the treatment, the loading medium 
was removed and the cells were washed with 1X PBS, and solubilized by adding 0.25% Triton X-
100 in 1X PBS.  Quantification of the cells was conducted using the CyQuant Cell Proliferation 
Assay (Life Technologies). BODIPY concentration was determined by reading fluorescence at 
355/700 nm with a FluoStar Optima micro-plate reader (BMG LRBTEH). Cellular uptake is 
expressed in nM compound/cell. 
 
4.4.4.2 Dark Cytotoxicity. The HEp2 cells were placed in a 96-well plate as above and allowed 
to incubate overnight. Following incubation, the cells were exposed to increasing concentrations 
of BODIPY, from 0 µM up to 400 µM, and then incubated at 37°C. After 24 hour incubation, the 
loading media containing compound was removed by washing the cells with 1X PBS. The media 
was replaced with media containing 20% Cell Titer Blue and the cells were incubated at 37°C for 
a subsequent 4 hours. Cell viability was determined by reading fluorescence at 570/615 nm with a 
FluoStar Optima micro-plate reader.  The dark toxicity is expressed in terms of the percentage of 
viable cells. 
 
4.4.4.3 Phototoxicity. The HEp2 cells were placed in 96-well plates as incubated as described 
above. Following incubation, the cells were exposed to increasing concentrations of BODIPY (0 
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µM, 3.125 µM, 6.25 µM, 12.5 µM, 25 µM, 50 µM, and 100 µM) and then incubated for 24 hours 
at 37°C. After the 24 hour treatment, the loading media was removed, the cells were washed with 
1X PBS and refilled with fresh media. The cells were then exposed to a 600 W halogen lamp light 
filtered through a water filter (Newport) and then through a beam turning mirror (200 – 3000 nm, 
Newport) to generate an approximate light dose of 1.5 J/cm2. After a 20 minute exposure time, the 
cells were incubated for another 24 hours. Following incubation, the medium was removed and 
replaced with medium containing 20% of Cell Titer Blue and the cells were incubated for a 
subsequent 4 hours. Cell viability was determined by reading fluorescence at 570/615 nm with a 
FluoStar Optima micro-plate reader. The phototoxicity is expressed in terms of the percentage of 
viable cells. 
 
4.4.5 Octanol-HEPES buffer coefficients 
The partition coefficients (log P) were measured at room temperature by adding 0.5 mL of 
a BODIPY stock solution in DMSO (50 µM) to a 15 mL volumetric tube containing 4.0 mL of 
HEPES buffer (1 M, pH 7.4), followed by addition of 4.0 mL of 1-octanol. After vortexing for 5 
min, the phases were allowed to separate completely. An aliquot of 0.5 mL from each layer was 
diluted with 0.5 mL of methanol and the absorbance was read on an Varian Cary 50 Bio UV/VIS 
Spectrophotometer with 10 mm path length quartz cuvette. 
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CHAPTER 5: SYNTHESIS, SPECTROSCOPIC, AND IN VITRO EVALUATION OF 
CARBORANYL-BODIPY DYES AS BNCT ANTI-CANCER AGENTS 
 
5.1 Introduction 
The treatment of late stage cancers of the brain is inundated by a multitude of challenges. 
The conventional approaches of cancer treatment, chemotherapy, radiation therapy, and surgery, 
all are plagued by drawbacks corresponding to the unique environment of the brain.1  Although, 
surgery to remove the bulk of a tumorous mass is often the most efficacious treatment method, it 
has its limitations in that not even the most skilled surgeons are able to remove every cancer cell. 
Currently, this “debulking” surgery is accompanied by chemotherapy and radiation treatments in 
an attempt to remove any persistent cells.1, 2   However, current chemotherapy drugs are unable to 
efficiently cross the blood brain barrier (BBB), thus limiting their effective doses of anticancer 
agents to the cancerous brain tissues while at the same time destroying normal cells as a result of 
unspecific cellular targeting. Additionally, radiation therapy is limited to tumors on the outermost 
parts of the brain due to limited penetration depth of radiation sources.3 As a result, the tumor often 
returns and becomes malignant, or spreads to other areas of the body. In response to the demand 
for brain-specific therapies, a multitude of anti-brain cancer agents have been developed. Several 
clinical trials are currently underway using various targeting therapies including PDT and boron 
neutron capture therapy (BNCT).4-8 
Current molecules used in the treatment of brain tumors have drawbacks which prevent 
them from being effective, including challenges with delivering the necessary concentration of 
their therapeutic component to tumor cells. Despite being under extensive clinical trials across the 
globe in the recent decade, the small molecules currently used in BNCT, sodium borocaptate 
(BSH) and boronophenylalanine (BPA), Figure 5.1, are flawed preventing them from being highly 
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therapeutic.2, 3  These small molecules, and many others that have been explored in vivo, tend to 
have low accumulation in tumor cells and lack selectivity of tumor cells over normal cells, as seen 
by low target-to-background ratios.  
 
a)   b)  
Figure 5.1: Chemical structures of a) BSH and b) BPA. 
 
On the other hand, some large molecules also under investigation, including porphyrins, 
tend to have high background signals, making them indistinguishable from normal tissues.  
Additionally, they tend to have high retention rates and clear from the body slowly.  A proposed 
solution to these challenges is through the design of an activatable boron-containing fluorescent 
probe that will allow for visualization and quantification of the compound within the body so that 
the anti-cancer agent may be activated when the ideal systemic localization is achieved.3, 9 
 
5.1.1 Brain Tumors 
A brain tumor is an abnormal mass of tissues caused by a dysregulation in the normal brain 
stem cell differentiation pathway, Figure 5.2 which causes uncontrolled growth and multiplication 
of brain cells. To be considered a cancerous brain tumor, the abnormal mass must be rapidly 
growing and invasive toward normal brain tissue.  They are named from the cell type of origin and 
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the location in the brain, and are graded on a scale of I to IV, with grade IV being the most 
aggressive.1 The most common brain cancer is metastatic glioblastoma multiforme (GBM).   
 
                     
Figure 5.2: The normal cell differentiation pathway of brain stem cells.10  
 
GBM is a grade IV astrocytoma, a type of brain tumor.  Astrocytomas develop from the 
star-shaped glial cells, called astrocytes, which support nerve cells (Figure 5.3).1  GBM is the final 
stage of astrocytoma formation and is the most invasive, readily spreading to near-by tissues.  Once 
the tumor has spread to surrounding tissues it is no longer made up of solely glial cells.  It may be 
composed of many different types of cells, which makes treatment increasingly difficult.  GBM is 
found in both men and women, typically affecting those ages 50 to 70, and is more prevalent in 
men.  According to the National Brain Tumor Society, GBM accounts for 17 percent of all primary 
brain tumors.1 In 2014, approximately 23,380 new cases of primary malignant brain tumors will 
be diagnosed in the United States, 12,820 in men and 10,560 in women. More than 14,000 
individuals are estimated to perish due to a lack to effective treatment.11 
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Figure 5.3: Structure and cellular support of a neuron.10 
 
Because brain tumors occupy space within the confines of the skull, their presence can 
interfere with normal brain activity.  Depending upon the location of the tumor, damage can occur 
to healthy nerves and tissues either through cellular infiltration or through deformation of the brain 
caused by increased intracranial pressure resulting from the compression of the brain against the 
skull. The areas typically affected by astrocytomas are the cerebrum, cerebellum, brain stem, and 
optic nerve.1  Symptoms caused by large astrocytomas are typically dependent upon the location 
of the tumor.  Diagnosis of brain tumor involves a neurological examination, brain scan, and 
analysis of the brain tissue via biopsy. After the composition of the tumor is identified a strategic 
therapeutic approach may be determined. 
 
5.1.2 Boron Neutron Capture Therapy (BNCT) 
BNCT is under-utilized as a cancer treatment option greatly due to the lack of efficient 
therapeutic agents.  BNCT is a binary radiation therapy involving irradiation of boron-10 
containing molecules that have the possibility of being selectively delivered to tumor cells with 
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low-energy thermal neutrons.12  Upon neutron-capture by a stable boron-10 atom, the nucleus 
splits, releasing highly charged, high linear energy transferring α-particles (4He), recoiling lithium-
7 (7Li) nuclei and kinetic energy which destroys the boron containing cell, Figure 5.4.3, 13-16 The 
amount of kinetic energy released during this process is only enough to cause expulsion of 
poisonous ions one cell diameter in length, thus containing destruction to only boron bearing cells 
and possibly to close proximity adjacent cells within the radiation path.12 
 
10B + nth  4He + 7Li + 2.31MeV 
 
Figure 5.4: Nuclear fission of a boron atom upon impact with a thermal neutron.17 
 
As of 2007, several carborane containing BNCT agents have been synthesized including 
nucleosides, nucleoside-sugar derivatives and porphyrins which show promising results including 
tumor targeting ability and low cytotoxicity, Figure 5.5.3, 13-15, 18 However, despite their promising 
preliminary studies, many of these boron delivery agents have yet to be subjected to preclinical 
and clinical studies to prove their effectiveness at delivering the necessary quantities of boron-10 
with great enough selectivity.19 
10B 
4He 
7Li 
nth 
1.47 MeV 
0.84 MeV 
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Figure 5.5: Boron containing potential BNCT agents.18  
 
5.1.3 Blood Brain Barrier 
The greatest challenge with chemically treating diseases of the brain is getting drug 
molecules through the BBB. The BBB is a protective barrier surrounding the blood vessels that 
feed the brain.  The BBB is formed when astrocytes, a type of nerve support cell, extend their foot 
processes to attach to and surround the blood vessels (Figure 5.6).  Where these processes meet 
the astrocytes secrete enzymes, called paracrines, which causes their edges to seal forming tight 
junctions.20, 21  Tight junctions prevent the passage of ions and large molecules through the spaces 
between the endothelial cells comprising the outer layer of blood vessels.  Many of the drug 
molecules that are used in chemotherapy treatment of cancer are incapable of permeating the BBB, 
thus reducing their efficacy.20 
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Figure 5.6:  Formation of tight junctions by astrocyte foot processes.22  
  
Various channels lie on the surface of the BBB allowing for the transport of water, 
nutrients, and specially designed drugs into and out of the brain.21  Water and ions necessary for 
normal cellular function pass through the membrane via passive diffusion and ion channels.  
Larger, more complex molecules must be brought across the BBB by way of transport proteins 
which lie at the surface of and traverse the cell membrane.  Receptor mediated endocytosis and 
absorptive-mediated transport are two ways in which these large molecules may cross the BBB.21, 
23 The lipophilic nature of these receptor proteins may be employed through strategically designed 
amphiphilic drugs that are capable of intravenously delivering therapeutic amounts of boron-10 to 
cancerous brain cells. 
 
5.1.4 Carboranes 
Icosahedral carboranes have become a popular delivery agent for boron-10 in regards to 
BNCT.3 Carboranes are electron deficient boron and carbon containing cages most commonly 
used in the neutral C2B10H12 form. This series of carboranes exists in three closed icosahedral 
stereoisomeric forms: ortho (1,2-C2B10H12), in which the two carbons are oriented adjacent to one 
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another, meta (1,7-C2B10H12), where a boron atom separates the two carbons, and para (1,12- 
C2B10H12), the most stable form, in which the carbon atoms lie at opposite apices of the 
icosahedron (Figure 5.7).24  
 
 
Figure 5.7: Stereoisomers of C2B10H12 closo-carboranes and [C2B9H12]
-1 nido-carborane 
(closed circle: CH, open circle: BH). 
 
 Thermodynamic rearrangement at elevated temperatures allows for conversion of ortho to 
meta (400 - 500°C) and meta to para (>620°C). Ortho and meta carboranes are sensitive to basic 
environments and effectively lose one boron atom to form negatively charged open nido-
carboranes.24 
Carboranes are electron deficient and possess special bonding in which the molecular 
orbitals (MOs) that participate in bonding extend over the entire cage creating a highly electron 
delocalized structure.  The extreme delocalization of electron density creates substantial stability.24  
These highly thermal and chemically stable compounds possess aromatic characteristics similar to 
benzene and as such, have been studied for their abilities to increase π-conjugation and enhance 
fluorescence of a conjugated fluorophore.24, 25 
The icosahedron can be split into equatorial and polar-regions in order to better explain 
bonding. The equatorial region houses boron atoms that lie in a planar ring and are sp2 hybridized 
similar to aromatic structures. The remaining p-orbitals not involved in cyclic formation are 
perpendicular to the ring and combine to form five delocalized MOs which can bond to apex boron 
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or carbon atoms.24  Bonds between carbon or boron and hydrogen are localized, forming sigma 
bonds. The cage has electrophilic nature that decreases with addition of substituents and readily 
undergoes substitution reactions without harming the integrity of the carborane cage.24, 25 
Incorporation of carboranes into the π-system of a fluorophore increases conjugation and 
structural rigidity resulting in a red-shift in absorption and emission wavelengths. Ortho-
carboranes have shown to cause the greatest red-shift with meta and para falling similarly in 
second. Thermal and chemical stability is enhanced with multiple carborane clusters, with ortho-
carborane appended structures owning the greatest thermal stability.25 
Carborane appended compounds have also shown to possess larger extinction coefficients 
than their structurally equivalent counterparts with meta-carboranes increasing emission intensity 
the greatest. The 3D structure of the cage prevents π-π stacking which also enhances fluorescence 
quantum yield, however carboranes tend to enhance aggregation which causes fluorescence 
quenching.25 In addition to their enhancement of a fluorophore’s photophysical properties, studies 
indicate carboranes show promise as boron-10 drug delivery agents due to their high stability and 
low cellular toxicity.3 
 
5.1.5 Research Prospective 
The objective of this work is to design a low molecular weight fluorescent molecule 
capable of delivering a therapeutic component for the treatment of late stage brain tumors via 
Boron Neutron Capture Therapy (BNCT).3 The compounds herein were designed to deliver boron-
10, which has been shown to cause cell death upon irradiation with low energy thermal neutrons.3, 
13-15 Carbon-boron cages, or carboranes, were attached to a fluorescent core in order to achieve a 
greater concentration of boron-10 delivered to tumor cells over current drug molecules.  
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Carboranes present an acceptable avenue for delivering the necessary quantity of boron-10 of 20 
μg/g tumor to the target cells.3, 13-15 The greatest challenge presents itself in getting the drug 
molecule across the BBB.  Molecules must be lipophilic in nature in order to enter the protective 
covering of the brain, yet must be hydrophilic in order to be administered intravenously.3 BODIPY 
serves as the fluorescent core to which the therapeutic components are attached.  BODIPY is 
hydrophobic by nature and provides a reasonable platform on which to build our drug molecule.  
In order to achieve amphiphilicity, water solubilizing groups must be added. The use of 
polyethylene glycols, polyamines, or charged amino acids may increase water solubility while at 
the same time enhancing BBB permeability.  
 
5.2 Results and Discussion 
5.2.1 Syntheses 
With iodines already installed at the 2,6-positions of several BODIPY platforms as detailed 
in Chapter 2,26 subsequent work was attempted to mount carborane moieties onto the core through 
various palladium-catalyzed coupling reactions. Previous endeavors by the Vicente group have 
shown that carboranes could be attached to a halogenated or boronic ester/acid derivatized benzyl 
moiety and subsequently subjected to a Suzuki-type coupling to readily incorporate boron-dense 
carboranes onto a fluorescent scaffold, Scheme 5.1.27 Under such mild basic conditions, the 
carborane maintained its structural integrity and the product of the coupling reactions retained the 
neutral charge of the closo-ortho-carborane. 
Halogenated BODIPYs have also been reported to readily undergo Sonogashira couplings 
with terminal alkynes in the presence of palladium (II) and copper iodide, as discussed in Chapter 
211 
 
1. Such facile and typically high yielding palladium couplings seemed desirable avenues to pursue 
to install the carboranes. 
 
 
Scheme 5.1: Suzuki couplings of porphyrin with functionalized carborane moieties.27 
 
 In order to attempt cross-couplings between the 2,6-diiodo-BODIPYs and a properly 
embellished carborane moiety, the boronic ester/acid and alkynyl reagents had to be synthesized. 
The synthesis of compounds 1 and 2 began with the deprotonation of methyl-o-carborane using n-
butyl lithium in dry tetrahydrofuran according to literature, Scheme 5.2.28  To the resulting 
carborane anion was added either 4-(bromomethyl)benzeneboronic acid pinacol ester or 4-
iodobenzyl bromide to yield 76% and 93% of compounds 1 and 2, respectively.  Compound 1, 
bearing the boronic ester, was suitable to attempt a Suzuki coupling to the diiodo-BODIPY 
compounds, whereas the iodo-benzyl-methyl-o-carborane, compound 2, could potentially undergo 
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a Sonogashira coupling with 2,6-diethynyl-BODIPY compounds after first installing an alkyne via 
Sonogashira coupling with the 2,6-diiodo-BODIPYs.  The structure of compound 2 was confirmed 
by X-ray analysis of a single crystal grown from the slow evaporation of acetone (Figure 5.8).29 
 
 
Scheme 5.2: Synthesis of carborane moieties 1 and 2. 
 
 
Figure 5.8: Molecular structure of compound 2 from X-ray crystal structure determinations. 
Ellipsoids are drawn at the 50% probability level. 
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Trimethylsilyl (TMS)-protected terminal alkynes were installed at the 2,6-positions of 
BODIPYs 3a, 4a, and 5a via palladium-catalyzed cross-couplings of the 2,6-diiodides of 3, 4, and 
5 with ethynyltrimethylsilane to produce BODIPYs 3a (87%), 4a (89%), and 5a (98%) as red 
crystalline solids, Scheme 5.3.30  Removal of the TMS protecting group was achieved through 
reaction with excess potassium hydroxide in MeOH/THF and provided BODIPYs 3b, 4b, and 5b 
as red crystalline solids (51%, 50%, and 51% yield, correspondingly).31  
 
 
Scheme 5.3: Functional modification of BODIPYs 3, 4, and 5. 
 
 All BODIPYs were confirmed by 1H-NMR, 13C-NMR, HRMS (ESI-TOF), and, in the case 
of 3b, X-ray crystallography. The 1H-NMR displayed two equivalent signals corresponding to the 
1,3,5,7-tetramethyls. The 3,5-dimethyls were visible as singlets between 1.36 and 1.63 ppm, while 
the 1,7-dimethyls appeared as singlets between 2.56 and 2.66 ppm. Singlets corresponding to the 
equivalent tert-butyl groups found in the 5 series was identified at 1.3 ppm, whereas the methoxy 
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groups seen in the 4 series could be found at 3.8 ppm. Signals corresponding to the phenyl-
hydrogens were identified as the only peaks that lie between 6.40 and 7.53 ppm. Installation of the 
TMS-protected ethynyl groups was accompanied by the appearance of a signal at 0.2 ppm (Figure 
5.9) and 0.08-0.09 ppm in the 13C-NMR. 
 
  
Figure 5.9: 1H NMR of BODIPY 5a at 400 MHz in deuterated chloroform. 
 
Subsequent removal of the TMS-group leaving the ethynyl unprotected was observed by 
the disappearance of the signal at 0.2 ppm and an appearance of the acetylene hydrogen peak at 
3.3 ppm, Figure 5.10. Identification by ESI-TOF or MALDI-TOF MS yielded corresponding m/z 
peaks: 3b, 517.253; 4b, 576.294; 5b, 628.403; 3c, 372.279; 4c, 433.189; 5c, 485.286. 
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Figure 5.10: 1H NMR of BODIPY 5b at 400 MHz in deuterated chloroform. 
 
A single crystal suitable for X-ray analysis was grown from the slow evaporation of 
acetone from a pure sample of BODIPY 3b (Figure 5.11). In comparison to previously reported 
boron-dipyrromethene compounds, and BODIPY 1a from Chapter 2, the BODIPY core of 3b 
adopts expected symmetry, bond lengths, planarity, and orthogonal dihedral angles of the F atoms 
relative to the C9N2B aromatic framework.
32, 33 The dihedral angle of the meso-substituent are also 
nearly 90° out-of-plane of the BODIPY core in the crystal structure at 88.01(5).° The refinement 
details and cell parameters are reported in the experimental details Section 5.4.3. 
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Figure 5.11: Molecular structure of BODIPY 3b from X-ray crystal structure determinations. 
Ellipsoids are drawn at the 50% probability level. 
 
Attaching the carboranyl-compounds 1 and 2 to BODIPYs 3 - 5 and 3b - 5b, respectively, 
was attempted via two synthetic routes, Suzuki and Sonogashira palladium-catalyzed couplings. 
In the first, the carborane functionality 1 was successfully added to the diiodo-BODIPY 
compounds 3b - 5b via a Suzuki coupling, Scheme 5.4, facilitated by refluxing palladium  
tetrakis(triphenylphosphine) in the presence of a mild inorganic base, sodium bicarbonate, in a 
solution of toluene and methanol under Argon atmosphere.28 
 
Scheme 5.4: Synthesis of BODIPYs 3c, 4c, and 5c via Suzuki couplings. 
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Although, the boronic ester was successfully added as confirmed by MALDI-TOF mass 
spectrometry with m/z peaks corresponding to the di-functionalized 3c, 4c, and 5c found at 797.53 
[M-F]+, 879.09 [M]+, and 929.18 [M]+, TLC analysis of the reaction mixture revealed low yield of 
the anticipated product and the production of numerous side products . As a result, the desired 
dicarboranyl-BODIPYs were never isolated in pure form. This may have been a result of 
inefficient in situ conversion of the boronic ester to the tetra-borane anion intermediate required 
to undergo oxidative addition to the BODIPY-containing palladium catalyst, Figure 5.12. 
 
 
Figure 5.12: Proposed catalytic cycle for palladium-mediated Suzuki couplings of BODIPYs. 
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Alternatively, an attempt was made to add the therapeutic carborane moiety to the 2,6-
diethynyl-BODIPY compounds 3b, 4b, and 5b via a Sonogashira coupling with compound 2, as 
shown in Scheme 5.5. The additional alkyne subunit was anticipated to allow for facile addition 
of the para-iodo-phenyl-carborane 2 as well as to extend the π-conjugation of the system to yield 
more red-shifted absorption and emission profiles compared to that of both the starting alkynes 
and of the products of the previously described Suzuki couplings.  BODIPY 3b, 4b, and 5b were 
stirred under argon at room temperature in a mixture of DCM and triethylamine in the presence of 
bis(triphenylphosphine) palladium dichloride and a copper iodide reducing agent. However, 
despite numerous attempts in which the palladium source, reaction time, and temperature were 
varied, the Sonogashira coupling produced limited amounts of the desired products 3d and 4d and 
none of 5d, as well as a multitude of inseparable bi-products as indicated by TLC. 
 
 
Scheme 5.5: Attempted syntheses of BODIPY 3d, 4d, and 5d via Sonogashira coupling. 
 
Analysis of the crude mixture obtained from the attempted Sonogashira couplings by 
MALDI-TOF mass spectrometry revealed successful coupling to a limited extent, yielding both 
mono and di-coupled products, and the loss of one or two boron atoms from the carborane to yield 
the anion nido-carboranes. Corresponding m/z peaks for the mono coupling products of 3b and 4b 
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were found as [M-B]+ at 711.13 and 771.15, whereas the di coupling product of 3b was found as 
[M+1]+ at 855.47, and the di coupling product of 4d was identified as [M-B]+ at 916.50. Despite 
innumerable attempts, pure forms of neither the mono nor di products could be isolated, even after 
careful preparative thin layer chromatography (TLC), and spectrometric results varied between 
runs. 
At this point it was realized that the triethylamine used to facilitate the conversion of the 
alkyne into the organocuprate was likely the tyrant preventing successful coupling, Figure 5.13.  
 
 
 
 
Figure 5.13: Proposed catalytic cycle for palladium-mediated Sonogashira couplings of 
BODIPYs. 
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The methyl-ortho-carborane which makes up compound 2, despite the added stability of 
the methyl substituent on the second carbon, was highly sensitive to organic base and would readily 
convert to the nido-carborane form, as shown in Scheme 5.6. Once in this form, extended exposure 
to base in the presence of palladium led to further decomposition and a multitude of side reactions. 
 
 
Scheme 5.6. Proposed mechanism for conversion of closo-o-carborane to nido-o-carborane.34 
  
Reevaluation of the Suzuki coupling attempts led to the thought to convert the boronic acid 
pinacol ester into the boronic acid to reduce potential steric repulsion. Several attempts were made 
to covert 1 into 6, following a published procedure using sodium periodate followed by overnight 
exposure to aqueous hydrochloric acid,27 Scheme 5.7.  
 
 
Scheme 5.7: Conversion of boronic acid pinacol ester 1 to boronic acid 6. 
221 
 
 This reaction produced inconsistent conversion, and afforded the desired boronic acid 6 in 
82% yield following 30 minute exposure to sodium periodate in THF/H2O (4:1) followed by the 
addition of 2N HCl and overnight stirring on only one occasion. Alternatively, the acid work-up 
was replaced by reaction of the ester/periodate mixture in acetone/H2O with ammonium acetate to 
afford 6 in 50% yield. 
With the boronic acid in hand, the Suzuki coupling could be attempted with a 2,6-diiodo-
BODIPY. Anticipating that the boronic acid would successfully yield the desired long wavelength 
absorbing and emitting, carborane-bearing BODIPY, a diiodo-BODIPY bearing a suitable 
appendage for further conjugation to targeting functionalities, such as biomolecules, was selected. 
BODIPY 7 which bears a methyl ester at the para-position of the meso-phenyl substituent, the 
synthesis of which was previously described in Chapter 2, underwent successful coupling with 
compound 6 after refluxing in toluene in the presence of Pd(PPh3)4 and 1M Na2CO3 for 15 hours 
to produce compound 8 in 89% yield after work up and column chromatography, Scheme 5.8, 
Figures 5.14 and 5.15. 
 
 
Scheme 5.8: Suzuki coupling of BODIPY 7 and compound 6. 
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Figure 5.14: 1H NMR spectrum of BODIPY 8 in deuterated chloroform at 400MHz. 
 
 
Figure 5.15: 13C NMR spectrum of BODIPY 8 in deuterated chloroform at 100MHz. 
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In order to explore the scope of the Suzuki cross-coupling of halogenated BODIPYs with 
the carboranyl-phenyl boronic acid, meso-chloro-1,3,5,7-tetramethyl BODIPY 9 was obtained 
from fellow group-mate Dr. Haijun Wang.35 Although many reports can be found in literature 
detailing the palladium-catalyzed cross-couplings of halogens located at the pyrrolic positions of 
the BODIPY core, Misra et al.36 described the only palladium-catalyzed couplings of meso-chloro-
BODIPY via Sonogashira protocol with alkynes. Compound 6 and BODIPY 9 were refluxed in 
toluene with Pd(PPh3)4 and 1M Na2CO3 for 18 hours to produce BODIPY 10 in 47% yield, as 
shown in Scheme 5.9.  
 
Scheme 5.9: Suzuki coupling of 6 with meso-chloro-BODIPY 9. 
  
The coupling at the meso-position of BODIPY was achieved in lower yields than that 
accomplished at the 2,6-positions, likely as a result of reduced reactivity of this position compared 
to the relatively more electron rich 2,6-positions, as well as the less favorable oxidative insertion 
of palladium between C8 and chlorine versus C2/6 and iodine. BODIPYs 8 and 10 along with two 
additional meso-carboranyl-BODIPYs, 11 and 12 synthesized by Dr. Haijun Wang (Figure 5.16),37 
were subjected to in vitro BBB permeability studies. 
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Figure 5.16: Chemical structures of BODIPYs 11 and 12. 
 
With the development of an efficient route to synthesizing carborane bearing BODIPYs, 
subsequent work was initiated to improve the water-solubility of BODIPY 8 and to enhance its 
cellular uptake and BBB permeability. Conjugation of polyamines, charged amino acids, such as 
arginine, lysine, and glutamate, and the biomolecule folate, through the carbonyl functionality on 
the meso-phenyl of BODIPY 8 may allow for the development of more effective BBB permeable 
BNCT agents. Polyamines have been shown to increase uptake into cancer cells due to up-
regulated polyamine transports on cancer cells,38-41 and folate, whose receptors are overexpressed 
on epithelial cells, has recently been shown by Ng et al. to favor greater internalization of 
BODIPYs in MCF-7 cells.42-45  
The initial strategy for incorporating these potential directing groups involved first 
installing the polyamine, folate, and amino acids to the meso-phenyl of BODIPY 7 followed by 
the previously described cross-coupling reaction with compound 6, as shown in Scheme 5.10. It 
was believed that the polyamines could be directly conjugated to the free acid, due to the limited 
steric strain they would encounter. On the other hand, the amino acids and folate were thought to 
be too sterically congested at the amino terminus desired for conjugation, and thus were expected 
to undergo more facile conjugation with a spacer between the BODIPY and the biomolecule. A 
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glycine spacer was selected for conjugation to the amino acids. Conversely, the folate would first 
be modified by conjugation with N-Boc-ethylenediamine through either of the free carboxylic 
acids. Following removal of the Boc-protecting group, the folate moiety could be conjugated to 
the BODIPY.  
Nonetheless, cleavage of the methyl ester from 7 to obtain the free carboxylic acid proved 
futile. Attempted hydrolysis following a procedure reported by Giessler et al.46 with dilute and 
concentrated HCl returned unreacted starting material even when heat was applied. Basic 
hydrolysis with NaOH, LiOH, and NaCN/DBU all resulted in immediate decomposition of starting 
material. Presence of iodines at the 2,6-positions was assumed to be the cause of rapid 
decomposition, therefore, the synthetic scheme was reevaluated to first cleave the methyl ester 
from unhalogenated BODIPY 13, conjugate the desired biomolecule, and complete with late stage 
iodination and Suzuki coupling to produce the desired conjugates. 
This latter approach proved successful in the early stages. BODIPY 13 underwent facile 
hydrolysis of the methyl ester, as indicated by loss of the methoxy signal at 6.96 ppm in the 1H-
NMR, by refluxing in methanol doped with 0.2 M sodium hydroxide for two hours to yield 67% 
of the free carboxylic acid BODIPY 14 as an orange solid following acidification of the condensed 
residue with 2N HCl and filtration, Scheme 5.11.47 Glycine tert-butyl ester hydrochloride (Gly-
OtBu.HCl) was then reacted with the free carboxylic acid of 14. BODIPY 14 was first treated with 
diisopropylethylamine in DCM for one hour followed by activation of the carboxylic acid with 
peptide coupling reagents HOBt and TBTU for an additional hour. Finally, Gly-OtBu was added 
and the resulting solution was allowed to stir overnight. The reaction was transferred to a 
separatory flask and quenched with 5% citric acid. The organic layer was subsequently washed 
with brine and water and dried over Na2SO4. Following removal of the solvent, the resulting 
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residue was purified by silica gel column chromatography using DCM as eluent to obtain the 
desired conjugate 15 in 35% yield. The 1H-NMR, shown in Figure 5.17, displays new signals at 
6.78, 4.19-4.17, and 1.52 ppm corresponding to the newly added NH-, CH2, and tert-butyl group 
of the glycine. 
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Scheme 5.10: Proposed synthetic pathway of BODIPY-biomolecule conjugates.  
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Typically, tert-butyl esters are readily cleaved with trifluoroacetic acid in high yields. 
Although this route would have been the easiest way to free the carboxylic acid, attempts to remove 
acid labile protecting groups from BODIPYs often results in the loss of the BF2 chelate and product 
decomposition as observed by countless failed experiments in the Vicente lab. As a result, the 
same procedure for removal of the methyl ester was employed to remove the tert-butyl ester to 
produce BODIPY 16 in 44% yield following purification, and was confirmed by the disappearance 
of the nine equivalent proton signal corresponding to the tert-butyl group at 1.52 ppm in the 1H-
NMR. 
 
 
Scheme 5.11: Synthesis of BODIPY 16. 
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Figure 5.17: 1H NMR spectrum of BODIPY 15 in deuterated chloroform at 400MHz. 
 
Preliminary attempts to synthesize the polyamine and amino acid conjugates from 
BODIPY 13 and BODIPY 16, respectively, produced a small amount of each conjugate from ~10 
mg of starting material, Schemes 5.12 and 5.13. The BODIPYs were dissolved in 5 mL of DCM 
to which six equivalents of diisopropylethylamine (DIEA) were added and the mixture was 
allowed to stir for one hour. The starting BODIPYs were poorly soluble in DCM prior to addition 
of base, but quickly solubilized once DIEA was added. Next, 1.25 equivalents of both HOBt and 
TBTU were added to activate the terminal carboxylic acid and stirred for an additional hour. 
Finally, polyamines PA2, PA3, and PA 7 (synthesized by Dr. Dinesh Bhupathiraju) were added to 
the solutions containing BODIPY 13, for BODIPYs 17 – 19, and L-glutamic acid diethyl ester was 
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added to the solution of BODIPY 16, for BODIPY 20. The resulting solutions were left to stir 
overnight.  
 
 
Scheme 5.12: Conjugation of polyamines to BODIPY 13. 
 
After 36 hours, samples of the crude mixtures were submitted to high resolution ESI-MS. 
The desired products were identified by their [M+H]+ peaks of 811.4724, 940.5516, and 611.2848 
for BODIPYs 17, 18, and 20, respectively, and by the [M+Na]+ peak of 847.4724 for BODIPY 19.  
The reactions were quenched with 5% citric acid and the organic layer was separated and washed 
with brine and water. The combined organic layers were dried over Na2SO4 and the solvent was 
removed under vacuum. TLC of the resulting residues revealed several fluorescent spots. Further 
purification to obtain pure produces for further characterization will be achieved by HPLC.  
Further optimization is required to synthesize the glycine-BODIPY conjugate 15 in greater 
yields, possibly through a change in solvent from DCM to DMF, the solvent of choice for most 
bench-top peptide coupling reactions. The coupling reagents HOBt/TBTU could also be 
exchanged for similar reagents, including DCC/DMAP, which may provide greater activation of 
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the carboxylic acid prior to the attempted conjugation. With conditions that return more efficient 
conversion of 14 to 15 deduced, attention can be turned to applying that protocol to the conjugation 
of the targeting biomolecules. Once conjugated, iodination and ensuing Suzuki coupling with 6 
will complete the synthesis and the carboranyl-BODIPYs can undergo in vitro uptake, 
cytotoxicity, and BBB permeability evaluations, as proposed in Scheme 5.14. 
 
 
Scheme 5.13: Conjugation of amino acid to BODIPY 16. 
 
5.2.2 Spectroscopic Investigations 
Preliminary photophysical evaluations were carried out on BODIPY 3a,b, 4a,b, and 5a,5b 
in dichloromethane and tetrahydrofuran, while evaluation of BODIPYs 8, 11, and 12 were 
conducted in dimethyl sulfoxide.  The fluorescent quantum yields were calculated using 
Rhodamine 6G in ethanol (ΦF = 0.95) as the standard, the results of which are shown in Figures 
5.18 – 20 and summarized in Table 5.1.  
As expected, BODIPYs 3a,b, 4a,b, and 5a,b displayed greater red-shifted absorption and 
emission profiles than their unsubstituted counterparts (abs/em 499-502 nm/507-511 nm). 
BODIPYs 3a, 4a, and 5a, bearing ethynyltrimethylsilane functionalities at the β-position displayed 
a Stokes’ shift of 52-56 nm for 3a and 4a, and 33 nm for 5a.  
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Scheme 5.14: Proposed synthetic completion of targeting carboranyl-BODIPYs. 
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It has been reported that addition of ethynyltrimethylsilane groups at the β-position induces 
a shift of approximately 50 nm in absorption accompanied by a 20 nm Stokes’ shift due to the 
extension of π-conjugation.48 The electron withdrawing effect of the silicon might play a role in 
decreasing the HOMO/LUMO gap thus increasing the λabs,max.49, 50 Removal of the TMS-group 
causes the energy of the LUMO to increase and creates a decrease in the λabs,max, as observed in 
BODIPYs 3b, 4b, and 5b. 
 
a)      b)  
 
Figure 5.18: Normalized absorption (solid line) and emission (dashed line) spectrum of BODIPYs 
3a (blue), 4a (red), and 5a (green) in DCM (a) and THF (b). 
 
 
 
a)     b)   
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Figure 5.19 Normalized absorption (solid line) and emission (dashed line) spectrum of BODIPYs 
3b (blue), 4b (red), and 5b (green) in DCM (a) and THF (b). 
 
 
The carboranyl-BODIPYs 8, 11, and 12 displayed similar absorption and emission shifts 
to the diiodo-BODIPYs (detailed in Chapter 2) in DMSO. All BODIPYs displayed the 
characteristic Q-band absorption around 530 nm with a shoulder at slightly lower wavelength. 
Additionally, large extinction coefficients were calculated (log ε = 4.68 - 4.37) as anticipated and 
Stokes’ shifts of 14 – 27 nm were observed. The extended π-conjugation through the 2,6-positions 
of BODIPY 8 produced an approximately 30 nm red-shift in absorption and a 45 nm red-shift in 
the emission profile in agreement with previously reports of similarly decorated BODIPYs.51 On 
the other hand, the electron-donating effect of the lone pairs on sulfur in BODIPYs 11 and 12 
increase the π-conjugation of the core. This stabilizes the LUMO via greater delocalization of 
electron density compared to the meso-aryl BODIPYs whose meso-substituents do not participate 
in the conjugation of the BODIPY core.50 The resultant decreased HOMO – LUMO gap 
corresponds to a red-shift in the photophysical profiles of 11 and 12. 
When excited at 500 nm, BODIPY 11’s emission profile overlapped with the long 
wavelength end of another fluorescence producing energy transition, preventing the visualization 
of the expected peak around 550 nm. When excited at a shorter wavelength, 490 nm, a sharp 
emission peak was produced centered around 509 nm. This product impurity or more fluorescent 
transition results in a blue shift compared to the absorption maximum at 538 nm.  
Due to an insufficient amount of BODIPY 10, its photophysical properties could not be 
evaluated. However, to the naked eye, 10 appears as an orange solid, a yellow solution, and emits 
green fluorescence, much like the meso-aryl tetramethyl-BODIPYs of Chapter 2. 
 
235 
 
 
Figure 5.20: Normalized absorption (solid line) spectra of BODIPYs 8 (green), 11 (red), and 12 
(blue) and emission (dashed line) spectra of 8 in DMSO. 
 
 
Table 5.1: Photophysical properties of BODIPY 3a - 5a and 3b - 5b in dichloromethane and 
tetrahydrofuran, and BODIPY 8 and 10-12 in dimethyl sulfoxide. 
 
Compound Solvent λmax abs  
(nm) 
λmax em 
(nm) 
log ε ΦF Stokes' 
Shift (nm) 
3a DCM 554 571 4.77 0.09 17 
  THF 552 569 4.80 0.15 17 
4a DCM 556 574 4.73 0.20 18 
  THF 554 570 4.75 0.50 16 
5a DCM 533 564 4.70 0.19 31 
  THF 533 562 4.68 0.08 29 
3b DCM 537 553 4.88 0.13 16 
  THF 537 557 5.05 0.27 20 
4b DCM 540 555 5.02 0.13 15 
  THF 540 556 5.05 0.14 16 
5b DCM 533 550 4.83 0.33 17 
  THF 533 552 5.04 0.11 19 
8 DMSO 534 561 4.38 0.99 27 
10 DMSO n/a n/a n/a n/a n/a 
11 DMSO 538 n/a 4.37 n/a n/a 
12 DMSO 531 545 4.68 0.03 14 
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5.2.3 In vitro BBB Permeability 
The BBB permeability of BODIPYs 8 and 10 - 12 was investigated by Dr. Dinesh 
Bhupathiraju using the human brain endothelial cell line hCMEC/D3. The hCME/D3 cell line was 
determined to be the ideal model for in vitro studies on the human BBB. Previous in vitro BBB 
studies have been successfully conducted to study the drug transportation across the BBB.52-54 
Therefore, the carboranyl-BODIPYs’ BBB permeability on hCMEC/D3 cells were investigated 
and were compared to a fluorescent molecule known to bypass the BBB, Lucifer yellow 
FTIC40K.52 Prior to being exposed to the compounds under investigation, the in vitro BBB model 
composed of basolateral and apical chambers as shown in Figure 5.21, was prepared from a known 
protocol.55  
 
 
Figure 5.21: Blood brain barrier model used in vitro.55 
 
Once prepared, the carboranyl-BODIPYs were added to the apical chamber containing a 
monolayered cell membrane. Then, at time intervals of 0, 30, and 60 minutes, the concentration of 
compounds in the basolateral layer was measured using a fluorescence plate reader. This 
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measurement was then applied to the equation for the permeability coefficient (P) (found in 
Section 5.4.4.4),55 the results of which are summarized in Table 5.3. 
 Only one carboranyl-BODIPY, 11, showed high permeability, and was more efficiently 
able to migrate to the basalateral layer than the standard. BODIPYs 8 and 10 in which the carborane 
moiety was conjugated to the BODIPY with a phenyl spacer, showed decreased solubility in the 
cellular media as a result of their highly hydrophobic character, noted by their Log P values of 
1.41, respectively compared to 0.85 and 0.89 of BODIPYs 11 and 12. In vitro investigations of the 
cellular uptake, cytotoxicity, and subcellular localization in T98G cells are planned in the near 
future. Subsequent work to promote water solubility and uptake potential of BODIPY 8 has been 
initiated, as detailed in Section 5.2.1, and will be completed in the near future. 
 
Table 5.3: In vitro permeability coefficient values for carboranyl-BODIPYs 8, 10 - 12. 
Compound Permeability coefficient 
(Pc) cm/s  
at 30 min 
Permeability coefficient 
(Pc) cm/s  
at 60 min 
Log P 
Lucifer 
Yellow 
2.9351e-5 
 
2.03585 e-5 
 
 
8 4.76443 e-8 
 
2.80537 e-8 
 
1.41 
10 6.58966 e-8 
 
3.98496 e-8 
 
n/a 
11 2.75514 e-5 
 
3.40739 e-5 
 
0.85 
12 3.23795 e-7 
 
2.79189 e-7 
 
0.89 
 
5.3 Conclusions 
The synthesis, spectroscopic properties and BBB permeability toward the human brain 
endothelial cell line hCMEC/D3 of four BODIPYs were investigated. Two different synthetic 
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routes, Suzuki and Sonogashira cross coupling reactions, were explored to provide a facile 
approach to attaching carborane-bearing moieties to the BODIPY scaffold. Attempts at utilizing 
the Sonogashira protocol led to decomposition of the carborane after prolonged exposure to 
organic, non-nucleophilic base. The Suzuki method with a boronic ester functionalized carborane 
moiety 6 proved successful, allowing for the synthesis of two carboranyl-BODIPYs 8 and 10 of 
different connectivity. Studies of the spectroscopic profile of BODIPY 8 revealed an absorption 
around 534 nm and emission of 561 nm. Along with two additional meso-carboranyl BODIPYs 
11 and 12 synthesized by Dr. Haijun Wang, the BBB permeability assessment of four carboranyl-
BODIPYs revealed only one, BODIPY 10, to efficiently penetrate the BBB. Subsequent work was 
initiated to install polyamines, amino acids, and a folate moiety to BODIPY 8 to aid in the water 
solubility, BBB permeability, and tumor selectivity of the carborane-containing BODIPY. 
 
5.4 Experimental 
5.4.1 General Information 
Reagents and solvents were acquired from Sigma Aldrich and used without further 
purification. Reactions were monitored by TLC using 0.2 mm silica plates with UV indicator 
(UV254). Column chromatography was executed using Sorbent Technologies 60Ȧ silica gel (230 
- 400 mesh). Merck TLC silica gel 60 glass plates were used for preparative thin layer 
chromatography. All 1H NMR and 13C NMR spectra were obtained using a Bruker AV-500, DPX-
400, AV-400, or DPX-250 spectrometer (500 MHz, 400 MHz or 250 MHz for 1H, 100 MHz for 
13C) with samples dissolved in deuterated chloroform or acetone using trimethylsilane as an 
internal indicator. Chemical shifts (δ) are conveyed in ppm with CDCl3 (1H: 7.27 ppm; 13C: 77.16 
ppm) and acetone-d6 (
1H: 2.05 ppm; 13C: 29.84 ppm) used as references. Coupling constants (J) 
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are stated in Hertz (Hz). High resolution ESI mass spectra were obtained using an Agilent 
Technologies 6210 ESI-TOF Mass Spectrometer. MALDI mass spectra were acquired using a 
Bruker UltrafleXtreme MALDI-TOF/TOF Mass Spectrometer. 
 
5.4.2 Syntheses 
Compound 1: In a round bottom flask equipped with magnetic stir bar, methyl-o-carborane (0.11 
g 0.67 mmol) was dissolved in 10 mL of dry THF.  The flask was purged of air and filled with 
argon three times before being cooled to 0°C.  nBuLi solution (0.5 mL, 0.74 mmol; 1.6 M in 
hexanes) was added drop-wise to the cooled mixture.  The mixture was brought to room 
temperature and stirred for 1 hour.  The mixture was then cooled to -78°C. 4-
(bromomethyl)benzeneboronic acid pinacol ester  (0.2 g, 0.67 mmol) was dissolved in 5 mL THF 
and added drop-wise to the chilled solution.  The mixture was warmed to room temperature and 
stirred until TLC indicated no starting materials remained.  The reaction mixture was poured into 
25 mL of brine and extracted with ethyl acetate (3 x 25 mL), dried over Na2SO4 and purified by 
silica gel column chromatography using 50:50 hexanes/dichloromethane yielding a white solid 
(0.185 g) in 76% yield.  
1H-NMR (400 MHz, CDCl3) δ 7.80-7.78 (d, J = 7.8, 2H), 7.39-7.37 (d, J = 7.8, 2H), 4.48 (s, 2H), 
1.99 (s, 3H), 3.2-1.2 (br m, 10H), 1.35 (s, 12H); 13C-NMR (100 MHz, CDCl3) δ 137.81, 134.93, 
129.62, 128.23, 83.84, 74.86, 41.16, 33.25, 24.85, 23.57; MS (ESI-TOF) m/z Calculated for 
C16H28B11O2: 373.3112; Found: negative ion [M-H]
+: 373.3349. The NMR data is in agreement 
with that already published.27 
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Compound 2: In a round bottom flask equipped with magnetic stir bar, methyl-o-carborane (0.11 
g 0.67 mmol) was dissolved in 10 mL of dry THF.  The flask was purged of air and filled with 
argon three times before being cooled to 0°C.  nBuLi solution (0.5 mL, 0.74 mmol; 1.6 M in 
hexanes) was added drop-wise to the cooled mixture.  The mixture was brought to room 
temperature and stirred for 1 hour.  The mixture was then cooled to -78°C. 4-iodobenzyl bromide 
(0.2 g, 0.67 mmol) was dissolved in 5 mL THF and added drop-wise to the chilled solution.  The 
mixture was warmed to room temperature and stirred until TLC indicated no starting materials 
remained.  The reaction mixture was poured into 25 mL of brine and extracted with ethyl acetate 
(3 x 25mL), dried over Na2SO4 and purified by silica gel column chromatography using 50:50 
hexanes/dichloromethane yielding a white solid (0.235 g) in 93% yield.  
1H-NMR (400 MHz, CDCl3) δ 7.69-7.67 (d, J = 8.2, 2H), 7.15-7.13 (d, J = 8.2, 2H), 4.43 (s, 2H), 
3.2-1.2 (br m, 10H), 2.04 (s, 3H); 13C-NMR (100 MHz, CDCl3) δ 137.97, 137.47, 130.83, 94.09, 
80.09, 61.52, 32.43, 25.91; MS (ESI-TOF, negative ion) m/z Calculated for C10H16B10I: 373.1227; 
Found: [M-H]+: 373.1449. The NMR data is in agreement with that already published.29 
 
BODIPY 3a: To a mixture of BODIPY 3 (0.16 g, 0.27 mmol), bis(triphenylphosphine) palladium 
(II) dichloride (0.009 g, 0.01 mmol), and copper iodide (0.002 g, 0.01 mmol) in triethylamine (10 
mL) and DCM (10 mL), ethynyl trimethylsilane (0.12 g, 0.74 mmol) was added drop-wise under 
Argon.  The resulting solution was stirred at room temperature for 12 hours. The mixture was 
quenched with water washed three times with water. The combined aqueous layers were extracted 
three times with ethyl acetate and passed through a bed of Na2SO4. The solvent was removed under 
vacuum and the resulting residue was purified using silica gel column chromatography with 50:50 
Hexanes/DCM as eluent yielding a red solid (0.122 g) in 87% yield.  
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1H-NMR (400 MHz, CDCl3) δ 7.51-7.50 (m, 3H), 7.25-7.23 (m, 2H), 2.64 (s, 6H), 1.45 (s, 6H), 
0.20 (s, 18H); 13C-NMR (100 MHz, CDCl3) δ 158.41, 157.09, 152.16, 145.53, 133.14, 130.97, 
122.30, 121.58, 83.91, 75.87, 35.00, 31.23, 13.36, 13.87; MS (ESI-TOF) m/z Calculated for 
C29H35BF2N2Si2: 516.2399; Found: [M+H]
+: 517.2530. 
 
BODIPY 3b: BODIPY 3a (0.006 g, 0.01 mmol) and freshly ground potassium hydroxide (0.005 
g, 0.08 mmol) were dissolved in 1:1 THF/MeOH (1 mL) at room temperature.  The reaction was 
stirred for 2 hours. The mixture was poured into water and the aqueous layer was extracted twice 
with DCM.  The combined organic layers were washed with water and dried over Na2SO4.  The 
solvent was evaporated under reduced pressure and resulting residue was purified by silica gel 
column chromatography using dichloromethane as eluent yielding a red solid (0.030 g) in 51% 
yield.  
1H-NMR (400 MHz, CDCl3) δ 7.53-7.52 (m, 3H), 7.27-7.25 (m, 2H), 3.22 (s, 2H), 2.66 (s, 6H), 
1.47 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 129.47, 129.45, 129.42, 129.40, 127.80, 127.76, 
127.71, 84.09, 75.91, 16.93, 16.03, 13.50, 13.22; MS (MALDI-TOF-TOF) m/z Calculated for 
C23H19BF2N2: 372.1609; Found: [M]
+:  372.297. 
 
BODIPY 4a: To a mixture of BODIPY 4 (0.096 g, 0.15 mmol), bis(triphenylphosphine) palladium 
(II) dichloride (0.005 g, 0.008 mmol), and copper iodide (0.001 g, 0.008 mmol) in triethylamine 
(10 mL) and DCM (10 mL), ethynyl trimethylsilane (0.075 g, 0.45 mmol) was added drop-wise 
under Argon.  The resulting solution was stirred at room temperature for 12 hours. The mixture 
was poured into water.  The aqueous layer was washed three times with water. The combined 
aqueous layers were extracted three times with ethyl acetate and passed through a bed of Na2SO4. 
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The solvent was removed under vacuum and the resulting residue was purified using silica gel 
column chromatography with 50:50 hexanes/DCM as eluent yielding a red solid (0.077 g) in 89% 
yield.  
1H-NMR (400 MHz, CDCl3) δ 6.58-6.57 (t, J = 2.3, 1H), 6.41-6.40 (d, J = 2, 2H), 3.80 (s, 6H), 
2.64 (s, 6H), 1.63 (s, 6H), 0.22 (s, 18H); 13C-NMR (100 MHz, CDCl3) δ 161.98, 158.91, 144.98, 
142.47, 135.94, 111.18, 105.72, 101.73, 101.44, 97.11, 55.58, 29.69, 13.56, 13.52, 0.08; MS (ESI-
TOF) m/z Calculated for C31H39BF2N2O2Si2: 576.2611; Found: [M]
+: 576.279. 
 
BODIPY 4b: BODIPY 4a (0.05 g, 0.1 mmol) and freshly ground potassium hydroxide (0.046 g, 
0.8 mmol) were dissolved in 1:1 THF/MeOH (25 mL) at room temperature.  The reaction was 
stirred for 2 hours. The mixture was poured into water and the aqueous layer was extracted twice 
with DCM.  The combined organic layers were washed with water and dried over Na2SO4.  The 
solvent was evaporated under reduced pressure and resulting residue was purified by silica gel 
column chromatography using dichloromethane as eluent yielding a red solid (0.043 g) in 50% 
yield.  
1H-NMR (400 MHz, CDCl3) δ 6.58-6.57 (t, J = 2.3, 1H), 6.41-6.40 (d, J = 2, 2H), 3.80 (s, 6H), 
3.32 (s, 2H), 2.64 (s, 6H), 1.63 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 161.98, 158.91, 144.98, 
142.47, 135.94, 111.18, 105.72, 101.73, 101.44, 97.11, 55.58, 29.69, 13.56, 13.52; MS (ESI-TOF) 
m/z Calculated for C25H24BF2N2O2: 433.1898; Found: [M+H]
+: 433.1896. 
 
BODIPY 5a: To a mixture of BODIPY 5 (0.11 g, 0.16 mmol), bis(triphenylphosphine) palladium 
(II) dichloride(0.006 g, 0.008 mmol), and copper iodide (0.002 g, 0.008 mmol) in triethylamine 
(10 mL) and DCM (10 mL), ethynyl trimethylsilane (0.08 g, 0.48 mmol) was added drop-wise 
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under Argon.  The resulting solution was stirred at room temperature for 12 hours. The mixture 
was poured into water.  The aqueous layer was washed three times with water. The combined 
aqueous layers were extracted three times with ethyl acetate and passed through a bed of Na2SO4. 
The solvent was removed under vacuum and the resulting residue was purified using silica gel 
column chromatography with 50:50 hexanes/DCM as eluent yielding a red solid (0.189 g) in 93% 
yield.  
1H-NMR (400 MHz, CDCl3) δ 7.51-7.50 (t, J = 1.7, 1H), 7.07-7.06 (d, J = 1.2, 2H), 2.64 (s, 6H), 
1.44 (s, 6H), 1.32 (s, 18H), 0.20 (s, 18H); 13C-NMR (100 MHz, CDCl3) δ 156.49, 152.23, 145.41, 
133.82, 122.47, 122.27, 121.88, 121.80, 101.52, 97.22, 85.44, 35.14, 31.37, 16.67, 15.96, 0.09; 
MS (ESI-TOF) m/z Calculated for C37H52BF2N2Si2: 629.3730; Found: [M+H]
+: 629.3648. 
 
BODIPY 5b: BODIPY 5a (0.11 g, 0.18 mmol) and freshly ground potassium hydroxide (0.08 g, 
1.4 mmol) were dissolved in 1:1 THF/MeOH (25 mL) at room temperature.  The reaction was 
stirred for 2 hours. The mixture was poured into water and the aqueous layer was extracted twice 
with DCM.  The combined organic layers were washed with water and dried over Na2SO4.  The 
solvent was evaporated under reduced pressure and resulting residue was purified by silica gel 
column chromatography using dichloromethane as eluent yielding a red solid (0.044 g) in 51% 
yield.  
1H-NMR (400 MHz, CDCl3) δ 7.53-7.52 (t, J = 1.7, 1H), 7.09-7.08 (d, J = 1.2, 2H), 3.31 (s, 2H), 
2.66 (s, 6H), 1.45 (s, 6H), 1.33 (s, 18H); 13C-NMR (100 MHz, CDCl3) δ 158.32, 152.42, 145.44, 
133.62, 122.59, 121.66, 114.81, 94.23, 83.82, 75.91, 35.01, 31.24, 13.39, 12.93; MS (ESI-TOF) 
m/z Calculated for C31H36BF2N2: 485.2939; Found: [M+H]
+: 485.2868. 
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Compound 6: In a round bottom flask equipped with a stir bar, compound 1 (0.1 g, 0.27 mmol) 
and sodium periodate (0.18 g, 0.83 mmol) were dissolved in a 4:1 mixture of THF/H2O (4 mL) 
and stirred at room temperature for 30 minutes. To this mixture was added 2N HCl (0.5 mL) and 
the reaction was allowed to stir overnight. The mixture was poured into water and extracted with 
EtOAc. The combined organic layers were dried over Na2SO4 and the solvent was removed under 
reduced pressure. The resulting residue was purified by silica gel column chromatography using 
EtOAc as eluent to obtain a white solid (0.064 g) in 82% yield.  
1H-NMR (400 MHz, CDCl3) δ 7.14-7.12 (d, J = 7.8, 2H), 7.00-6.97 (d, J = 7.8, 2H), 3.41 (s, 2H), 
2.75-1.50 (br m, 10H), 2.14 (s, 3H). The 1H-NMR was in agreement with that already published.27 
 
Compound 8:  BODIPY 7 (0.02 g, 0.03 mmol), compound 6 (0.04 g, 0.13 mmol), and Pd(PPh3)4 
(0.004 g, 0.003 mmol) were dissolved in dry toluene (2 mL) over 3Å molecular sieves. A solution 
of 1M Na2CO3 (0.5 mL) was added and the mixture was stirred at reflux for 15 hours. The reaction 
was quenched with water and extracted with DCM. The combined organic layers were dried over 
Na2SO4 and the solvent was evaporated. The resulting residue was purified by silica gel column 
chromatography using a gradient from hexanes to 50:50 hexanes/DCM as eluent to obtain a red 
crystalline solid (0.025 g) in 89% yield.  
1H-NMR (400 MHz, CDCl3) δ 8.21-8.20 (d, J = 8, 2H), 7.50-7.48 (d, J = 8, 2H), 7.23-7.21 (d, J = 
7.8, 4H), 7.15-7.13 (d, J = 7.8, 4H) 3.96 (s, 3H), 3.48 (s, 4H), 2.8-1.5 (br m, 22H), 2.56 (s, 6H), 
2.18 (s, 6H), 1.30 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 166.40, 157.74, 140.79, 140.09, 139.11, 
133.99, 133.35, 133.27, 130.95, 130.89, 130.53, 130.34, 130.31, 128.42, 77.44, 74.86, 52.45, 
40.94, 23.73, 13.50, 13.03; MS (ESI-TOF) m/z Calculated for C41H57B21F2N2O2: 874.6488; 
Found: [M]+: 874.6523. 
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Compound 10: BODIPY 9 (0.01 g, 0.035 mmol), compound 6 (0.022 g, 0.074 mmol), and 
Pd(PPh3)4 (0.004 g, 0.0035 mmol) were dissolved in dry toluene (2 mL) over 3Å molecular sieves. 
A solution of 1M Na2CO3 (0.5 mL) was added and the mixture was stirred at reflux for15 hours. 
The reaction was quenched with water and extracted with DCM. The combined organic layers 
were dried over Na2SO4 and the solvent was evaporated. The resulting residue was purified by 
preparative thin layer chromatography using 5:1 hexanes/EtOAc as eluent to obtain an orange solid 
(0.008 g) in 47% yield. 
1H-NMR (400 MHz, CDCl3) δ 7.35-7.33 (d, J = 7.8, 2H), 7.31-7.30 (d, J = 7.8, 2H) 5.99 (s, 2H), 
3.55 (s, 2H), 3.0-1.0 (br m, 10H), 2.56 (s, 6H), 2.20 (s, 3H), 1.40 (s, 6H); 13C-NMR (100 MHz, 
CDCl3) δ 155.75, 142.98, 140.73, 135.84, 131.27, 128.41, 123.20, 121.38, 95.34, 82.90, 71.40, 
41.07, 37.50, 14.57, 13.93; MS (ESI-TOF) m/z Calculated for C23H34B11F2N2: 495.3786; Found: 
[M+H]+: 495.3772. 
 
Compound 14: In a round bottom flask equipped with a stir bar, BODIPY 13 (0.25 g, 0.65 mmol) 
was dissolved in MeOH (150 mL). A solution of 0.2 M NaOH (20 mL) was added and the resulting 
mixture was refluxed for two hours. After allowing the mixture to cool, the solvent was evaporated 
under reduced pressure. The resulting residue was acidified with 2 M HCl and the resulting 
precipitate was removed by filtration. The dry orange solid (0.160 g) yielded the target compound 
in 67% yield.  
1H-NMR (400 MHz, CDCl3) δ 8.25-8.23 (d, J = 7.8, 2H), 7.47-7.45 (d, J = 7.8, 2H), 6.00 (s, 2H), 
2.57 (s, 6H), 1.38 (s, 6H); MS (ESI-TOF) m/z Calculated for C20H21BF2N2O2: 369.1586; Found: 
[M+H]+: 369.1576. The NMR data was in agreement with that already published.47 
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Compound 15: BODIPY 14 (0.01 g, 0.016 mmol) was dissolved in dry DCM (5 mL). 
Diisopropylethylamine (0.0125 g, 0.98 mmol) was added and the mixture was allowed to stir for 
one hour. HOBt (0.003 g, 0.02 mmol) and TBTU (0.007 g, 0.02 mmol) were added consecutively 
and the resulting solution stirred for an additional hour. Finally, glycine tert-butyl ester 
hydrochloride (0.003 g, 0.019 mmol) was added and the mixture stirred overnight. The solution 
was transferred into a separatory funnel and quenched with 5% citric acid. The organic layer was 
then washed with brine and water and dried over Na2SO4. The solvent was evaporated under 
reduced pressure and the resulting solid was purified by silica column chromatography using DCM 
as eluent to obtain a red-orange solid (0.0046 g) in 37% yield.  
1H-NMR (400 MHz, CDCl3) δ 7.97-7.95 (d, J = 7.8, 2H), 7.41-7.39 (d, J = 7.8, 2H), 6.78 (s, 1H), 
5.98 (s, 2H), 4.18-4.17 (d, J=4.6, 2H), 2.55 (s, 6H), 1.52 (s, 9H), 1.35 (s, 6H); MS (ESI-TOF) m/z 
Calculated for C26H30BF2N3O3: 482.2427; Found: [M+H]
+: 482.2419. 
 
Compound 16: In a round bottom flask equipped with a stir bar, BODIPY 15 (0.018 g, 0.037 
mmol) was dissolved in MeOH (15 mL). A solution of 0.2 M NaOH (0.5 mL) was added and the 
resulting mixture was refluxed for two hours. After allowing the mixture to cool, the solvent was 
evaporated under reduced pressure. The resulting residue was acidified with 2 M HCl and the 
resulting precipitate was removed by filtration. The dry orange solid (0.007 g) yielded the target 
compound in 44% yield. 
1H-NMR (400 MHz, CDCl3) δ 7.98-7.96 (s, J = 7.8, 2H), 7.42-7.40 (d, J = 7.8, 2H), 6.75 (s, 1H), 
6.00 (s, 2H), 4.20-4.18 (d, J = 4.6, 2H), 2.56 (s, 6H), 1.36 (s, 6H); 13C-NMR (100 MHz, CDCl3) δ 
206.41, 206.03, 171.39, 167.06, 156.51, 143.96, 142.25, 138.92, 136.02, 129.37, 129.20, 122.32, 
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41.97, 14.76; MS (ESI-TOF) m/z Calculated for C22H23BF2N3O3: 426.1801; Found: [M+H]
+: 
426.1796. 
 
5.4.3 X-ray Determined Molecular Structures 
Diffraction data were collected at 95 K on a Bruker Kappa Apex-II DUO diffractometer 
equipped with MoK radiation ( = 0.71073 Å). Refinement was by full-matrix least squares using 
SHELXL, with H atoms in idealized positions.  
Crystal data for 3b: C23H19BF2N2, M = 372.21, triclinic space group P1, a = 10.1333 (10) Å, b = 
10.5938 (10) Å, c = 10.9775 (10) Å,  = 113.773 (4)°, U = 942.87 (17) Å3, T = 95 K, Z = 2, A 
total of 8,560 reflections were measured (Rint = 0.0000). R = 0.044 for 8,560 data points with  I > 
2 (I) of 7,042 unique data points and 257 refined parameters.  
 
5.4.4 Steady-state Absorption and Fluorescence Spectroscopy 
The spectroscopic properties of BODIPYs 3a,b, 4a,b, 5a,b, 8, 11, and 12 were determined 
on solutions prepared by dissolving crystalline compound in dichloromethane, THF, or DMSO. 
Stock solutions (5x10-5 M) were prepared and diluted to appropriate concentrations for collection 
of absorbance and emission spectra. Absorption spectra were obtained on a PerkinElmer Lambda 
35 UV/VIS Spectrometer for BODIPYs 3a,b, 4a,b, and 5a,b and on a Varian Cary 50 Bio UV/VIS 
Spectrophotometer for BODIPYs 8, 11, and 12. Measurements obtained for determining optical 
density were taken from solutions with concentrations between 1.2x10-5 and 5x10-5 M so that λmax 
was between 0.5 and 1.0. Fluorescence measurements were recorded on solutions with 
concentrations between 1.2x10-6 and 2.5x10-5 M to attain an optical density at the excitation 
wavelength between 0.04 and 0.06 to minimize intermolecular reabsorption and inner-filter 
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effects. Compounds were excited at 500 nm for 3a,b, 4a,b, and 5a, b, 500 nm for 8, 480 nm for 
11, and 490 nm for 12. Emission spectra were acquired on a Fluorolog3 Fluorometer with the slit 
width set at 5 nm for BODIPYs 3a, 4a, and 5a and 2 nm BODIPYs 3b, 4b, and 5b and on a PTI 
QuantaMaster4/2006SE spectrofluorometer with the slit width set at 3 nm for 8, 11, and 12. 
Rhodamine 6G was used as a standard in calculating the fluorescence quantum yields (Φf = 0.95 
in ethanol). All measurements, both absorbance and emission, were acquired within 4 h of solution 
preparation at room temperature (23 – 25 °C), using a 10 mm path length quartz 
spectrophotometric cell. 
 
5.4.5 Cell Studies 
5.4.5.1 BBB Permeability 
The hCMEC/D3 cells were incubated in a 6-well, 0.4 μm porosity PET transwell plate 
(Corning) and allowed to grow for 48 h. EBM-2 medium containing 5% FBS (Fetal Bovine 
Serum), 1% Penicillin-Streptomycin, hydrocortisone, ascorbic acid, chemically defined lipid 
concentrate (1/100), HEPES, and bFGF was used as growth medium. A 0.5 ml sample of each 
carboranyl-BODIPY at 1 mg/ml concentration was added to the upper chamber and 1.5 ml HBSS 
buffer was added to the lower chamber. The cells were incubated for 0, 30, and 60 minutes, and at 
the end of each incubation time five aliquots of 100 L of solution from the lower chamber is 
pipetted and fresh 500 L HBSS buffer is added back to the lower chamber. The five 100 L (five 
replicates) solutions that were collected from the lower chamber were pipetted in a 96 well plate. 
To determine the BODIPY concentration, fluorescence emission was read at 520/590 using a BMG 
FLUOstar plate reader. The permeability coefficients (P, expressed in cm.s-1) were calculated using 
the following equation: 
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𝑃 =
(𝐶𝑓 − 𝐶0)
(𝑡𝑓 − 𝑡0)
 ×  
1
60𝐴.𝐶0
 
Where 𝐶𝑓 is the final concentration of the compound (ng/ml), 𝐶0 is the initial concentration of 
compound (ng/ml), 𝑡𝑓 is the final time (minutes), 𝑡0 is the initial time (minutes) and 𝐴 is the surface 
area of the filter (cm2). 
 
5.4.6 Octanol-HEPES buffer partition coefficients 
The partition coefficients (log P) were measured at room temperature by adding 0.5 mL of 
a BODIPY stock solution in DMSO (50 µM) to a 15 mL volumetric tube containing 4.0 mL of 
HEPES buffer (1 M, pH 7.4), followed by addition of 4.0 mL of 1-octanol. After vortexing for 5 
min, the phases were allowed to separate completely. An aliquot of 0.5 mL from each layer was 
diluted with 0.5 mL of methanol and the absorbance was read on an Varian Cary 50 Bio UV/VIS 
Spectrophotometer with 10 mm path length quartz cuvette. 
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APPENDIX A: NMR SPECTRA OF COMPOUNDS FOUND IN CHAPTER 2 
 
Figure A.1: 1H NMR spectrum of BODIPY 1 in deuterated chloroform at 400MHz. 
 
Figure A.2: 13C NMR spectrum of BODIPY 1 in deuterated chloroform at 100MHz. 
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Figure A.3: 1H NMR spectrum of BODIPY 2 in deuterated chloroform at 400MHz. 
 
 
Figure A.4: 13C NMR spectrum of BODIPY 2 in deuterated chloroform at 100MHz. 
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Figure A.5: 1H NMR spectrum of BODIPY 3 in deuterated chloroform at 400MHz. 
 
 
Figure A.6: 13C NMR spectrum of BODIPY 3 in deuterated chloroform at 100MHz. 
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Figure A.7: 1H NMR spectrum of BODIPY 4 in deuterated chloroform at 400MHz. 
 
 
Figure A.8: 13C NMR spectrum of BODIPY 4 in deuterated chloroform at 100MHz. 
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Figure A.9: 1H NMR spectrum of BODIPY 5 in deuterated chloroform at 400MHz. 
 
 
Figure A.10: 13C NMR spectrum of BODIPY 5 in deuterated chloroform at 100MHz. 
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Figure A.11: 1H NMR spectrum of BODIPY 6 in deuterated chloroform at 400MHz. 
 
 
Figure A.12: 13C NMR spectrum of BODIPY 6 in deuterated chloroform at 100MHz. 
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Figure A.13: 1H NMR spectrum of BODIPY 7 in deuterated chloroform at 400MHz. 
 
 
Figure A.14: 13C NMR spectrum of BODIPY 7 in deuterated chloroform at 100MHz. 
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Figure A.15: 1H NMR spectrum of BODIPY 8 in deuterated chloroform at 400MHz. 
 
 
Figure A.16: 13C NMR spectrum of BODIPY 8 in deuterated chloroform at 100MHz. 
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Figure A.17: 1H NMR spectrum of BODIPY 9 in deuterated chloroform at 400MHz. 
 
 
Figure A.18: 13C NMR spectrum of BODIPY 9 in deuterated chloroform at 100MHz. 
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Figure A.19: 1H NMR spectrum of BODIPY 10 in deuterated chloroform at 400MHz. 
 
 
Figure A.20: 13C NMR spectrum of BODIPY 10 in deuterated chloroform at 100MHz. 
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Figure A.21: 1H NMR spectrum of BODIPY 11 in deuterated chloroform at 400MHz. 
 
Figure A.22: 13C NMR spectrum of BODIPY 11 in deuterated chloroform at 100MHz. 
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Figure A.23: 1H NMR spectrum of BODIPY 1a in deuterated chloroform at 400MHz. 
 
 
Figure A.24: 13C NMR spectrum of BODIPY 1a in deuterated chloroform at 100MHz. 
267 
 
 
Figure A.25: 1H NMR spectrum of BODIPY 2a in deuterated chloroform at 400MHz. 
 
 
Figure A.26: 13C NMR spectrum of BODIPY 2a in deuterated chloroform at 100MHz. 
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Figure A.27: 1H NMR spectrum of BODIPY 3a in deuterated chloroform at 400MHz. 
 
 
Figure A.28: 13C NMR spectrum of BODIPY 3a in deuterated chloroform at 100MHz. 
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Figure A.29: 1H NMR spectrum of BODIPY 4a in deuterated chloroform at 400MHz. 
 
 
Figure A.30: 13C NMR spectrum of BODIPY 4a in deuterated chloroform at 100MHz. 
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Figure A.31: 1H NMR spectrum of BODIPY 5a in deuterated chloroform at 400MHz. 
 
 
Figure A.32: 13C NMR spectrum of BODIPY 5a in deuterated chloroform at 100MHz. 
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Figure A.33: 1H NMR spectrum of BODIPY 6a in deuterated chloroform at 400MHz. 
 
 
Figure A.34: 13C NMR spectrum of BODIPY 6a in deuterated chloroform at 100MHz. 
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Figure A.35: 1H NMR spectrum of BODIPY 7a in deuterated chloroform at 400MHz. 
 
 
Figure A.36: 13C NMR spectrum of BODIPY 7a in deuterated chloroform at 100MHz. 
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Figure A.37: 1H NMR spectrum of BODIPY 8a in deuterated chloroform at 400MHz. 
 
 
Figure A.38: 13C NMR spectrum of BODIPY 8a in deuterated chloroform at 100MHz. 
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Figure A.39: 1H NMR spectrum of BODIPY 9a in deuterated chloroform at 400MHz. 
 
 
Figure A.40: 13C NMR spectrum of BODIPY 9a in deuterated chloroform at 100MHz.  
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Figure A.41: 1H NMR spectrum of BODIPY 10a in deuterated chloroform at 400MHz. 
 
 
Figure A.42: 13C NMR spectrum of BODIPY 10a in deuterated chloroform at 100MHz. 
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Figure A.43: 1H NMR spectrum of BODIPY 11a in deuterated chloroform at 400MHz. 
 
 
Figure A.44: 13C NMR spectrum of BODIPY 11a in deuterated chloroform at 100MHz. 
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APPENDIX B: NMR SPECTRA OF COMPOUNDS FOUND IN CHAPTER 3 
 
Figure B.1: 1H NMR spectrum of BODIPY 2a in deuterated chloroform at 400MHz. 
 
Figure B.2: 13C NMR spectrum of BODIPY 2a in deuterated chloroform at 100MHz. 
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Figure B.3: 1H NMR spectrum of BODIPY 2b in deuterated chloroform at 400MHz. 
 
 
Figure B.4 13C NMR spectrum of BODIPY 2b in deuterated chloroform at 100MHz. 
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Figure B.5: 1H NMR spectrum of BODIPY 2c in deuterated chloroform at 400MHz. 
 
 
Figure B.6: 13C NMR spectrum of BODIPY 2c in deuterated chloroform at 100MHz. 
280 
 
 
 
Figure B.7: 1H NMR spectrum of BODIPY 2d in deuterated chloroform at 400MHz. 
 
 
 
Figure B.8: 13C NMR spectrum of BODIPY 2d in deuterated chloroform at 100MHz. 
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Figure B.9: 1H NMR spectrum of BODIPY 2e in deuterated chloroform at 500MHz. 
 
 
 
Figure B.10: 13C NMR spectrum of BODIPY 2e in deuterated chloroform at 100MHz.  
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Figure B.11: 1H NMR spectrum of BODIPY 3a in deuterated chloroform at 400MHz. 
 
 
 
Figure B.12: 13C NMR spectrum of BODIPY 3a in deuterated chloroform at 100MHz. 
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Figure B.13: 1H NMR spectrum of BODIPY 3b in deuterated chloroform at 400MHz. 
 
 
Figure B.14: 13C NMR spectrum of BODIPY 3b in deuterated chloroform at 100MHz. 
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Figure B.15: 1H NMR spectrum of BODIPY 3c in deuterated chloroform at 500MHz. 
 
 
 
 
Figure B.16: 13C NMR spectrum of BODIPY 3c in deuterated chloroform at 100MHz. 
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Figure B.17: 1H NMR spectrum of BODIPY 3d in deuterated DMSO at 500MHz. 
 
 
 
 
Figure B.18: 13C NMR spectrum of BODIPY 3d in deuterated DMSO at 100MHz. 
286 
 
 
Figure B.19: 1H NMR spectrum of BODIPY 3e in deuterated acetone at 500MHz. 
 
 
 
 
Figure B.20: 13C NMR spectrum of BODIPY 3e in deuterated acetone at 500MHz. 
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Figure B.21: 1H NMR spectrum of Compound 4 in deuterated chloroform at 400MHz. 
 
 
 
Figure B.22: 13C NMR spectrum of Compound 4 in deuterated chloroform at 100MHz. 
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APPENDIX C: NMR SPECTRA OF COMPOUNDS FOUND IN CHAPTER 4 
 
Figure C.1: 1H NMR spectrum of BODIPY 1a in deuterated chloroform at 400MHz. 
 
 
Figure C.2: 13C NMR spectrum of BODIPY 1a in deuterated chloroform at 100MHz. 
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Figure C.3: 1H NMR spectrum of BODIPY 1b in deuterated chloroform at 400MHz. 
 
 
Figure C.4: 13C NMR spectrum of BODIPY 1b in deuterated chloroform at 100MHz. 
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Figure C.5: 1H NMR spectrum of BODIPY 2a in deuterated chloroform at 400MHz. 
 
 
Figure C.6: 13C NMR spectrum of BODIPY 2a in deuterated chloroform at 100MHz. 
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Figure C.7: 1H NMR spectrum of BODIPY 2b in deuterated chloroform at 400MHz. 
 
 
Figure C.8: 13C NMR spectrum of BODIPY 2b in deuterated chloroform at 100MHz. 
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Figure C.9: 1H NMR spectrum of BODIPY 4 in deuterated chloroform at 400MHz. 
 
Figure C.10: 13C NMR spectrum of BODIPY 4 in deuterated chloroform at 100MHz. 
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